The role of PGC-1α and PGC-1β during inflammatory processes in skeletal muscle by Eisele, Petra S
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
The role of PGC-1￿ and PGC-1￿ during inflammatory processes in skeletal
muscle
Eisele, Petra S
Abstract: Transcription is a fundamental cellular process which is tightly regulated by transcription
factors and cofactors to maintain homeostasis, even under changing conditions. The family of peroxisome
proliferator-activated receptor (PPAR) ￿ coactivator (PGC) 1 transcription cofactors comprises PGC-1,
PGC-1 and PRC, which all induce oxidative metabolism including mitochondrial biogenesis and fatty
acid oxidation. PGC-1 and PGC-1 have been studied in greater detail than PRC and are predominantly
expressed in tissues with high oxidative capacity like brown adipose tissue (BAT), heart and skeletal
muscle. Inflammation is the protective response of the body to infection and injury involving tissue as
well as immune cells. During this process, a complex cytokine network governs communication between
cells, coordinates elimination of pathogens, regeneration and finally drives resolution of the inflammatory
reaction. If persistently active, inflammation however becomes detrimental and in fact, accompanies a
large number of chronic diseases like type 2 diabetes. In skeletal muscle of diabetic patients, levels of
PGC-1 and PGC-1 are diminished and a mouse model with skeletal muscle-specific deletion of PGC-1
shows elevated inflammatory markers both locally and systemically. These findings suggest a causal role
of PGC-1 coactivators in counteracting inflammation. The work presented here explored the relationship
of those coactivators with inflammatory reactions in skeletal muscle in vitro and in vivo. In vitro, PGC-1
and PGC-1 were expressed using adenoviral vectors in a C2C12 myotube model. Tumour necrosis factor
(TNF) , different toll-like receptor agonists and free fatty acids all elicited pro-inflammatory cytokine
expression that was diminished by both coactivators in a stimulus- and gene-dependent manner. To
further elucidate the mechanism behind this repressive action, TNtreatment was chosen as paradigm. A
microarray experiment with subsequent bioinformatic analysis revealed that the NF-B pathway, which is
a major driver of inflammatory reactions, plays an important role in PGC-1-controlled inflammatory gene
expression. This prediction was validated as NF-B reporter gene activity was inhibited by both PGC-1
and PGC-1. However, neither changes in mRNA nor in protein expression of components of the NF-B
signalling pathway explained the repression. Rather, PGC-1 coactivators affected the post-translational
modification of p65, a NF-B subunit. Diminished phosphorylation at serine 536 precluded complete
transcriptional activation by p65 leading to lower cytokine levels. .
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-164219
Dissertation
Published Version
Originally published at:
Eisele, Petra S. The role of PGC-1￿ and PGC-1￿ during inflammatory processes in skeletal muscle. 2013,
University of Zurich, Faculty of Science.
 The Role of PGC-1 and PGC-1  
during Inflammatory Processes in Skeletal Muscle 
 
 
 
Dissertation 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
von 
 
 
Petra S. Eisele 
aus 
Deutschland 
 
 
 
 
Promotionskomitee 
 
Prof. Dr. Christoph Handschin (Leitung der Dissertation) 
 
Prof. Dr. Thierry Hennet (Vorsitz) 
 
Prof. Dr. Marc Donath 
 
Prof. Dr. Johan Auwerx 
 
 
Zürich, 2013 
Table of Contents 
TABLE OF CONTENTS 
 
TABLE OF CONTENTS ......................................................................................................... 1 
SUMMARY ............................................................................................................................... 4 
ZUSAMMENFASSUNG ......................................................................................................... 6 
ABBREVIATIONS .................................................................................................................. 9 
1 INTRODUCTION ...................................................................................................... 14 
1.1 THE PGC-1 FAMILY OF TRANSCRIPTION COACTIVATORS ............................................... 14 
1.1.1 Structure and molecular mechanism of action ................................................................. 14 
1.1.2 Expression and function of PGC-1 coactivators .............................................................. 16 
1.1.3 Modulation of PGC-1 activity ......................................................................................... 20 
1.1.4 PGC-1 coactivators in skeletal muscle physiology .......................................................... 22 
1.1.5 PGC-1 coactivators in skeletal muscle pathology ........................................................... 26 
1.2. INFLAMMATION .................................................................................................................. 29 
1.2.1 Molecular mechanisms of inflammation: the NF-B pathway ........................................ 29 
1.2.2 Inhibition of inflammation: interference with the NF-B pathway ................................. 33 
1.2.3 Macrophage polarization ................................................................................................. 36 
1.2.4 Inflammation, obesity and insulin resistance ................................................................... 39 
1.3 PGC-1 COACTIVATORS AND INFLAMMATION IN SKELETAL MUSCLE ............................. 42 
1.4 HYPOTHESIS ........................................................................................................................ 44 
2 THE PGC-1 COACTIVATORS REPRESS TRANSCRIPTIONAL ACTIVITY 
OF NK-B IN SKELETAL MUSCLE CELLS (MANUSCRIPT 1) ..................... 45 
2.1 ABSTRACT ........................................................................................................................... 46 
2.2 INTRODUCTION ................................................................................................................... 46 
2.3 MATERIALS AND METHODS ............................................................................................... 48 
2.3.1 Cell culture and treatments .............................................................................................. 48 
2.3.2 Semiquantitative real-time PCR ...................................................................................... 48 
2.3.3 ELISA .............................................................................................................................. 49 
1
Table of Contents 
2.3.4 NF-B Customized Array analysis .................................................................................. 49 
2.3.5 Dual-luciferase reporter gene assays ............................................................................... 49 
2.3.6 TransAM NF-B DNA binding assays............................................................................ 50 
2.3.7 Western Blotting .............................................................................................................. 50 
2.3.8 Statistical analysis ............................................................................................................ 51 
2.4 RESULTS .............................................................................................................................. 52 
2.4.1 PGC-1 and PGC- differentially suppress pro-inflammatory cytokine expression and 
secretion ........................................................................................................................... 52 
2.4.2 PGC-1 and PGC-1 target the NF-B pathway to suppress inflammation ................... 56 
2.4.3 PGC-1 reduces p65 and p50 expression levels .............................................................. 58 
2.4.4 PGC-1 and PGC-1 diminish the transcriptional activity of p65 .................................. 60 
2.4.5 Dephosphorylation and transrepression of p65 are potential molecular mechanisms for 
diminished cytokine expression ....................................................................................... 61 
2.5 DISCUSSION ......................................................................................................................... 65 
2.6 REFERENCES ....................................................................................................................... 68 
2.7 SUPPLEMETAL MATERIAL ................................................................................................. 72 
3 THE PGC-1 COACTIVATORS PROMOTE M2 POLARIZATION OF TISSUE 
MACROPHAGES IN SKELETAL MUSCLE (MANUSCRIPT 2) ...................... 80 
3.1 ABSTRACT ........................................................................................................................... 80 
3.2 INTRODUCTION ................................................................................................................... 81 
3.3 MATERIAL AND METHODS ................................................................................................. 83 
3.3.1 Mice and treatments ......................................................................................................... 83 
3.3.2 Cell culture ....................................................................................................................... 83 
3.3.3 Semiquantitative real-time PCR ...................................................................................... 83 
3.3.4 ELISA .............................................................................................................................. 84 
3.3.5 Histology.......................................................................................................................... 84 
3.3.6 Statistical analysis ............................................................................................................ 84 
3.4 RESULTS .............................................................................................................................. 85 
3.4.1 PGC-1 and PGC-1 do not alter systemic cytokine levels in inflammation ................. 85 
3.4.2 PGC-1 and PGC-1 alter macrophage populations in skeletal muscle after injection of 
inflammatory agents ........................................................................................................ 86 
3.4.3 PGC-1 and PGC-1 evoke an anti-inflammatory environment in skeletal muscle after 
injection of inflammatory agents ..................................................................................... 88 
2
Table of Contents 
3.4.4 PGC-1 and PGC-1 alter macrophage populations in skeletal muscle after downhill 
running ............................................................................................................................. 90 
3.4.5 PGC-1 and PGC-1 cause an anti-inflammatory environment in skeletal muscle after 
downhill running .............................................................................................................. 92 
3.4.6 PGC-1 and PGC-1 suppress IL-12 in isolated skeletal muscle cells after treatment 
with inflammatory agents ................................................................................................ 93 
3.5 DISCUSSION ......................................................................................................................... 95 
3.6 REFERENCES ....................................................................................................................... 98 
3.7 SUPPLEMENTAL MATERIAL ............................................................................................. 100 
4 DISCUSSION ............................................................................................................ 104 
4.1 GENERAL DISCUSSION ...................................................................................................... 104 
4.2 THE PGC-1 COACTIVATORS REPRESS TRANSCRIPTIONAL ACTIVITY OF NF-B IN 
SKELETAL MUSCLE CELLS ................................................................................................ 108 
4.2.1 Inflammatory stimuli and their influence on PGC-1 coactivators in skeletal muscle cells
 ....................................................................................................................................... 108 
4.2.2 Regulation of other NF-B pathway modulators by PGC-1 coactivators ..................... 112 
4.2.3 Direct interaction of PGC-1 coactivators and NF-B subunits ..................................... 115 
4.3 THE PGC-1 COACTIVATORS PROMOTE M2 POLARIZATION OF TISSUE MACROPHAGES IN 
SKELETAL MUSCLE ........................................................................................................... 117 
4.3.1 Anaesthesia and PGC-1 transgene expression in skeletal muscle ................................. 117 
4.3.2 PGC-1 coactivators and anti-inflammatory cytokines ................................................... 118 
4.4 COMPARISON OF IN VITRO AND IN VIVO MODELS ............................................................ 121 
4.5 PERSPECTIVES ................................................................................................................... 123 
5 REFERENCES ......................................................................................................... 125 
6 CURRICULUM VITAE .......................................................................................... 140 
7 ACKNOWLEDGEMENTS ..................................................................................... 142 
3
Summary 
SUMMARY 
 
Transcription is a fundamental cellular process which is tightly regulated by transcription 
factors and cofactors to maintain homeostasis, even under changing conditions. The family of 
peroxisome proliferator-activated receptor (PPAR)  coactivator (PGC) 1 transcription cofactors 
comprises PGC-1, PGC-1 and PRC, which all induce oxidative metabolism including 
mitochondrial biogenesis and fatty acid oxidation. PGC-1 and PGC-1 have been studied in greater 
detail than PRC and are predominantly expressed in tissues with high oxidative capacity like brown 
adipose tissue (BAT), heart and skeletal muscle.  
 Inflammation is the protective response of the body to infection and injury involving tissue as 
well as immune cells. During this process, a complex cytokine network governs communication 
between cells, coordinates elimination of pathogens, regeneration and finally drives resolution of the 
inflammatory reaction. If persistently active, inflammation however becomes detrimental and in fact, 
accompanies a large number of chronic diseases like type 2 diabetes.  
 In skeletal muscle of diabetic patients, levels of PGC-1 and PGC-1 are diminished and a 
mouse model with skeletal muscle-specific deletion of PGC-1 shows elevated inflammatory markers 
both locally and systemically. These findings suggest a causal role of PGC-1 coactivators in 
counteracting inflammation. The work presented here explored the relationship of those coactivators 
with inflammatory reactions in skeletal muscle in vitro and in vivo.  
 In vitro, PGC-1 and PGC-1 were expressed using adenoviral vectors in a C2C12 myotube 
model. Tumour necrosis factor (TNF) , different toll-like receptor agonists and free fatty acids all 
elicited pro-inflammatory cytokine expression that was diminished by both coactivators in a stimulus- 
and gene-dependent manner. To further elucidate the mechanism behind this repressive action, TNF 
treatment was chosen as paradigm. A microarray experiment with subsequent bioinformatic analysis 
revealed that the NF-B pathway, which is a major driver of inflammatory reactions, plays an 
important role in PGC-1-controlled inflammatory gene expression. This prediction was validated as 
NF-B reporter gene activity was inhibited by both PGC-1 and PGC-1. However, neither changes 
in mRNA nor in protein expression of components of the NF-B signalling pathway explained the 
repression. Rather, PGC-1 coactivators affected the post-translational modification of p65, a NF-B 
subunit. Diminished phosphorylation at serine 536 precluded complete transcriptional activation by 
p65 leading to lower cytokine levels.  
Protein kinase B (Akt) activity was concomitantly lowered by PGC-1 and PGC-1. Upon 
stimulation, Akt initiates IKK-dependent phosphorylation of p65, which in this case is decreased 
with lower Akt activity. There are hints that an unknown phosphatase participates in 
dephosphorylation of p65. Transrepression represents a second link between PGC-1 coactivators and 
inflammatory reactions: PGC-1 and PGC-1 both induced expression of the nuclear receptor PPAR 
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which has known anti-inflammatory properties. In fact, inhibition of PPAR in our system recovered 
pro-inflammatory cytokine levels and thus abolished the repressive effect at least of PGC-1. 
Therefore, in vitro Akt inhibition and PPAR-mediated transrepression caused by PGC-1 coactivators 
lead to incomplete activation of p65-dependent transcription of pro-inflammatory cytokines. 
Furthermore, PGC-1 but nor PGC-1 induced components of the noncanonical NF-B 
signalling pathway while PGC-1 but not PGC-1 decreased expression and DNA binding of the NF-
B subunits p65 and p50 in the basal state. The latter very likely accounts for repression of cytokine 
expression by PGC-1 without stimulation.  
In vivo, mouse models with skeletal muscle-specific PGC-1 or PGC-1 overexpression were 
either injected into tibialis anterior with TNF or lipopolysaccharide or exposed to a single bout of 
downhill running on a treadmill. Pro-inflammatory cytokine levels neither differed systemically, nor 
locally in skeletal muscle. Unexpectedly, transgenic animals displayed higher numbers of 
macrophages in this tissue, which were however skewed towards an alternatively activated (M2) 
phenotype. The presence of M2 signature cytokines further supported the influence of muscle PGC-1 
expression on alternative macrophage activation creating an anti-inflammatory environment. Most of 
these cytokines however derived from immune cells as only a PGC-1-mediated suppression of IL-12 
expression could be replicated in vitro. Thus, insufficient IL-12 levels are presumably the root of M2 
skewing.  
The study presented here establishes PGC-1 and PGC-1 as regulators of immune function 
in skeletal muscle. A direct effect on NF-B signalling and pro-inflammatory cytokine expression was 
detected in vitro while in vivo, those coactivators more indirectly influenced the inflammatory milieu 
through alternative macrophage activation. In the context of metabolic disorders like type 2 diabetes, 
these findings are of interest because low PGC-1 expression and chronic inflammation accompany 
diseases progression. It appears that targeting PGC-1 and PGC-1 in skeletal muscle offers a 
potential treatment strategy to avoid entering the vicious circle of deteriorating metabolic function and 
heightened inflammation. The results further provide evidence that metabolic and inflammatory 
pathways are more tightly linked than previously reported and skeletal muscle should be considered an 
organ as much involved into metabolic fluxes as in immune responses contributing to an overall 
healthy state.  
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ZUSAMMENFASSUNG 
 
Transkription ist ein grundlegender, zellulärer Prozess, der durch Transkriptionsfaktoren und 
Kofaktoren genauestens geregelt wird, um Homöostase auch unter sich ändernden Bedingungen zu 
erhalten. Zur Familie der „peroxisome proliferator-activated receptor (PPAR)  coactivator (PGC) 1”-
Transkriptionskofaktoren gehören PGC-1, PGC-1 und PRC, die alle den oxidativen Stoffwechsel 
anregen, was mitochondrielle Biogenese und Fettsäureoxidation einschliesst. PGC-1 und PGC-1 
wurden bereits genauer untersucht als PRC und sind hauptsächlich in Geweben mit hoher oxidativer 
Kapazität wie braunem Fettgewebe, Herz und Skelettmuskel vorhanden. 
 Entzündung ist die schützende Antwort des Körpers auf Infektionen und Verletzungen, an der 
sowohl Körper- als auch Immunzellen beteiligt sind. Während dieses Prozesses stimmt ein komplexes 
Netzwerk aus Zytokinen die Kommunikation zwischen diesen Zellen ab, lenkt die Beseitigung von 
Krankheitserregern, die Heilung und veranlasst schliesslich die Auflösung der entzündlichen Reaktion. 
Wenn Entzündungen jedoch chronisch werden, können sie schädliche Wirkungen entfalten, und 
tatsächlich treten sie bei vielen chronischen Erkrankungen wie z.B. Typ-2-Diabetes als 
Begleiterscheinung auf.  
 Diabetiker weisen im Skelettmuskel einen reduzierten Gehalt an PGC-1 und PGC-1 auf, 
und in einem Mausmodell, dem PGC-1 im Skelettmuskel fehlt, werden sowohl im Blutkreislauf als 
auch lokal erhöhte Entzündungswerte gemessen. Diese Ergebnisse deuten darauf hin, dass PGC-1 
Koaktivatoren eine ursächliche Rolle bei der Bekämpfung von Entzündungen spielen könnten. Die 
vorliegende Arbeit setzt sich mit der Beziehung zwischen diesen Koaktivatoren und 
Entzündungsreaktionen im Skelettmuskel in vitro und in vivo auseinander. 
 In vitro wurden PGC-1 und PGC-1 von adenoviralen Vektoren in einem C2C12 
Myotubenmodell exprimiert. Tumornekrosefaktor (TNF) , spezifische Aktivatoren verschiedener 
toll-like Rezeptoren und freie Fettsäuren riefen alle die Expression proentzündlicher Zytokine hervor, 
die von beiden Koaktivatoren in einer stimulus- und genabhängigen Art und Weise beeinträchtigt 
wurde. Um den Mechanismus dieser Repression genauer zu verstehen, wurde die Behandlung mit 
TNF als Musterbeispiel gewählt. Ein Microarray-Experiment und dessen anschliessende, 
bioinformatische Auswertung ergaben, dass der NF-B Signalweg, einer der Haupteinflussfaktoren 
entzündlicher Reaktionen, eine entscheidende Rolle bei der von PGC-1 kontrollierte Genexpression 
spielt. Diese Vorhersage wurde dadurch bestätigt, dass PGC-1 und PGC-1 beide die Aktivität eines 
NF-B Reportergens einschränkten. Allerdings konnte diese Repression weder durch Änderungen des 
mRNA-Gehalts noch des Proteingehalts einzelner Komponenten des NF-B Signalweges erklärt 
werden. Die PGC-1 Koaktivatoren beeinflussten vielmehr die posttranslationale Modifikation von 
p65, einer NF-B Untereinheit. Die verringerte Phosphorylierung am Serin 536 verhinderte die 
vollständige transkriptionelle Aktivität von p65, was zu niedrigeren Zytokinspiegeln führte.  
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 Parallel dazu war die Aktivität der Proteinkinase B (Akt) durch PGC-1 und PGC-1 
reduziert. Akt ist für die IKK-abhängige Phosphorylierung von p65 nach einem Stimulus 
verantwortlich, die in diesem Falle durch die geringere Akt Aktivität vermindert war. Es gibt 
ausserdem Hinweise, dass eine unbekannte Phosphatase an der Dephosphorylierung von p65 beteiligt 
ist. Ein zweites Bindeglied zwischen PGC-1 Koaktivatoren und Entzündungsreaktionen ist die 
Transrepression: PGC-1 und PGC-1 erhöhten beide die Expression des nukleären Rezeptors 
PPAR, der antientzündliche Eigenschaften besitzt. Demzufolge normalisierte die Hemmung von 
PPAR tatsächlich die Zytokinspiegel in unserem System und hob damit die repressive Wirkung 
zumindest von PGC-1 auf. Somit führen Akt Hemmung und PPAR-vermittelte Transrepression in 
vitro zu unvollständiger Aktivierung p65-abhängiger proentzündlicher Gentranskription.  
 Des Weiteren steigerte PGC-1 aber nicht PGC-1, die Expression von Komponenten des 
nicht-kanonischen NF-B Signalweges, wohingegen PGC-1 aber nicht PGC-1, sowohl den Gehalt 
als auch die DNS-Bindung der NF-B Untereinheiten p65 und p50 im Grundzustand verminderte. 
Letzteres erklärt sehr wahrscheinlich die Repression der Zytokinexpression durch PGC-1 in 
Abwesenheit eines Stimulus.  
 In vivo wurde Mausmodellen mit skelettmuskelspezifischer PGC-1 oder PGC-1 
Überexpression entweder TNF oder Lipopolysaccharid in den Musculus tibialis anterior gespritzt 
oder sie mussten einmalig bergab auf einem Laufband laufen. Der  Spiegel proentzündlicher Zytokine 
unterschied sich weder systemisch noch lokal im Skelettmuskel. Die transgenen Tiere hatten aber 
unerwartet eine grössere Anzahl Makrophagen im Gewebe, die sich jedoch stärker in einem 
alternativen Aktivierungszustand (M2) befanden. Der Nachweis von Zytokinen, die für diesen M2 
Zustand charakteristisch sind, deutete ebenfalls auf den Einfluss von Muskel-PGC-1 auf die alternative 
Makrophagenaktivierung hin, was zur Schaffung eines antientzündlichen Milieus beitrug. Der 
Grossteil dieser Zytokine stammte jedoch von Immunzellen, da nur die PGC-1-bedingte Hemmung der 
IL-12 Expression in vitro repliziert werden konnte. Demzufolge sind zu niedrige IL-12-Spiegel 
wahrscheinlich der Grund für die Verschiebung des M1-M2 Gleichgewichts. 
 Die hier vorgestellte Studie etabliert PGC-1 und PGC-1 als Regulatoren der 
Immunfunktion im Skelettmuskel. Ein direkter Effekt auf den NF-B Signalweg und auf 
proentzündliche Zytokinexpression konnte in vitro nachgewiesen werden, wohingegen diese 
Koaktivatoren in vivo vor allem indirekt auf das Entzündungsumfeld durch alternative 
Makrophagenaktivierung wirkten. Im Zusammenhang mit Stoffwechselkrankheiten wie z.B. Typ-2-
Diabetes sind diese Ergebnisse von Interesse, da niedrige PGC-1 Expression und eine chronische 
Entzündung den Krankheitsverlauf begleiten. Behandlungsmethoden, die auf PGC-1 und PGC-1 im 
Skelettmuskel abzielen, könnten so möglicherweise helfen, den Teufelskreis aus sich 
verschlechterndem, metabolischem Zustand und gesteigerter Entzündung zu durchbrechen. Die 
Ergebnisse weisen ausserdem darauf hin, dass Stoffwechsel- und Entzündungssignalwege enger 
miteinander verbunden sind als bisher angenommen, und dass der Skelettmuskel nicht nur ein 
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Stoffwechselorgan ist, sondern auch an Immunantworten beteiligt, und dadurch zu einem gesunden 
Gesamtzustand beiträgt.  
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ABBREVIATIONS 
 
Abbreviation 
 
Full name 
 
AD activation domain 
ALAS-1 5-aminolevulinate synthase 
ALS amyotrophic lateral sclerosis 
AMPK adenosine monophosphate-activated protein kinase 
AP-1 activator protein 1 
ATF2 activating transcription factor 2 
ATM adipose tissue macrophage 
BAF60 BRG-1-associated factor 60 
BAFFR B-cell activating factor receptor 
BAT brown adipose tissue 
Bcl3 B-cell lymphoma 3 
Bcl6 B-cell lymphoma 6 
BMI body mass index 
CaMKIV calcium/calmodulin-dependent protein kinase type IV 
cAMP cyclic adenosine monophosphate 
CAR constitutive androstane receptor 
CBP CREB-binding protein 
CCL1 C-C motif chemokine 1 
CCL17 C-C motif chemokine 17 
CCL2 C-C motif chemokine 2 (MCP-1) 
CCL22 C-C motif chemokine 22 
CCL3 C-C motif chemokine 3 (MIP-1 
CCL5 C-C motif chemokine 5 (RANTES) 
ChIP chromatin immunoprecipitation 
CKII casein kinase II 
CMV cytomegalovirus 
CnA calcineurin A 
COPD chronic obstructive pulmonary disease 
COX IV cytochrome c oxidase subunit 4 
COX2 cyclooxygenase 2 
CPT1 carnitine O-palmitoyltransferase 1 
CRE cyclic adenosine monophosphate response element 
CREB cyclic adenosine monophosphate response element-binding protein 
CRP C-reactive protein 
CtBP C-terminal binding protein 
Ctrl control 
CXCL1 C-X-C motif chemokine 1 
CXCL10 C-X-C motif chemokine 10 
CYP7A1 cholesterol 7--hydroxylase 1 
DAPI 4',6-diamidino-2-phenylindole 
DAX-1 
 
dosage-sensitive sex reversal adrenal hypoplasia congenital critical region on  
X chromosome, gene 1 
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DD death domain 
DMD Duchenne muscular dystrophy 
DMEM Dulbecco’s Modified Eagle Medium 
DNA deoxyribonucleic acid 
DNMT3B DNA methyltransferase 3B 
DRIP vitamin D receptor-interacting protein 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmic reticulum 
ER estrogen receptor  
ERK extracellular signal-related kinase 
ERR estrogen-related receptor   
ERR estrogen-related receptor   
ETC electron transport chain 
FADD Fas–associated DD 
FFA free fatty acid 
FGF21 fibroblast growth factor 21 
FoxO1 forkhead box protein  O1 
FoxO3a forkhead box protein  O3a 
Fsk forskolin 
FXR farnesoid X receptor 
G-6-Pase glucose-6-phosphatase 
GCN5 general control of amino acid synthesis 5 
GFP green fluorescent protein 
GLUT4 glucose transporter 4 
Gpx-1 glutathione peroxidise 1 
GR glucocorticoid receptor 
GRIP1 glutamate receptor-interacting protein 1 
GSK3 glycogen synthase kinase 3 
h hour 
H&E Mayer’s hematoxylin and eosin 
HAT histone acetyltransferase 
HD Huntington´s disease 
HDAC histone deacetylase 
HFD high fat diet 
HIF1 hypoxia-inducible factor 1 
HNF4 hepatic nuclear factor 4 
HO-1 heme oxygenase 1 
Hsp27 heat shock protein 27 
i.m. interamuscular 
i.p. intraperitoneal 
IFN interferon   
IgG immunoglobulin G 
IB inhibitor of NF-B 
IKK IB kinase 
IL-10 interleukin 10 
IL-12 interleukin 12 
IL-13 interleukin 13 
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IL-15R interleukin 15 receptor  
IL-1 interleukin 1   
IL-1Ra interleukin 1 receptor antagonist 
IL-4 interleukin 4 
IL-6 interleukin 6 
IL-6R interleukin 6 receptor 
IRAK1 interleukin 1 receptor-asscoiated kinase 1 
IRAK4 interleukin 1 receptor-asscoiated kinase 4 
IRE insulin response element 
IRF3 interferon regulatory factor 3 
IRF7 interferon regulatory factor 7 
Irs1 insulin receptor substrate 1 
JAK Janus kinase 
JNK c-Jun N-terminal kinase 
kb kilobase 
KLF4 Krüppel-like factor 4 
LPS lipopolysaccharide 
LTR lymphotoxin  receptor 
LXR liver X receptor 
Ly6C lymphocyte antigen 6C 
Mal Myd88 adaptor-like protein 
MAPK mitogen-activated protein kinase 
MCAD medium-chain acyl-coenzyme A dehydrogenase 
MCK muscle creatine kinase 
MCK PGC-1 skeletal muscle-transgenic mice 
MCK PGC-1 skeletal muscle-transgenic mice 
MCP-1 monocyte chemoattractant protein 1 (CCL2) 
MCSF macrophage colony-stimulating factor 
MEF2 myocyte-specific enhancer factor 2 
MEK1/2 MAPK/ERK kinase1/2 
min minute 
MIP-1 macrophage inflammatory protein 1CCL3) 
MK2 MSK kinase 2 
MKO Mice with skeletal muscle-specific deletion of PGC-1 
MRC1 macrophage mannose receptor 1 (CD206) 
mRNA messenger ribonucleic acid 
Ms1 manuscript 1 
Ms2 manuscript 2 
MSK1 mitogen- and stress-activated protein kinase 1 
MSR-1 macrophage scavenger receptor 1 (CD204) 
MuRF1 muscle-specific RING finger protein 1 
Myd88 myeloid differentiation primary response gene 88 
NADPH nicotinamide adenine dinucleotide phosphate 
NcoR nuclear receptor corepressor 1 
NEMO NF-B essential modulator 
NF-B nuclear factor -light-chain-enhancer of activated B cells 
NFAT nuclear factor of activated T cells 
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NIK NF-B inducing kinase 
NO nitric oxide 
Nox-1 NADPH oxidase 1 
NR nuclear receptor 
NRF1 nuclear respiratory factor 1 
NRF2 nuclear respiratory factor 2 
nTrip6 nuclear TR-interacting protein 6 
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WIP-1 wt-p53-induced phosphatase 
WT wild-type 
YY1 yin and yang 1 
 
13
Introduction 
1 INTRODUCTION 
 
1.1 The PGC-1 family of transcription coactivators 
 
1.1.1 Structure and molecular mechanism of action 
 
Transcription is a fundamental, biological process that requires complex regulation. In a first step of 
many ultimately leading to gene expression, transcription factors bind to specific DNA sequences, so-
called response elements, in the promoters of target genes. Subsequent recruitment of chromatin 
remodelling enzymes and the RNA polymerase complex then enables initiation of transcription. 
Transcription coregulators confer specificity and either potentiate (coactivators) or constrain 
(corepressors) initiation through interaction with specific transcription factors. One such example is 
the peroxisome proliferator-activated receptor (PPAR)  coactivator 1 (PGC-1) family of transcription 
coactivators which comprises 3 members: PGC-1, PGC-1 and PGC-1-related coactivator (PRC). 
They all share a similar structure with an N-terminal activation domain (AD), one or several LXXLL-
motifs (where L is leucine and X is any amino acid) and a C-terminal RNA recognition and splicing 
domain (Fig. 1A). PGC-1 and PGC-1 further comprise an inhibitory region of about 200 amino 
acids adjacent to the AD. The main mechanism by which PGC-1s facilitate transcription after binding 
to a transcription factor is the simultaneous recruitment of protein complexes that all propagate 
transcription initiation (Fig. 1B). For PGC-1 this assembly has been studied in great detail: The AD  
 
 
Figure 1 PGC-1 structure and function A. Domain structure of PGC-1 family members. B. Schematic 
representation of transcription initiation facilitated by PGC-1. Adapted from (3). 
 
 
interacts with the histone acetyltransferases (HATs) steroid receptor-1 (SRC-1) and cyclic AMP 
response element-binding protein (CREB) binding protein (CBP)/p300, which mediate decondensation 
of chromatin (1). BRG-1-associated factor (BAF) 60a recruits the chromatin remodelling 
switch/sucrose nonfermentable (SWI/SNF) complex to a central stretch within the PGC-1 protein 
(2), while the C-terminal region binds the thyroid receptor-associated protein (TRAP)/vitamin D 
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receptor-interacting protein (DRIP) or Mediator complex that directly associates with the basal 
transcription machinery and thus contributes to preinitiation complex formation (4).  
As PGC-1 does not contain a DNA-binding domain, PGC-1-mediated gene expression 
depends on its affinity to certain transcription factors. First described as a coactivator of PPAR and 
the thyroid hormone receptor (TR) (5), PGC-1 was subsequently show to interact with most nuclear 
receptors (NRs) including PPAR (6), PPAR (7), liver X receptor (LXR) (8), farnesoid X receptor 
(FXR) (9), vitamin D receptor (VDR) (10), constitutive androstane receptor (CAR) (11), pregnane X 
receptor (PXR) (12), estrogen receptor (ER)  (13), estrogen-related receptor (ERR)  and  (14), 
glucocorticoid receptor (GR) (15), hepatic nuclear factor (HNF) 4 (15,16), and retinoid X receptor 
(RXR) (17). PGC-1 also coactivates PPAR (18), ER (19), and ERR (20), while both PGC-1 and 
PRC are able to enhance ERR-dependent transcription (21,22). 
Binding of PGC-1 to NRs can be either constitutive or ligand-dependant, and indeed, human 
PGC-1 was identified in a screen for steroid-responsive genes (23). Although the three dimensional 
structure of none of the PGC-1 coactivators has been resolved yet, N-terminal fragments of PGC-1 
were crystallized in complex with ERR (24), ERR (25), PPAR (26), and HNF4 (27) highlighting 
the requirement of the LXXLL motifs as crucial NR binding interfaces. These leucine-rich domains 
are also essential for the interaction of PGC-1 with ER (19). Contact to a NR causes a 
conformational change in PGC-1 which compacts its AD and thus favours interaction with HATs 
(25). Therefore, the transcription activation potential of PGC-1 depends on its association with NRs. 
This association can be prevented by competition for binding sites on NRs resulting in diminished 
target gene expression. Corepressors that were shown to act as such competitors and displace PGC-1 
include small heterodimer partner (SHP) on GR (28), SHP interacting leucine zipper protein (SMILE) 
on ERR (29) and dosage-sensitive sex reversal adrenal hypoplasia congenital critical region on X 
chromosome, gene 1 (DAX-1) on ERR and HNF4 (30,31).  
PGC-1 is also able to coactivate some non-NR transcription factors like forkhead box protein 
(Fox) O1 (32), FoxO3a (33), nuclear respiratory factor (NRF) 1 (34), myocyte-specific enhancer factor 
(MEF) 2A (35), and MEF2C (36). They bind PGC-1 at domains different from NRs and the presence 
of leucine-rich motifs for this interaction is dispensable. NRF-1 can also be coactivated by PRC (37) 
while PGC-1 is an important cofactor for sterol regulatory element-binding protein (SREBP) 1a 
and 1c (38), and FoxA2 (39,40). Beyond the initiation of RNA polymerisation, PGC- is also 
implicated in RNA processing via the RNA recognition and splicing domain at the C-terminus (41). 
Several isoforms of PGC-1 have been identified: The naturally occurring NT-PGC-1 arises 
from alternative splicing and contains amino acids 1-270 (42). Compared to the full-length form, NT-
PGC-1 is more stable and localized in the cytoplasm due to continuous exported from the nucleus 
(43). Furthermore, alternative promoter usage produces 2 isoforms termed PGC-1-b and PGC-1-c 
(PGC-1-a denotes the full-length form) that play a role in rodent and human skeletal muscle (44,45). 
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A liver-specific isoform (L-PGC-1) that lacks amino acids 1-127 is only present in humans (46). 
Analogous to PGC-1, transcription of PGC-1 may also start from two different promoters giving 
rise to the PGC-1-1 and PGC-1-2 isoforms, while alternative splicing of exon 11 generates PGC-
1-a and PGC-1-b respectively (47). No isoforms of PRC are known so far.  
 
 
1.1.2 Expression and function of PGC-1 coactivators 
 
 PGC-1 orthologues are present in all vertebrates species, with 95% sequence homology 
between mouse and human, and a high degree of conservation in the AD and NR interaction domain 
due to their importance in mediating PGC-1 action (23,48). In Drosophila, the PGC-1 homologue 
Spargel is essential in mitochondrial genes expression and spargel mutants display respiration defects 
(49). This fundamental role of PGC-1 in cellular respiration is conserved across species, redundant 
between all 3 family members and important in all tissues that express PGC-1. Therefore, the 
coordination of oxidative metabolism is the central property of this coactivator family. PGC-1 and 
PGC-1 are consequently enriched in tissues with high oxidative capacity like skeletal muscle, heart, 
brown adipose tissue (BAT), kidney, and brain (5,18) whereas PRC is expressed ubiquitously (37).  
Mitochondria are the main site of oxidative energy production and comprise 2 membrane 
layers, the inner and the outer mitochondrial membrane. The inner membrane is folded into cristae 
enlarging its surface, and contains proteins which engage in oxidative phosphorylation to supply the 
cell with ATP (50). The inner space or mitochondrial matrix harbours enzymes of  oxidation, 
pyruvate decarboxylation and the tricarboxylic acid (TCA) cycle as well as mitochondrial DNA. To 
produce ATP from nutrients, on the one hand, lipids are activated in the cytosol and shuttled into 
mitochondria as acylcanitines. Mitochondrial  oxidation then generates acetyl-CoA which is fed into 
the TCA cycle (50). On the other hand, carbohydrates are converted into pyruvate by glycolysis in the 
cytosol. Upon import into mitochondria, pyruvate is transformed into acetyl-CoA by pyruvate 
decarboxylation. Using acetyl-CoA as substrate, the TCA cycle through a series of reactions then 
provides NADH which acts as electron donor in the electron transport chain (ETC). The electrons 
from NADH are transferred between different donor and acceptor proteins (complex I – IV) to finally 
reduce oxygen to water (50). During this electron passage energy is liberated and stored as an 
electrochemical proton gradient across the inner mitochondrial membrane. Dissipation of this gradient 
finally drives ATP production by ATP synthase (50).  
Increasing the number of mitochondria to meet higher energy demands is a complex process 
that requires a high degree of coordination as it involves transcription of nuclear genes, import of the 
resulting proteins into mitochondria, transcription of mitochondrial DNA and its replication. PGC-1 
integrates these steps by coactivating the nuclear transcription factors NRF-1 and ERR on promoters 
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of nuclear encoded mitochondrial genes (Fig. 2) (21,22,34,37,51). These include cytochrome c oxidase 
subunit 4 (COX IV) which forms a part of the ETC, -ATP synthase, as well as the transcription factor 
A, mitochondrial (Tfam). Tfam governs transcription and replication of mitochondrial DNA yielding 
mitochondrial encoded parts of the ETC and the genetic material required for mitochondrial 
biogenesis. In addition to coactivation, PGC-1 also induces the expression of NRF-1, NRF-2 and 
ERR (Fig. 2) (34,52). NRF-2 and ERR further amplify their own as well as each others expression 
thus constituting a powerful positive regulatory mechanism for oxidative phosphorylation (53). Yet, 
mice with a global deletion of either PGC-1 (54,55) or PGC-1 (56,57) are viable, fertile and do not 
show overtly deranged mitochondria. Their ability to cope with different stress conditions (for 
example exposure to cold) is however grossly compromised. This indicates that PGC-1 coactivators 
are not required for mitochondrial function in the basal state, but if the cell needs to meet higher 
energy demands, PGC-1 coactivators are crucial to coordinate the program of mitochondrial 
biogenesis. 
 The coupling of electron transport and production of ATP is not complete and protons may 
leak over the inner mitochondrial membrane thereby generating heat. Ectopic expression of PGC-1 
and PGC-1 increases mitochondrial proteins and respiration to a similar degree, but proton leak in 
cells expressing PGC-1 is higher (58). Thus PGC-1 and PGC-1 have shared but also distinct 
properties.  
 
 
 
Figure 2 Schematic representation of PGC-1´s role in coordinating oxidative metabolism. From (59). 
 
 
Reactive oxygen species (ROS) are free radicals that arise as byproducts from the ETC when 
oxygen is prematurely reduced. As highly reactive molecules, they have the capacity to damage 
components of the cell and therefore, ROS levels need to be tightly controlled. An increase in 
mitochondrial biogenesis is inevitably accompanied by an increase in ROS production. To alleviate 
17
Introduction 
this oxidative stress, PGC-1 and PGC-1 enhances the expression of ROS detoxifying enzymes like 
glutathione peroxidise 1 (GPx-1) and superoxide dismutase [Mn], mitochondrial (Sod2). Along these 
lines, mice carrying a PGC-1 deletion are more susceptible to neurodegeneration caused by oxidative 
stressors while PGC-1 protects neurons from ROS-induced cell death (60). One of the transcription 
factors that partners with PGC-1 to coordinate ROS detoxification is FoxO3a. While both are 
activated by high ROS levels, FoxO3a also induces PGC-1 transcription. This signal amplification 
with positive feedback loop finally ensures non-toxic ROS levels in the cell (33).  
Beyond oxidative phosphorylation itself, PGC-1 coactivators also augment substrate 
availability. Both, PGC-1 and PGC-1 coactivate ERR and PPAR, master regulators of 
mitochondrial fatty acid oxidation, in a constitutive and a ligand-dependant manner, respectively 
(6,61,62). The induction of key enzymes in  oxidation like medium-chain specific acyl-CoA 
dehydrogenase (MCAD) and carnitine O-palmitoyltransferase (CPT) 1 allows the cell to rely mainly 
on fatty acids as energy substrate (Fig. 2). This notion is extended as PGC-1 was shown to also 
induce peroxisome biogenesis, an organelle that participates in the catabolism of very long and 
branched chain fatty acids (63). Accordingly, PGC-1 coactivators co-ordinately heighten a whole 
program of oxidative metabolic pathways turning them into chief mediators of cellular energy 
metabolism.  
Besides their role in respiration, PGC-1 coactivators also execute an array of tissue-specific 
functions. In liver, PGC-1 is markedly upregulated upon fasting downstream of glucocorticoids and 
the glucagon/cAMP/CREB axis (64) regulating several important starvation pathways. These include 
gluconeogenesis and ketogenesis (16), the former being induced by PGC-1-mediated coactivation of 
HNF4 and FoxO1, which leads to the expression of major gluconeogenic enzymes like 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-Pase) (15,32). Under 
the control of the same transcription factors, selenoprotein P (SeP) expression in liver is also governed 
by PGC-1 illustrating its important role in selenium homeostasis (65). PGC-1 has been further 
implicated in hepatic heme and bile acid biosynthesis through the induction of 5-aminolevulinate 
synthase (ALAS-1) and cholesterol 7--hydroxylase (CYP7A1) respectively (66,67). Finally, 
regulation of homocysteine homeostasis has been assigned to PGC-1 (68). By contrast, PGC-1 is 
not able to induce gluconeogenesis due to lack of binding to HNF4 and FoxO1 (62). Yet, PGC-1 
plays an important role in hepatic lipid metabolism by its ability to stimulate lipogenic gene 
expression through coactivation of SREBP-1a and SREBP-1c (38). In concert with FoxA2, PGC-1 
also promotes mitochondrial  oxidation and triglyceride/VLDL secretion into plasma thus reducing 
accumulation of fat in the liver (40). Interestingly, SREBP-1 may also interfere with the HNF4/PGC-
1 interaction and as a result suppress gluconeogenesis (69). Therefore, PGC-1 and PGC-1 have 
distinct functions in liver but the pathways they regulate intersect at different levels and mutually 
influence each other.  
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 In the heart, PGC-1 induction coincides with perinatal mitochondrial biogenesis which 
causes a switch in fuel usage from glucose to fatty acids and occurs after fasting when ATP is needed. 
Hearts from mice with PGC-1 deletion fail to augment cardiac output in response to chemical or 
electrical stimulation while cardiac stress and aging lead to heart failure (70,71). Comparably, lack of 
PGC-1 accelerates heart failure (72), but in both cases the phenotype only manifests under stress 
conditions. By contrast, animals with double deficiency die shortly after birth with small hearts that 
are defective in maturation keeping a fetal gene expression pattern (73). This illustrates that both 
coactivators can partly compensate for each other in the heart. Notably, cardiac PGC-1 transgenic 
animals lose the sarcomer structure in the heart and develop dilated cardiomyopathy (74). The 
cardioprotective function of PGC-1 is therefore confined to a certain therapeutic window.  
Originally, PGC-1 was discovered as a thermogenic regulator in BAT induced upon 
exposure to cold (5). The main function of BAT is the production of heat by uncoupled respiration 
while white adipose tissue (WAT) stores energy in the form of lipid droplets. The relevance of both 
PGC-1 and PGC-1 in BAT was confirmed in vitro and in vivo with double deletion models that 
exhibited severe defects in mitochondrial function and density (73,75). Moreover, PGC-1 and PGC-
1 are crucial in BAT differentiation because they coactivate PR domain zinc finger protein (PRDM) 
16 on promoters of brown adipocyte lineage genes whereas C-terminal binding protein (CtBP) 
prevents recruitment of PGC-1/ on promoters of white adipocyte lineage genes (76). Hence, 
suppression of PGC-1 e.g. by twist-1 or retinoblastoma proteins favours a white over a brown fat 
phenotype (77,78). On the other hand, induction of PGC-1 in WAT e.g. by fibroblast growth factor 
(FGF) 21 leads to “browning” characterized by the expression of genes like UCP-1 that are able to 
dissipate energy (79,80). In light of metabolic diseases that arise from obesity, this property of PGC-1 
coactivators is of prime interest. A recent mouse model with an adipose tissue-specific deletion of 
PGC-1 confirms this concept because the animals develop insulin resistance on a high fat diet due to 
high circulating lipid levels (81). 
In pancreas, both PGC-1 and PGC-1 are invovlved in glucose-stimulated insulin secretion 
from  cells; the precise role of both coactivators is however controversial as suppression and 
induction of insulin release have been reported (39,82,83).  
Additive and independently, PGC-1 and PGC-1 control mitocondrial density in neurons 
and, as mentioned above, PGC-1 acts neuroprotective under conditions of oxidative stress through its 
ability to detoxify ROS (60,84). Its beneficial effect was further shown in the context of amyotrophic 
lateral sclerosis (ALS) (85) whereas suppressed levels of PGC-1 have been reported in different 
neurodegenerative disorders like Huntington´s disease (86) and Alzheimer´s diesase (87). 
Consistently, global and brain-specific deficiency of PGC-1 causes striatal degenerative lesions that 
dysregulate systemic energy balance (54,88). Therefore, PGC-1 is not only implicated in peripheral 
but also in central regulation of energy metabolism.  
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Finally, PGC-1 has been associated with retinal susceptibility to light damage (89) and 
chondrogenesis (90) while osteoclast activation is coordinated by PGC-1 (91). A non-redundant 
function in proliferative growth has been assigned to PRC (92). The role of PGC-1 coactivators in 
skeletal muscle will be discussed in more detail below (see 1.1.4).  
 
 
1.1.3 Modulation of PGC-1 activity 
 
 PGC-1 coactivators translate various environmental stimuli into adaptive, transcriptional 
programs in different tissues. These external cues therefore induce PGC-1 expression through several 
molecular cascades. The signalling network involved has been best studied for PGC-1 and will be 
described in the following. CREB is a potent inducer of PGC-1 expression in different tissues (64) 
and binds to cAMP response elements (CRE) in the promoter region after being phosphorylated. 
Protein kinase A (PKA) can mediate this phosphorylation e.g. upon cold exposure and subsequent 3-
adrenergic signalling in BAT or after glucagon stimulation in liver (93). In skeletal muscle, 
calcium/calmodulin-dependent protein kinase type (CaMK) IV is able to phosphorylate CREB and 
augment PGC-1 transcription. CaMK IV activation occurs after exercise-mediated calcium release. 
Free, cytosolic calcium also induces calcineurin A (CnA) which enhances MEF2C and MEF2D 
binding to MEF2 sites in the PGC-1 promoter. As PGC-1 coactivates MEF2 on these sites, a 
positive regulatory loop controls PGC-1 expression (94). Negative regulation occurs via the 
recruitment of histone deacetylase (HDAC) 5 to MEF2 (95). Another important kinase in PGC-1 
transcription is p38/MAPK (96). Activated in response to exercise or PKA signalling, p38/MAPK 
targets MEF2 and activating transcription factor (ATF) 2, which both bind to their cognate response 
elements in the PGC-1 promoter and enhance transcription (97). As sensor of low energy levels in 
the cell, AMP-activated protein kinase (AMPK) is also active upon muscle contraction and promotes 
PGC-1 expression (98). An autoregulatory loop as described above for MEF2 also exists for PPARs: 
PPAR activation induces PGC-1 which coactivates PPAR on PGC-1´s own promoter in 
adipocytes (99). In skeletal muscle, PPAR/ is both a target of PGC-1 and coactivated by it on the 
PGC-1 promoter (99). Finally, PPAR governs the determination of brown adipocytes by inducing 
PRDM16 which in turn coactivates PPAR on the PGC-1 promoter (100). Positive feed-forward 
mechanisms are thus common in the induction of PGC-1 offering the possibility of signal 
amplification and fine-tuned expression.  
Repression of the PGC-1 gene has also been described: Activation of protein kinase B 
(PKB)/Akt upon insulin stimulation leads to phosphorylation of FoxO1 resulting in dissociation from 
insulin response elements (IREs) in the PGC-1 promoter and hence diminished expression (101). 
20
Introduction 
Furthermore, corepressor recruitment to the promoter suppresses PGC-1 transcription. Examples are 
SHP binding to ERR decreasing energy production in BAT (102) and nuclear receptor corepressor 
(NcoR) 1/HDAC3 docking to Rev-erb to block heme biosynthesis (103). A more general mechanism 
of repression is hypermethylation of non-CpG nucleotides in the PGC-1 promoter which is caused by 
DNA methyltransferase (DNMT) 3B and reduces mitochondrial content (104). 
 Besides changes in PGC-1 expression levels, the regulation of protein stability is of 
fundamental importance. Different post-translational modifications (PTMs) of PGC-1 and PGC-1 
that influence coactivator potential have been reported. These include phosphorylation, acetylation, 
methylation, GlcNAcylation, sumoylation and ubiquitylation. Phosphorylation can occur at several 
serine and threonine residues either enhancing or repressing PGC-1 activity (Fig. 3). Being a short-
lived and aggregation-prone protein (105), PGC-1 is stabilized by p38/MAPK phosphorylation (Fig. 
3) (106) and the interaction with the repressor p160 myb binding protein (p160 mbp) decreased 
resulting in transcriptional activation (107). As p38/MAPK also targets PGC-1 expression, this 
kinase acts in a dual mode of action with a fast (direct phosphorylation) and a sustained (induction of  
 
 
 
Figure 3 Post-translational modifications of PGC-1. From (110). 
 
 
expression) effect. Likewise, AMPK phosphorylates PGC-1 (Fig. 3) while at the same time spurring 
its expression (98). For NT-PGC-1 a similar mechanism was found: PKA-mediated phosphorylation 
(Fig. 3) diminishes nuclear export resulting in enhanced nuclear availability and stronger coactivation 
potential (43). Simultaneously, PKA activates CREB. This double regulation also exists reciprocally 
for PGC-1 deactivation. While Akt causes FoxO1 release from the PGC-1 promoter, it also 
phosphorylates PGC-1 directly (Fig. 3) to inhibit its recruitment to transcription factors (108). 
Another negative phoshphorylation is mediated by glycogen synthase kinase (GSK) 3 (Fig 3) (109).  
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A second PTM that impacts on PGC-1 activity is acetylation. The acetyltransferase general 
control of amino acid synthesis (GCN) 5 acetylates PGC-1 at multiple lysine residues (Fig. 3) 
rendering it inactive due to relocalisation to nuclear foci (111). Acetylation by GCN5 was also shown 
to repress PGC-1 activity (112). Opposed to GCN5, NAD-dependent protein deacetylase sirtuin 
(Sirt) 1 removes acetyl residues from PGC-1 (Fig. 3) resulting in higher transcription activation 
potential (113,114). As Sirt1 is an energy sensor, this is an important mechanism to secure cellular 
energy supply. Moreover, Sirt1 acts in concert with AMPK to control the energy status of the cell by 
co-ordinately activating PGC-1 (115).  
Polyubiquitylation targets proteins for proteasomal degradation which determines their 
stability within the cell. Skp1/Cullin/F-box cell division control 4 (SCF
Cdc4
) was shown to be a PGC-
1 E3 ubiquitin ligase (Fig. 3) and their interaction requires prior negative phosphorylation e.g. by 
GSK-3 (116). Ubiquitylation then leads to proteasomal degradation of PGC-1 in the nucleus thus 
abrogating its transcription activation capacity.  
Another negative PTM is SUMOylation at lysine 183 albeit without changing subcellular 
localisation or stability of PGC-1 (117). Presumably, SUMOylation enables a stable interaction with 
receptor-interacting protein (RIP) 140, a known repressor of PGC-1 activity (118).  
Finally, PGC-1 is activated by O-linked beta-N-acetylglucosylation (Fig. 3) (119) and 
arginine methylation by protein arginine methylatransferase (PRMT) 1 (Fig. 3) (120). The many 
possible PTMs and various combinations thereof show that a complex network converges on PGC-1 
to tightly control its activity.  
 
 
1.1.4 PGC-1 coactivators in skeletal muscle physiology 
 
Skeletal muscle is built up of several muscle bundles called fasciculi that are surrounded by 
connective tissue (epimysium) and attached to the bone by tendons (Fig. 4A). Each bundle comprises 
parallel running myofibers. These myofibers are postmitotic, syncytial cells that are formed by the 
fusion of mononucleated myoblasts (muscle stem cells / satellite cells) which line muscle fibers and 
retain the potential to regenerate injured muscle cells (121). Each myofiber contains numerous 
myofibrils (Fig. 4A). Myofibrils are linear sequences of sarcomers, the fundamental contractile unit of 
skeletal muscle. The appearance of these sarcomer repeats as distinct brighter and darker bands under 
the microscope gives skeletal muscle its striated pattern (121). Sarcomers are composed of the 
interdigitating myofilaments myosin and actin with actin being anchored in the Z disk (Fig. 4A). For 
contraction, these two filaments slide along each other thus shortening the muscle (Fig. 4B). 
Contraction is initiated after motor neuron excitation which results in an action potential and finally 
release of acetylcholine into the synaptic cleft at the neuromusulcar junction. This depolarizes the 
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muscle membrane (sarcolemma) at the motor end plate and causes a muscle action potential that 
propagates along the fiber (121). The sarcolemma has deep invaginations (transverse tubules) which 
lie in close proximity to the intracellular sarcoplasmic reticulum (Fig. 4A). Upon depolarization, 
voltage-gated dihydropyridine receptors in the sarcolemma of transverse tubules directly couple to and 
activate ryanodine receptors in the sarcoplasmic reticulum, which consequently release calcium into 
the cytoplasm. Free calcium then enables the sarcomer to contract (Fig. 4B). This occurs through 
binding of calcium to troponin thus changing the conformation of the troponin-tropomyosin complex 
that winds around actin and prevents myosin binding in the basal state (Fig. 4B 1). Upon calcium 
binding, the active sites on actin are exposed and the myosin heads form cross bridges (Fig. 4B 2) 
which subsequently move, sliding the filaments against one another (Fig. 4B 3). The tight link 
between electrical stimulation and muscle contraction is called excitation-contraction coupling. The 
interaction of myosin and actin is released by binding of ATP to the myosin head enabling another 
cycle of contraction (Fig. 4B 4). Contraction is terminated when calcium is pumped back into the 
sarcoplasmic reticulum (Fig. 4B 5) (121).  
 
 
 
Figure 4 Skeletal muscle structure and function. A. Organization of skeletal muscle in fasciculi (bundles), 
myofibers, myofibrils and sarcomers. Adapted from (122). B. Stages of muscle contraction according to the 
sliding filament theory. From (123). 
 
 
Skeletal muscle is a plastic organ and myofibers can be distinguished by the type of myosin 
they express. Type I or slow fibers appear red, are highly resistant to fatigue but produce relatively low 
maximal force while type II fibers appear white, fatigue rapidly but produce high maximal force (121). 
The latter can be further subdivided into type IIa (moderately fast), and type IIx (fast) fibers in 
humans, while rodents also posses type IIb (very fast) fibers. Corresponding to the different properties, 
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type I and IIa fibers rely on oxidative metabolism as energy source and exhibit high mitochondrial 
density while type IIx and IIb fibers mainly depend on glycolcytic metabolism (121).  
PGC-1 is abundant in skeletal muscle and especially enriched in slow / oxidative muscle 
fibers that contain high numbers of mitochondria. Forced expression converts white muscles with 
mainly fast fibers into red muscles with properties of slow type I and IIa fibers (124). PGC-1 is thus 
sufficient for a slow fiber type switch. PGC-1 on the other hand was shown to drive the formation of 
type IIx fibers that however still posses a relatively high oxidative capacity (125). In agreement with 
its role in oxidative myofiber determination, PGC-1 is transiently induced in skeletal muscle after a 
single bout of endurance exercise and chronically elevated in endurance trained muscle both in rodents 
and humans (126-128). This induction is caused by pathways that are active in contracting skeletal 
muscle including calcium signalling, p38/MAPK and AMPK (see 1.1.3) and in large part due to an 
increase in the alternative isoforms PGC-1-b and PGC-1-c (44). Elevated PGC-1 levels in turn 
mediate the major adaptation that skeletal muscle undergoes in response to endurance training (Fig. 5).  
 
 
 
Figure 5 Schematic overview of pathways and the most important proteins regulated by PGC-1 in skeletal 
muscle. From (130). 
 
 
These concern substrate supply, utilization, energy generation and protection of muscle fibers 
from damage. More precisely, formation of a larger proportion of oxidative fibers requires 
mitochondrial biogenesis which is coordinated by PGC-1 through induction of Tfam and nuclear 
encoded subunits of the ETC (Fig. 5 and see 1.1.2). During exercise, the initial phase of mitochondrial 
biogenesis is mediated by an activation of PGC-1 protein followed by a second phase characterized 
by elevated PGC-1 gene expression (129). 
To secure cellular energy supply under conditions of continuous muscle contraction, the 
induction of mitochondria is accompanied by an induction of enzymes involved in fatty acid uptake 
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and oxidation like CD36, CPT1 and MCAD (Fig. 5 and see 1.1.2) (131). In addition, expression of the 
glucose transporter GLUT4 is elevated by PGC-1 in vitro (36) and in vivo (131) resulting in higher 
glucose transport into the muscle cell (Fig. 5). At the same time, PGC-1 mediates a rise in pyruvate 
dehydrogenase kinase (PDK) 4 which inhibits the pyruvate dehydrogenase complex (PDC) thus 
shutting down glucose oxidation (Fig. 5) (132). Therefore, PGC-1 favours fatty acids as energy 
substrate coherent with their role in aerobic exercise. Excess glucose that cannot be diverted through 
glycolysis, is then stored in form of glycogen (Fig. 5) (131,133). As higher mitochondrial activity is 
accompanied by the production of larger amounts of ROS, which are potentially detrimental for the 
cell, PGC-1 also acts on ROS detoxifying enzymes like Sod2 (Fig. 5) thus protecting the cell from 
oxidative damage (134). Moreover, ROS were shown to be important for the induction of PGC-1 
thus forming a negative feedback loop (135). Apart from metabolic fluxes within the cell, PGC-1 
ensures tight linkage between muscle and nerve through regulation of genes of the neuromuscular 
junction and promotion of acetylcholine receptors clustering at the motor end plate (136). 
Furthermore, PGC-1 potently induces vascular endothelial growth facto (VEGF) (137). VEGF 
mediates angiogenesis thus maintaining sufficient nutrient and oxygen supply to muscles during 
endurance exercise (138). In conjunction, all these PGC-1-mediated changes enable muscle cells to 
adapt to endurance training. Functionally, this translates into a higher endurance capacity of PGC-1 
skeletal muscle-transgenic mice (MCK) (133) whereas the skeletal muscle-specific deletion of PGC-
1 (MKO) deteriorates performance (139). Inflammatory changes in that latter model will be 
discussed below (see 1.3).  
In contrast to PGC-1, PGC- is not uniformly influenced by exercise. Still, when 
overexpressed in skeletal muscle, genes involved in oxidative phosphorylation and fatty acid oxidation 
are upregulated resulting structurally in higher mitochondrial density and functionally in a better 
endurance performance (125). Inversely and resembling the MKO model, skeletal muscle-specific 
PGC-1 deletion causes lower endurance capacity (140). A combined global deficiency of PGC-1 
with muscle-specific gene ablation of PGC-1 aggravates this phenotype with a very severe exercise 
deficit, strongly reduced oxidative capacity and mitochondrial structure and function derangements. 
However, fiber type determination is only slightly changed towards more type I fibers (140). Like 
PGC-1, PGC-1 was also shown to induce angiogenesis (141). It therefore appears that PGC-1 and 
PGC-1 share some properties in skeletal muscle. The role as “exercise factor” is however unique to 
PGC-1 and such a clear function could not be assigned to PGC-1 so far. 
Apart from the regulation of endurance adaptations, PGC-1 was also shown to be a target of 
the myogenic regulatory MyoD in terminal muscle differentiation (142). Furthermore, PGC-1 has an 
impact on the circadian rhythm by stimulating clock genes thus integrating the cell-autonomous clock 
and energy metabolism (143). Interestingly, MyoD itself is a target of circadian transcription activators 
and their disruption perturbs muscle function as well as PGC-1 and PGC-1 expression (144). 
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Further studies are needed to investigate the mutual dependencies of PGC-1 coactivators, MyoD and 
clock genes to define their contribution to skeletal muscle physiology.  
 
 
1.1.5 PGC-1 coactivators in skeletal muscle pathology 
  
Skeletal muscle plasticity does not only comprise the ability to adapt to different kinds of 
training (strength versus endurance) with respective enrichment of type II or type I fibers, but also the 
capacity to match different amounts of use. While endurance training induces PGC-1, muscle disuse 
or unloading e.g. through denervation results in muscle wasting (atrophy) with markedly decreased 
PGC-1 and PGC-1 levels (145,146). Concomitantly, the ubiquitin ligases atrogin-1 and muscle-
specific RING finger protein (MuRF) 1 are induced mediating higher protein degradation rates that are 
characteristic for the atrophic state. Overexpression of PGC-1 and PGC-1 is able to suppress both 
atrogin-1 and MuRF-1 resulting in lower protein degradation rates and thus rescues muscle cells from 
atrophy in vitro and in vivo (147,148). Mechanistically, the suppression of FoxO3 transcriptional 
activity by both coactivators is responsible for diminished atrogen expression. Low levels of PGC-1 
have further been shown in a number of muscle wasting conditions like diabetes, uremia and cancer 
cachexia (148) as well as after statin treatment which is used against hypercholesterolemia and induces 
muscle breakdown as a side effect. This statin-induced muscle damage can also be prevented by PGC-
1 overexpression (149). It is therefore evident, that PGC-1 and PGC-1 are able to preserve muscle 
structure and function under conditions where these are usually lost. This observation extends to 
sarcopenia denoting progressive muscle loss with age. Old mice with skeletal muscle-specific 
overexpression of PGC-1 perform better in exercise tests than old wild-type mice exhibiting 
improved mitochondrial function and a higher degree of overall muscle integrity (134).  
 Besides its beneficial effect in muscle wasting, PGC-1 also conveys improved phenotypes in 
some inherited muscle disorders. First, Duchenne muscular dystrophy (DMD) is caused by an X-
linked mutation in dystrophin which anchors the cytoskeleton in the extracellular matrix. The mutation 
renders the protein defective thus leading to degeneration of muscles and premature death. Skeletal 
muscle-specific overexpression of PGC-1 improves symptoms of sedentary as well as exercised mdx 
mice (a mouse model for DMD) with markedly decreased fiber damage (136). Second, mitochondrial 
myopathies stem from mutations in mitochondrial DNA generating deficits in energy metabolism. 
Again, skeletal muscle-specific overexpression of PGC-1 ameliorated muscle function with higher 
ATP levels and delayed onset of disease (150). A similar effect could be achieved by endurance 
exercise (151). Third, Huntington´s disease (HD) is characterized by weight loss due to loss of muscle 
mass early on in HD etiology. In mouse models of HD and HD patients, PGC-1 was found to be 
repressed in skeletal muscle. Overcoming this repression by ectopic expression of PGC-1 from an 
adenoviral vector improves pathology in the mouse model (152). Targeting PGC-1 and PGC-1 
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pharmacologically or increasing PGC-1 by endurance training when possible thus represents a 
promising treatment strategy in a number of skeletal muscle disorders.  
 Apart from muscle disorders, metabolic diseases are linked to dysregulation of PGC-1 
coactivators. Insulin resistance is a hallmark of type 2 diabetes and arises from overnutrition with 
constant oversupply of fatty acids that mitochondria do not accomplish to oxidize completely. 
Therefore, lipid metabolites like diacylglycerol accumulate within muscle cells activating serine 
kinases like protein kinase C (PKC) and others. These kinases phosphorylate insulin receptor substrate 
(Irs) 1 at inhibitory serine residues thus blocking tyrosine phosphorylation upon insulin binding to the 
insulin receptor. This in turn impairs phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) and 
downstream Akt activation which blunts GLUT4 recruitment to the membrane. Consequently, insulin-
stimulated glucose uptake into the muscle is diminished contributing to hyperglycaemia in diabetes. 
Obesity is a common risk factor for diabetes and both genetic and acquired obesity lead to 
downregulation of PGC-1 and PGC-1 in skeletal muscle of rodents, presumably due to high levels 
of saturated free fatty acids (FFAs) (153). Furthermore, a coordinate suppression of genes involved in 
oxidative phosphorylation has been observed in human diabetic patients alongside a reduction of both 
PGC-1 and PGC-1 levels in some, but not all studies (154-156). Along these lines, a moderate 
increase of PGC-1 in skeletal muscle improves insulin sensitivity by selectively augmenting fatty 
acid oxidation in subsarcolemmal but not intermyofibrillar mitochondria (157). The relation between 
PGC-1 coactivators and insulin resistance is however more complex. Mice from two independent lines 
with a global PGC-1 deletion are less susceptible to diet-induced obesity and stay lean due to 
profound hyperactivity caused by striatal lesions in the brain (54,55). To circumvent this phenotype, a 
model with PGC-1 deletion exclusively in skeletal muscle has been developed. Yet, these mice 
display increased peripheral insulin sensitivity even though they become glucose intolerant on a high 
fat diet because of muscle-islet crosstalk: Muscle-derived interleukin 6 (IL-6) likely impairs insulin 
secretion from pancreatic  cells. The lack of insulin then prevents sufficient uptake of glucose into 
the muscle (158). Inversely, MCK mice also exhibit a complex phenotype as they are more prone to 
diet-induced insulin resistance than wild-type mice. The reason for inhibited insulin signalling 
presumably is an increased content of intracellular lipids which accumulate because of unbalanced 
lipid supply that exceeds mitochondrial fatty acid oxidation capacity (159). During aging however, this 
same model preserves insulin signalling and is protected from age-associated insulin resistance (134). 
Correspondingly, in a twin study, both PGC-1 and PGC-1 were determined to be reduced by age 
representing an explanation for an increased risk of diabetes at older age (160). This decline is further 
associated with the common Gly482Ser variant in PGC-1. Genetic linkage studies that tried to 
establish a relationship between this polymorphism and diabetes however yielded inconsistent results 
(161,162) and no functional consequence of the serine form is detectable (163). Analogous, a variant 
of PGC-1 (Ala203Pro) was associated with obesity in one study (164) but protection from diabetes in 
another study (165). In contrast, polymorphisms in the promoter of the PGC-1 gene were shown to 
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contribute to diabetes in Koreans and Austrians (166,167). Concerning PGC-1, transgenic expression 
protects mice from diet-induced and genetically determined obesity (21), however, no direct influence 
on glucose metabolism is evident as global deletion of the protein does not affect whole body glucose 
or insulin tolerance on high fat diet (56), nor does a hypomorphic mutation influence these parameters 
or muscle glucose uptake (168). Both strains do however develop hepatic insulin resistance due to 
accumulation of lipids in the liver. Surprisingly, the double deletion of PGC-1 and PGC-1 does not 
have an impact on glucose or insulin tolerance neither on chow nor on high fat diet (HFD). As the 
model employs the global PGC-1 deletion as background for muscle-specific PGC-1 gene ablation, 
the same concerns (cerebral lesions) apply and weight gain between the groups might be different 
possibly explaining the phenomenon (140).  
On the contrary, treatment of mice with resveratrol protects them from diet-induced obesity 
and insulin resistance. This effect is due to higher oxidative capacity of their muscle fibers induced by 
Sirt1-mediated PGC-1 deacetylation and consequently higher PGC-1 activity (169,170). The 
insulin-sensitizing properties of thiazolidinediones are also partially ascribed to an induction of PGC-
1 and the concomitant restoration of mitochondrial bioenergetics in muscle e.g. in db/db mice (171). 
It therefore appears that targeting PGC-1 can be beneficial to counteract metabolic diseases. The 
therapeutic window of PGC-1 induction is however somewhat narrow and an overkill of PGC-1 in 
muscle acts rather detrimental. Dysregulation of PGC-1 in other organs that point in the opposite 
direction e.g. excess PGC-1 in liver and pancreas in diabetes further complicate treatment strategies 
aimed at PGC-1 (172).  
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1.2. Inflammation 
 
1.2.1 Molecular mechanisms of inflammation: the NF-B pathway 
 
 Inflammation has evolved to protect the organism from harmful insults by initiating an 
immune response that drives defence and repair mechanisms of the body, and is characterized by 
redness (rubor), swelling (tumor), heat (calor), and pain (dolor) due to higher blood flow to the injured 
site. During the course of an inflammation, a complex interplay between cells of the injured tissue and 
cells of the innate and adaptive immune system orchestrates clearance of pathogens and wound 
healing. Innumerous signals participate in this process depending on the site and degree of injury, the 
pathogen(s) involved, the infection history of the individual etc. In this context, cytokines play an 
important role, as they mediate cell-cell communication and are able to elicit, potentiate or dampen an 
inflammatory reaction thus exerting major influence on the progression of the inflammatory reaction. 
 At the molecular level, the NF-B pathway is central to inflammatory processes. Induced by 
various external stimuli and therefore downstream of different cell surface receptors, signals converge 
 
 
 
Figure 6 The NF-kB pathway. A. Members of the NF-B, IB and IKK family, their domains and selected 
PTMs. B. Signalling cascade of the NF-B pathway. Adapted from (173). 
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at inhibitor of B (IB) kinase (IKK) phosphorylation (Fig. 6A and B). Activated IKK subsequently 
phosphorylates IB, which forms a cytosolic complex with an NF-B dimer. Phosphorylation-induced 
polyubiquitylation targets IB for proteasomal degradation consequently releasing NF-B and 
allowing for nuclear translocation (173). In the nucleus, NF-B then binds to B sites and initiates 
transcription of pro-inflammatory cytokines (Fig. 6B). As IKK, IB and NF-B all constitute protein 
families with several members, a multitude of different signalling possibilities abounds. The NF-B 
family comprises 5 members, namely RelA/p65, RelB, c-Rel, p100/p52 and p105/p50 that all share an 
N-terminal Rel homology domain (RHD) (Fig. 6A). These subunits form homo-and heterodimers that 
bind to DNA at the B consensus site 5´-GGGRNWYYCC-3´ (where N is any base, R is purine, W is 
adenine or thymine, and Y is pyrimidine). Only p65, RelB and c-Rel additionally contain a C-terminal 
transactivation domain (TAD) which enables them to initiate transcription once bound to DNA,  
whereas p50 and p52 as homodimers act repressive as they lack this TAD (173). The most common 
and best studied dimer is p65/p50.  
The IB family comprises the typical members IB, IB and IB and the atypical 
members IB, B-cell lymphoma (Bcl) 3, and IB which all possess several ankyrin repeat domains 
(Fig. 6A). The typical members sequester NF-B dimers in the cytosol thus preventing transcription 
from b site in unstimulated cells (174,175). Upon stimulation, the typical IBs are degraded at 
different rates, whereby IB has the fastest kinetics (176,177). This leads to exposure of the nuclear 
localization sequence on NF-B dimers and their entry into the nucleus where they drive transcription 
(Fig. 6B). As the IBs are also NF-B target genes, their resynthesis terminates the signal representing 
a negative feed-back loop (178). Again, IB, IB and IB display different resynthesis kinetics 
(179).  
The atypical IBs all act in the nucleus by binding to NF-B dimers and thus have quite 
different functions from typical IBs. They confer either inhibitory or activating properties to the 
dimers they bind to, causing potentiation or repression of transcription. Bcl-3 contains a TAD (in 
contrast to other IBs) and interacts with p50 or p52 homodimers in the nucleus. This enables 
transcription driven by otherwise repressive NF-B dimers (180). However, Bcl-3 might also displace 
p50 and p52 homodimers from DNA thus allowing active NF-B forms to bind to these sites or 
stabilize the repressive forms on DNA with the opposite effect (181). These contradictory functions of 
Bcl-3 depend on the cellular context and are likely regulated by PTMs. Outside of the NF-B 
pathway, Bcl-3 also acts as cofactor for other transcription factors. IB is induced by some, but not 
all stimuli of the NF-B pathway and associates mainly with p50 homodimers. Although IB does 
not contain a TAD, it transactivates p50 homodimers while inhibiting p65-containing NF-B 
complexes (182). The precursor proteins p100 and p105 can also be classified as IBs as they contain 
ankyrin repeats domains and serve the purpose of preventing NF-B dimers from entering the nucleus 
(183). While constitutive processing of p100 and p105 yields the NF-B subunits p52 and p50, 
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respectively (184,185), unprocessed p100 associates with p65/p50 dimers acting as classical IB, 
which is entirely degraded upon stimulation (186). Both, p100 and p105 also form dimers with various 
NF-B subunits and retain them in the cytoplasm: RelB selectively binds to p100, and induced 
processing to p52 generates the RelB/p52 dimer that has an important function in the alternative 
pathway (see below). Likewise, p105 associates with cytosolic p65 or c-Rel and prevents nuclear 
entry. Stimulus-dependent processing of p105 then yields the p65/p50 or c-Rel/p50 dimers that 
translocate to the nucleus and activate transcription (187). Finally, an alternative transcript of the p105 
gene gives rise to IB whose role is not yet defined (188). 
The IKK family consist of the three members IKK, IKK and IKK/NF-B essential 
modulator (NEMO) (Fig. 6B). IKK (189) and IKK (190) are closely related and both contain a 
kinase domain rendering them catalytically active while NEMO is structurally unrelated and acts as 
regulatory subunit (191). Two major pathways have been described in NF-B signalling: the canonical 
and the noncanonical or alternative pathway. Canonical signalling leads to activation of the 
heterotrimeric IKK complex consisting of all 3 IKK subunits. IKK-mediated phosphorylation of 
IB subsequently frees p65/p50 that further acts as transcription factor in the nucleus (192). While 
IKK is dispensable for canonical signalling, it is required for noncanonical NF-B activation (193). 
Thereby and independent of NEMO, IKKdimers phosphorylate p100 which complexes RelB. 
Processing to p52 then results in formation of the RelB/p52 dimer that translocates to the nucleus and 
induces a subset of NF-B target genes (194). The multitude of possible interaction within the NF-B 
pathway illustrates the complexity of inflammatory signalling but at the same time allows a specific 
and appropriate reaction to different kinds of injury and infection.  
Upstream of IKK, various receptors transmit signals that lead to NF-B activation: Cytokines 
produced either by cells of the immune system or by cells from an affected tissue signal via cytokine 
receptors. Tumor necrosis factor (TNF)  (195) is one such cytokine that has a well-established role in 
inducing inflammatory reactions and binds to TNF receptor (TNFR) 1 and TNFR2 (196). Upon 
stimulation TNFR1 oligomerizes and recruits TNFR-associates death domain protein (TRADD) (197) 
via death domain (DD) interaction. TRADD acts as a platform to assemble the NF-B-activating 
complex. Therefore, TNFR-associated factor (TRAF) 2 (197), the kinase receptor interacting protein 
(RIP) 1 (198) and the ubiquitin ligases inhibitor of apoptosis (cIAP1 and cIAP2) (199) sequentially 
bind to TRADD. Lysine 63-linked (200) ubiquitylation of RIP1 then facilitates recruitment of 
transforming growth factor (TGF)  activating kinase (TAK) 1 and IKK resulting in IKK activation by 
TAK-1-dependent and transautophosphorylation (Fig. 6B) (201). In the absence of cIAP 1/2, TNFR1 
may trigger apoptosis via recruitment of Fas–associated DD (FADD) and caspase-8 (197). TNFR2 
ligation also causes oligomarization but the receptor does not contain a DD (202). Therefore, direct 
association with TRAF2 results in the recruitment of the components of the IKK activating complex 
(RIP1, cIAP, TAK1). TNFR1 and TNFR2 are both also able to induce activator protein (AP) 1 
signalling via c-Jun N-terminal kinase (JNK) (203).  
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Receptors that recognize conserved bacterial or viral structures, so-called pathogen-associated 
molecular patterns (PAMPs) belong to the toll-like receptor (TLR) family. So far, 12 different 
mammalian TLRs have been identified with the following specificities: TLR2 forms heterodimers 
with TLR1 or TLR6 recognizing bacterial lipoproteins. TLR4 in conjunction with CD14 reacts to 
lipopolysaccharide (LPS), TLR5 to flagellin and TLR9 to unmethylated CpG all characteristic of 
bacterial pathogens. As these are mostly outside of the cell, the corresponsing TLRs are located on the 
cell surface (except for TLR9). TLR3, TLR7 and TLR8 recognize viral RNA (TLR3: double stranded, 
TLR7 and TLR8: single stranded) and are therefore located within the cell (204). Upon ligation, TLRs 
recruit adaptor proteins via Toll IL-1R (TIR) domains. For most TLRs, these adaptors are myeloid 
differentiation primary response gene (Myd) 88 and Myd88 adaptor-like protein (Mal) (205,206), 
which in turn associate with IL-1R-asscoiated kinase (IRAK) 4 that further binds IRAK1 (206). This 
complex is responsible for phosphorylation of TRAF6 (207), which finally leads to the TAK1 and 
IKK recruitment and subsequent activation (208). Downstream of TLR3 and TLR4, TIR domain-
containing adaptor molecule (TRIF) and TRIF-related adaptor molecule (TRAM) act as adaptor 
proteins to induce TRAF3-dependent interferon expression via interferon regulatory factor (IRF) 3 
(209-211). TRIF may also activate RIP1 and thus induce the NF-B pathway (209). Free fatty acids 
share structural similarity with bacteria-derived ligands and therefore activate TLR2 and TLR4 in the 
absence of pathogens (212,213). As FFAs are elevated in plasma of obese individuals, this aberrant 
activation represents one link between metabolic dysregulation and inflammatory signalling. 
In lymphocytes, the alternative NF-B pathway has been characterized downstream of CD40 
(214), lymphotoxin  receptor (LTR) (215), B-cell activating factor receptor (BAFFR) (216) and 
receptor activator of NF-B (RANK) (217). These signals lead to activation of NF-B inducing kinase 
(NIK), which in turn phosphorylates IKK thus initiating p100 processing and noncanonical 
signalling (Fig. 6B).  
 Another layer of complexity is added to NF-B signalling by PTMs. Due to its particular 
importance, p65 has been studied extensively in this regard and inducible phosphorylation as well as 
acetylation (218), ubiquitylation (219), prolyl isomerisation (219), poly(ADP-ribosyl)ation (220), 
monomethylation (221) and S-nitrosylation (222) were reported. These PTMs affect subcellular 
localization, the stability of DNA-bound NF-B dimers or their ability to interact with coactivators 
and corepressors thus fine-tuning inflammatory responses. Phosphorylation of p65 at serine 276 within 
the RHD is crucial for the recruitment of CBP/p300 and the ensuing transcriptional activation (223). 
PKA (223) and mitogen- and stress-activated protein kinase (MSK) 1 (224) can phosphorylate this 
residue upon stimulation whereas a mutation to alanine abrogates the inducible expression of a subset 
of target genes (225). In turn, this phosphorylation is a prerequisite for acetylation of lysine 310, which 
also facilitates transcription by recruiting HATs and displacing HDACs from NF-B (226). IKK 
(227), IKK (228,229), IKK (230), TRAF family member-associated NF-B activator (TANK) 
binding kinase (TBK) 1 (230) and ribosomal S6 kinase (RSK) 1 (231) phosphorylate p65 at serine 536 
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within the TAD. Analogous to serine 276, serine 536 phosphorylation propagates CBP/p300 
association resulting in augmented transcription while mutation to alanine abolishes this effect and 
reduces p65 acetylation at lysine 310 (232). In this state, corepressors like NCoR1 or silencing 
mediator of retinoic acid and thyroid hormone receptor (SMRT) preferentially bind to p65 and inhibit 
transcription. Importantly, changes in transcriptional activation through shifted coactivator/corepressor 
balance can occur without alterations in DNA binding of NF-B. Transcriptional activity is further 
modulated by inducible phosphorylation of serine 529 within the TAD by casein kinase (CK) II (233) 
and serine 311 within the RHD by PKC (234). Several other serine and threonine residues within p65 
can be phosphorylated, the functional consequences of these PTMs however remain poorly defined to 
date.  
 
 
1.2.2 Inhibition of inflammation: interference with the NF-B pathway 
 
Inflammatory reactions are transient responses that protect against injury and infection but if 
rendered chronic, they in fact become detrimental to the organism. Therefore, tight control 
mechanisms govern inflammation and may inhibit the process at several levels. Concerning the NF-B 
pathway, interference with the signalling cascade can occur during virtually all steps. Some important 
negative regulators of NF-B will be discussed in the following section grouped by their mode of 
action. 
Enrichment of typical IB proteins (see 1.2.1) fosters the retention of NF-B dimers in the 
cytosol thus blocking nuclear entry and binding to DNA which blunts pro-inflammatory gene 
expression. The same applies to p100 and p105 elevation as they bind cytosolic NF-B subunits; 
however, the effect depends vitally on the specificity of this binding because an elevation of RelB/p52 
for example displaces p65-containing complexes from B sites (235). As the different dimers do not 
have the same transcriptional activation capacity on a promoter, this might decrease target gene 
expression but can also sustain the response as RelB/p52 is resistant to IB resynthesis (235). 
Induction of atypical IBs can also inhibit pro-inflammatory gene expression by stabilizing repressive 
p50 or p52 dimers on DNA thereby blocking access of activating dimers to B sites (181,182,236). 
These effects are target gene-specific and therefore always affect only a subset of NF-B inducible 
genes.  
Ubiquitylation has a dual function in NF-B signalling: Lysine 48-linked polyubiquitylation 
targets proteins for proteasomal degradation. This might initiate target gene expression as in case of 
IBs or terminate the signal e.g. through degradation of p65 (237). Ubiquitylation of p65 is mediated 
by suppressor of cytokine signalling (SOCS) 1 whose overexpression blocks IL-1-dependent NF-B 
activation (219). In contrast, regulatory lysine 63-linked ubiquitylation activates distinct steps in the 
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signalling cascade and therefore regulates target gene expression positively. A20 is an ubiquitin 
editing enzyme and A20-deficient mice develop severe inflammation (238). That is due to the ability 
of A20 to remove regulatory lysine 63-linked ubiquitin modifications from RIP1 and instead attach 
lysine 48-linked degradative ubiquitin chains which terminates TNFR signalling (239). A similar 
mechanism has been reported downstream of TLRs where A20 removes regulatory ubiquitylation 
from TRAF6 again shutting down the signal (240).  
Multiple phosphorylation events are part of NF-B activation and therefore, kinase 
dysregulation may impede signalling. By blocking access of the IKK complex -arrestin inhibits 
phosphorylation of IB and subsequently its degradation thus diminishing NF-B activation (241). 
Further downstream, kinases that mediate p65 phosphorylation (see 1.2.1) can be modulated. Among 
these, MSK1 is regulated by p38. MSK kinase (MK) 2 and its substrate heat shock protein (Hsp) 27 
sequester p38 in the cytosol thus preventing p65 hyperphosphorylation (242). Moreover, Akt 
signalling has been implicated in inflammatory gene expression downstream of TNFR (243). The 
effect of Akt on NF-B activation is dependent on both IKK and IKK and on serine 536 within the 
TAD of p65 (244,245). As canonical signalling relies on IKK, IKK-deficient MEFs can neither 
phosphorylate IB nor p65 while IKK-deficient MEFs normally degrade IB but are still unable 
to phosphorylate p65 which blunts transcription from NF-B-inducible promoters (245). Although 
phosphorylation of p65 appears critical in NF-B activation and several kinases that target p65 have 
been identified, knowledge about phosphatases that remove this modification is scarce. Inhibition of 
protein phosphatase (PP) 1 and PP2A by calyculin A (246) or okadaic acid (OA) (247) leads to an 
accumulation of serine 536-phosphorylated p65 in the basal state while inducible serine 536 
phosphorylation cannot be released under these conditions. Therefore, PP1 and PP2A target p65 but 
their substrate specificity is rather broad. The only p65-specific serine phosphatase discovered so far is 
Wip1. Wip1 dephosphorylates p65 at serine 536 and mice lacking this phosphatase display increased 
NF-B target gene expression alongside higher p65 phosphorylation levels (248).  
The importance of p65 phosphorylation derives from the ability of the phosphoprotein to 
recruit transcription coactivators. The exchange of corepressors for coactivators depends on transducin 
-like protein 1X (TBL1)/TBL-1-related protein (TBLR) 1 which mediate binding of the ubiquitin-
proteasome complex to corepressor followed by their degradation (249). Sustained binding of 
corepressor like SMRT to p65 conversely inhibits transcription of pro-inflammatory factors (250) as 
SMRT recruits HDAC3. This interaction is disrupted if IKK phosphorylates SMRT (232). 
Furthermore, competition for coactivators has been proposed as model to limit transcriptional 
activation. For example, p53 also employs CBP/p300 from a limited pool decreasing the chances of 
p65 to interact with CBP (251). This transcriptional crosstalk is further refined by IKK (252) and 
GSK3 (253). 
Lastly, transrepression through NRs is a potent mechanism to dampen inflammatory gene 
expression. Activation of PPAR was accordingly shown to reduce expression of IL-6, 
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cyclooxygenase (COX) 2, vascular cell adhesion molecule (VCAM) 1 and other inflammatory factors 
in different cell types (254,255) while mice with a PPAR deletion react hypersensitive to LPS (256). 
Similarly, PPAR ligands strongly inhibit expression of pro-inflammatory mediators (257,258) and 
glucocorticoids that signal via GR exert well-established anti-inflammatory effects (259,260). In 
contrast to NR transcriptional activation, transrepression does not require DNA binding, and the 
pathways targeted (NF-B and AP-1) are not interrupted upstream but modulation commonly occurs 
in the nucleus at the level of DNA-bound transcription factor.  
Several molecular mechanisms of transrepression were established so far, some of which 
resemble inhibitory processes also employed by other factors that are described above. First, NRs may 
induce IB (Fig. 7a) in a DNA-binding dependent or –independent manner as shown for PPAR 
thus terminating NF-B dependent gene expression (261-264). Second, competition for a limiting pool  
 
 
Figure 7 Molecular mechanisms of transrepression. Adapted from (265). 
 
 
of coactivators like for example CBP (Fig. 7b) can entice these coactivators away from NF-B and 
result in mutual antagonism between inflammatory and NR pathways (266,267). Coactivators are also 
able to directly recruit NRs to NF-B resulting in transrepression as reported for GR and nuclear TR-
interacting protein (nTrip) 6 (268). Third, direct interaction between NRs and inflammatory 
transcription factors can interfere with activation of pro-inflammatory promoters hindering DNA-
binding of NF-B or AP-1 (269). In particular, downstream of TLR4, IRF3 requires p65 as 
transcription cofactor that can be tethered by GR (Fig. 7c) (270,271). IRF3 might conversely act as a 
cofactor for p65 and this interaction is also sensitive to GR blockade as direct binding of GR to p65 
precludes IRF3 recruitment (Fig. 7d) (271). GR transrepression can be potentiated by secondary 
recruitment of cofactors like glutamate receptor-interacting protein (GRIP) 1 (272); binding of NUR-
related factor (Nurr) 1 to p65 and further recruitment of CoREST constitutes a similar mechanism 
limiting inflammatory gene expression in microglia and astrocytes (273). Competition between GR 
and the transcription elongation factor P-TEFb explains the repressive effect of GR on the IL-8 
promoter. Although RNA polymerase II is recruited, GR prevents phosphorylation of the C-terminal 
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domain of RNA polymerase II which is a prerequisite for elongation (Fig. 7e) (274,275). Forth, 
chromatin remodelling plays a role in transrepression as reported for the IL-1 promoter. GR recruits 
HDAC2 to NF-B in this promoter fostering corepressor complex stabilization and transcriptional 
repression (Fig 7f) (276,277). Finally, inhibition of corepressor clearance from DNA-bound NF-B 
constitutes a complex mechanism of transrepression: In the basal state, NF-B is occupied by a 
corepressor complex that undergoes proteasomal degradation upon stimulation and further 
replacement by coactivaotrs. Proteasomal degradation of this corepressor complex can be inhibited by 
PPAR and LXRs. This requires ligand-dependent SUMOylation which enhances the affinity of 
PPAR or LXRs for NcoR/HDAC resulting in decreased inflammatory gene expression (Fig. 7g) 
(278,279). LXRs are also implicated in transrepression of signal transducer and activator of 
transcription (STAT) 1 downstream of interferon signalling (280). All the abovementioned 
mechanisms are examples of transrepression. A unified model that would explain under which 
conditions different NRs act transrepressive, how different stimuli (like TNF or TLR ligation) 
contribute and how target genes-specificity is achieved still needs to be developed.  
 
 
1.2.3 Macrophage polarization 
 
Macrophages are cells of hematopoietic origin that serve vital functions in tissue homeostasis 
and immune defence. Their precursors develop in the bone marrow from hematopoietic stem cells 
through multipotent progenitor stages committing to the myeloid lineage. Under the influence of 
macrophage colony-stimulating factor (MCSF), these progenitors differentiate into monoblast, and 
further into pro-monocytes and monocytes that leave the bone marrow to become circulating 
peripheral blood mononuclear cells (PBMCs) (281). Under homeostatic conditions, PBMCs invade 
different organs and terminally differentiate thus replenishing the pool of tissue-resident macrophages 
(282). These may be activated in response to different signals like injury or infection. During an 
inflammation, more PBMCs are attracted to the inflamed site by chemokines and differentiate into 
inflammatory macrophages that support clearance of pathogens and tissue debris by phagocytosis 
(281,282). They further contribute to the inflammatory process by secreting specific cytokines. There 
is evidence that at least two subsets of circulating monocytes exist which differ in their expression of 
surface markers like lymphocyte antigen (Ly) 6C (282). How these monocyte subsets give rise to 
different macrophage population is however not fully understood yet. 
Macrophage diversity is evident from their appearance in different tissues, e.g. Kuppfer cells 
in liver, alveolar macrophages in the lungs and microglia in the nervous system. Further plasticity 
abounds in immune activation with two types of macrophages generally distinguishable from one 
another: classically and alternatively activated cells, also referred to as M1 and M2 macrophages. This 
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classification follows the Th1/Th2 paradigm established in T cell biology reflecting a highly 
inflammatory, cytotoxic or a immunomodulatory, humoral immune response, respectively (283). M1 
macrophages are therefore primed by interferon (IFN)  (284) and further activated by cytokines like 
TNF or pathogenic signals like LPS that signal via TLRs (285). This classical activation augments 
phagocytic activity leading to engulfment of pathogens and necrotic cells. Concomitantly, production 
of toxic intermediates like nitric oxide (NO) and ROS is increased to effectively destroy pathogens 
within phagolysosomes (286). High antigen presentation capacity complements the ability of these M1 
cells to sustain an adaptive type 1 immune reaction. This is further fostered by the cytokine profile 
they start to express: High levels of IL-12 contribute to Th1 polarization while neutrophils, natural 
killer cells, and activated T cells are attracted by chemokines like macrophage inflammatory protein 
(MIP) 1/CCL3, CXCL10 or IL-8 (285). The pro-inflammatory environment created at the site of 
infection is preserved by secretion of TNF, IL-6 and IL-1 while the release of proteolytic enzymes 
facilitates degradation of extracellular matrix components (281,285). Therefore, permanent M1 
macrophages activation may lead to profound tissue damage.  
Conversely, M2 macrophages are activated in a Th2 cytokine environment. Originally 
characterized in response to treatment with IL-4 as macrophages that are less inflammatory than those 
activated by IFN (287), alternative activation became an umbrella term for several forms of non-M1 
cells. They all share low IL-12 and medium to high IL-10 expression but other than that have quite 
divergent traits. Several criteria to subdivide M2 macrophages have been proposed either according to 
function (host defence, wound healing and immune regulation) (281) or according to stimulus 
(282,285). First, macrophages that are activated in response to IL-4 or IL-13 are termed M2a. They 
secrete low levels of pro-inflammatory cytokines like TNF, IL-6 or MIP-1 but high levels of anti-
inflammatory IL-10, IL-1 receptor antagonist (IL-1Ra) and decoy IL-1RII. Moreover, release of the 
chemokines CCL17, CCL18, CCL22 and CCL24 attracts cells involved in type 2 immune responses 
like Th2 cells, regulatory T cell, basophils and eosinophils (288-290). Intracellularly, arginase is 
induced which metabolizes arginine to ornithin (a precursor of polyamines) and inhibits NO 
production thus ensuring efficient wound healing and helminthic parasite clearance (286). Second, 
macrophages that are activated in response to immune complexes and TLR or IL-1R ligation are 
termed M2b (291). These cells retain higher levels of pro-inflammatory cytokines (TNF, IL-6, IL-1, 
but not IL-12) alongside a potent IL-10 and a selective CCL1 release (292). CCL1 acts on Th2 and 
regulatory T cells as well as eosinophils that all express CCR8. M2b macrophages therefore play a 
predominantly immunoregulatory role (293). Third, macrophages activated by IL-10 are termed M2c. 
They share low pro-inflammatory cytokine expression and arginase induction with M2a cells and 
further propagate the IL-10 signal. IL-10 has an important role in uncoupling chemokine receptors 
which renders M2c macrophages unresponsive to chemokines and converts them into a mode of 
deactivation (294). Their capacity to act on B cells is caused by expression of CXCL13 thereby 
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favouring humoral immunity, while release of TGF and matrix components like versican and 
pentaxin-related protein PTX3 promotes tissue remodelling and repair (295,296).  
The dichotomy of M1 and M2 is a useful model but does not entirely reflect the in vivo 
situation. M1 and M2 are probably extremes of a continuous spectrum of possible activation states and 
therefore, intermediate forms exist. Plasticity may even be retained in a way that macrophages 
reconvert their phenotype depending on the cytokine environment although these phenomena are 
poorly understood so far (297). It is known however that M2 cytokines (IL-4, IL-10, IL-13) suppress 
M1 activation by interfering with NF-B and STAT1 signalling (298) e.g. through upregulating 
inhibitory p50 dimers (299) and STAT3/STAT6. SOCS proteins are critically involved in this cross-
talk with SOCS3 polarizing towards M1 and SOCS1 towards M2 macrophages (300,301). Yet another 
determinant of macrophage polarization is Krüppel-like factor (KLF) 4 which cooperates with STAT6 
to induce M2 and inhibit M1 genes consequently being merely present in M1 cells (302). Analogous, 
KLF2 impairs NF-B activation in macrophages (303). Myeloid deletion studies revealed that both 
PPAR (304) and PPAR/ (305,306) are important M2 drivers and recently, c-myc was shown to 
induce PPAR, STAT6 and some M2 genes making it an important mediator of alternative activation 
(307). On the cell surface, M1 and M2 cells preferentially express different receptors that can be 
exploited experimentally to discriminate between the two activation types including Fc-RI, II and III 
(CD16, CD32, CD64), C68, CD80 and CD86 for M1 and scavenger receptors like Msr-1 and CD163, 
mannose receptor (MRC1/CD206), and CD14 for M2 macrophages (285).  
Excessive M1 and M2 activation have both been linked to different pathologies: Tumour 
tolerance (308), allergy and asthma (309) are related to M2 activation whereas unresolved M1 
activation leads to chronic inflammation and tissue damage as observed in autoimmune disease like 
rheumatoid arthritis (310). The detrimental effect in obesity will be discussed in the next chapter. 
During skeletal muscle repair and regeneration, macrophages also play an important role with an early 
M1 and a delayed M2 wave (311). The CD68
+
/CD163
-
 M1 cells readily remove cellular debris by 
phagocytosis directly after injury and activate satellite cells while CD68
-
/CD163
+ 
M2 macrophages 
invade the tissue later (311). They promote differentiation of satellite cells and muscle growth to 
restore muscle function (312). The M1/M2 switch is presumably orchestrated by muscle-derived IL-4 
(313). In dystrophic muscle, M1 activation and concomitant M2 repression e.g. by IFN exacerbates 
muscle wasting in DMD (314). Conversely, IL-10-mediated M2 activation and M1 repression 
alleviates symptoms (315).  
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1.2.4 Inflammation, obesity and insulin resistance 
 
Obesity as defined by a body mass index (BMI) >30 has become a global epidemic with 500 
million affected and numbers still on the rise according to the World Health Organization. The 
principle reason for this development is an increasingly sedentary lifestyle with a caloric intake that 
exceeds energy expenditure by far. Evolutionary, the human body was optimized to survive times of 
famine and therefore, efficient energy storage was vital which nowadays causes severe public health 
problems. Obesity and its sequelae like insulin resistance, type 2 diabetes, fatty liver disease, 
atherosclerosis, hypertension and stroke, commonly subsumed as the metabolic syndrome, are the 
leading cause of mortality in developed countries. Insulin resistance is thereby especially important as 
insulin coordinates glucose and fatty acid uptake into skeletal muscle and adipose tissue, respectively, 
with lipolysis in adipose tissue and gluconeogenesis in liver thus determining circulating 
concentrations of glucose and fatty acids. Apart from a mere dysregulation of metabolism, an immune 
component to overweight and obesity has been appreciated for decades as patients possess higher 
levels of circulating pro-inflammatory cytokines (IL-1, IL-6, IL-8, IL-12, and TNF), chemokines 
(monocyte chemoattractant protein (MCP) 1/CCL2, RANTES/CCL5, MIP-1), acute phase proteins 
(C-reactive protein (CRP), serum amyloid A, ferritin), adipokines associated with insulin resistance 
(retinol binding protein 4 and resistin), and procoagulative and hypertensive factors (plasminogen 
activator inhibitor 1 and angiotensinogen) constituting a chronic, low-grade inflammation. 
Reciprocally, negative acute phase proteins (transcortin and transferrin) and adipokines associated 
with insulin sensitivity (adiponectin, visfatin, omentin, and vaspin) are lowered in plasma of obese 
subjects (316).  
As expansion of adipose depots is the prime effect of obesity, an inflammatory reaction in 
WAT is the major source of elevated circulating cytokines and the driver of insulin resistance (317). 
Mechanistically, inflammation impinges on metabolism at the level of Irs1, the downstream effector of 
the insulin receptor which is tyrosin-phosphorylated in response to insulin stimulation (Fig. 8A and 
see 1.1.5). This activation can be prevented by inhibitory serine phosphorylation through kinases 
involved in inflammatory signalling like IKK and JNK (Fig. 8A). Therefore, JNK deletion ameliorates 
insulin resistance and improves insulin receptor signalling in obese animals (318). A multitude of 
stimuli feeds into the NF-B and AP-1 pathway, several of which are aberrantly induced in WAT of 
obese subjects thereby evoking IKK/JNK activation. First, cytokines may promote these pathways and 
indeed, treatment of adipocytes with TNF directly leads to inhibitory Irs1 phosphorylation (Fig. 8A) 
(319), while animals with disrupted TNF signalling are protected from obesity-induced insulin 
resistance (320). Second, high levels of saturated FFAs bind TLR4 due to structural similarity with 
bacterial ligands inducing IKK and JNK (Fig. 8A and see 1.2.1). Consequently, TLR4 deletion 
protects from obesity-induced insulin-resistance (212). Third, ER stress is a result of overnutrition, as 
the capacity of adipocytes to store fatty acids in form of triglycerides is exceeded and FFAs leak into 
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the cytoplasm in turn activating JNK (Fig. 8A) (321). Forth, the expansion of adipocytes to store 
increasing amounts of fat outbalances angiogenesis leading to tissue hypoxia and hypoxia-inducible 
factor (HIF) 1 expression (322). HIF-1 itself induces pro-inflammatory cytokine expression and 
thus IKK/JNK activation as do, fifth, increased levels of ROS that derive from hyperactive NADPH  
 
 
Figure 8 Inflammation and insulin resistance in obesity A. Inhibition of Irs signalling by inflammatory kinases 
that are activated in adipocytes by different signals in obesity B. Schematic representation of the ATM switch 
from M2 in lean to M1 macrophages in obese adipose tissue. Adapted from (316). 
 
 
oxidase (323). In conjunction, endoplasmic reticulum (ER) stress and hypoxia bring about adipocyte  
necrosis. The dying cells then nucleate the formation of crown-like structures, i.e. areas of necrotic 
cells surrounded by macrophages which are absent in lean animals (324).  
In lean animals, adipose tissue macrophages (ATMs) are polarized towards an M2 phenotype 
(Fig. 8B and see 1.2.3) with anti-inflammatory properties that preclude M1 activation. It is not 
completely clear how this alternative activation is driven, but several nonexclusive possibilities have 
been studied: Adipocytes from lean mice release IL-13 and to a lesser extent IL-4, which locally cause 
M2 activation (see 1.2.3) without overspill into the circulation (306). Adiponectin from the same 
source has also been shown to polarize macrophages towards an M2 phenotype (325) and unsaturated 
FFAs prevail in lean subjects both systemically as well as in adipose tissue (326). All those cues lead 
directly or via STAT6 induction to activation of PPARs which promote an oxidative metabolic 
program in macrophages that corresponds to M2 activation (306). Accordingly, myeloid ablation of 
PPAR or PPAR/ impairs M2 skewing and fosters an inflamed and insulin resistant environment 
with M1 activated macrophages (304,306). PGC-1 is further essential in driving oxidative 
metabolism characteristic of M2 activation as RNAi-mediated downregulation of PGC-1 attenuates 
the anti-inflammatory phenotype (327). Mechanistically, PGC-1 coactivates STAT6 and PPARs to 
initiate M2 gene expression. Therefore, in lean animals M2 macrophages are the prevalent ATMs in 
adipose tissue that contribute to sustaining an insulin sensitive milieu.  
In contrast, highly inflammatory M1 macrophages accumulate in WAT of obese animals (Fig. 
8B) (328,329). An altered adipokine expression profile, high levels of saturated FFA and the 
engulfment of necrotic adipocytes switch ATMs from the anti-inflammatory M2 towards the M1 
phenotype (Fig. 8B) (330). These M1 cells secret large amounts of pro-inflammatory cytokines like 
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TNF, IL-1 and IL-6 thus constituting a feed-forward loop that amplifies and sustains adipose tissue 
inflammation, which aggravates insulin resistance and attracts more monocytes into WAT (Fig. 8B). 
MCP-1 plays an important role in monocyte recruitment and adipose tissue-specific overexpressing of 
MCP-1 renders animals insulin resistant (331,332) phenocopying the M1 accumulation during obesity. 
Correspondingly, deletion of the MCP-1 receptor CCR2 prevents this accumulation and rescues 
insulin sensitivity if animals are fed a high fat diet (333). Interfering with M1 activation by myeloid 
deletion of TLR4 (334), JNK (335) or IKK (336), also preserves insulin sensitivity under conditions 
of high fat feeding, importantly without differences in weight gain. This observation underlines the 
detrimental effect of M1 ATMs that couple nutrient excess to insulin resistance reinforcing 
inflammation as central mechanism in metabolic disorders.  
Recent studies revealed that other cells of the immune system also contribute to both an anti-
inflammatory M2 environment in lean animals and to obesity-induced inflammation. Eosinophils, and 
CD4
+
 regulatory T and Th2 cells are all present in WAT of lean animals sustaining M2 macrophage 
polarization and insulin sensitivity while T cell balance in obsess animals tips towards Th1 cells (337-
339). By virtue of IFN production, Th1 cells skew ATMs towards an M1 phenotype (340). Strikingly, 
in the course of weight gain, these Th1 cells exhibit a T cell receptor bias arguing for an antigen-
specific expansion which would assume an autoantigen from WAT (338). Preceding macrophage 
accumulation, neutrophils (341) and CD8
+
 effector T cells (342) can be detected in WAT. They 
contribute to M1 polarization while B cells that are also recruited to WAT early in obesity activate T 
cells, which in turn potentiate M1 polarization leading to insulin resistance (343). Hence, depletion of 
immune cells types associated with M1 polarization or induction of M2-sustaining immune cells 
ameliorates insulin resistance (337,338,343,344).  
In liver, M1 activation of Kuppfer cells contributes to inflammation, hepatic insulin resistance 
and steatosis similar to the situation in WAT, while in skeletal muscle these processes have received 
less attention. Intramuscular fat depots that form in obese animals attract inflammatory macrophages 
similar to adipose tissue but to a much smaller extend (328). The detrimental effect of these cells on 
muscle insulin sensitivity was proven in obese animal models with myeloid deletion of either JNK 
(335) or IKK (336) where blockade of M1 macrophage activation preserves muscle insulin 
sensitivity. Depletion of Cd11c
+
 cells that represent the main M1 macrophage subset has the same 
effect (345) while even lean mice devoid of myeloid PPAR and thus impaired in M2 activation 
develop muscle insulin resistance which deteriorates under high fat feeding conditions (346). 
However, myeloid deletion of PPAR/ (306) or TLR4 (334) does not entail any effect on muscle 
insulin sensitivity implying a mechanism different from WAT. Details of this mechanism, e.g. how the 
M1/M2 switch in muscle is regulated and which signals from muscle cells sustain an M2 phenotype or 
induce M1 activation respectively are not understood yet and warrant further investigation.  
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1.3 PGC-1 coactivators and inflammation in skeletal muscle 
 
Although substantial amounts of different NF-B subunits are detectable in adult skeletal 
muscle, for a long time, NF-B signalling was mainly associated with different muscle diseases that 
are accompanied by an inflammatory reaction like cachexia, muscular dystrophy, atrophy, and 
inflammatory myopathies (347). In all of these disorders, inflammation contributes to deterioration of 
muscle function and progression of the disease, also exemplified by skeletal muscle-specific 
overexpression of IKK which causes severe muscle wasting (348). Accordingly, a muscle-specific 
deletion of IKK improves muscle strength and counteracts denervation-induced loss of muscle mass 
while preserving fiber types (349). This model, as well as a model with p65 deletion, exhibits faster 
regeneration after injury (350) underlining the detrimental effect of canonical NF-B signalling in 
unsound muscle. 
In healthy muscle, NF-B has been shown to influence myogenesis, reports are however 
conflicting as to whether NF-B is a positive (351-353) or a negative (354-356) regulator of muscle 
differentiation. Suppression of myogenesis by canonical NF-B signalling is mediated by induction 
and stabilization of cyclin D (357,358), inhibition of MyoD and myogenin expression (355), and Yin 
and yang (YY) 1-mediated silencing of myofibrillar genes (350). Conversely, an unexpected role for 
noncanonical NF-B signalling was recently described in vivo (359): IKK and RelB induce oxidative 
muscle fibrers and stimulate mitochondrial biogenesis by targeting PGC-1 but without impact on 
myogenesis. The physiological meaning of this mechanism still needs to be determined. 
Exercise is also implicated in NF-B activation in skeletal muscle (360,361), but the function 
thereof is unclear. ROS defence, post-exercise regeneration of damaged fibers or adaptations in fuel 
metabolism have been suggested as putative and non-exclusive NF-B actions (362). Myokines like 
IL-8, IL-15 and particularly IL-6 are released from contracting skeletal muscle (363) rendering muscle 
an endocrine organ. The induction of IL-6 in muscle under these conditions however does not seem to 
be under the control of NF-B but was speculated to depend on nuclear factor of activated T cells 
(NFAT) and/or p38/MAPK (364). Although IL-6 elevation is associated with chronic inflammation, 
transient exercise-derived IL-6 mediates some of the beneficial effects of physical activity. Therefore, 
IL-6 infusion increases insulin-stimulated glucose disposal in humans (365) and IL-6 deletion in mice 
results in mature-onset diabetes (366). As IL-6 receptor expression also increases after exercise, the 
beneficial versus detrimental effect of that cytokine might also be explained by “IL-6 resistance” 
(analogous to insulin resistance) under conditions of low-grade inflammation (367). IL-6 is further 
required for hypertrophic muscle growth through stimulation of satellite cell proliferation (368) as is 
IL-4 by promoting myoblast fusion (313). Satellite cells also attract and interact with 
monocytes/macrophages to foster muscle growth (369) illustrating yet another example of muscle and 
immune cell crosstalk.  
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Lack of exercises, i.e. a sedentary lifestyle, is a major risk factor for many chronic diseases 
including the metabolic syndrome, cardiovascular diseases, musculoskeletal and neurological 
disorders and even some cancers (370) while exercise capacity is a strong predictor of all-cause 
mortality (371). Many of these chronic diseases are correlated with a systemic, sterile, sub-acute 
inflammation as described for obesity and insulin resistance above (see 1.2.4). In contrast, physical 
activity may prevent the development and antagonize the progression of some of these diseases e.g. 
diabetes (372), sarcopenia (373), and neurodegeneration (374), and counteract systemic inflammation 
(375). Muscle-derived IL-6 thereby increases the anti-inflammatory cytokines IL-1Ra and IL-10 in 
blood (376) while inhibiting TNF production (377) thus skewing immune function towards a type 2 
response. Contraction also increases plasma levels of hormones like adrenalin, cortisol, growth 
hormone and prolactin that have an immunomodulatory function (375). On monocytes, exercise 
reduces TLR1, TLR2, and TLR4 expression and function, alongside a decrease in MHC II and 
costimulatory molecules (378). Potentiation of these effects leads to a temporary immunodepression 
after very strenuous training (375).  
PGC-1 is a powerful mediator of training adaptation as explained under 1.1.4, but no direct 
action on myokine expression or immunomodulation after exercise has been reported. Inversely, a 
downregulation of PGC-1 and PGC-1 is evident in skeletal muscle of diabetic patients (155) that 
exhibit both higher levels of IL-6 and TNF in skeletal muscle and a higher circulating IL-6 
concentration. More precisely, expression levels of PGC-1 inversely correlated with IL-6 and TNF 
expression independent of BMI (158) suggesting a causal relationship between PGC-1 and 
expression of pro-inflammatory cytokines. This is further underscored by the MKO and SKM-Het 
models (see 1.1.4) with complete deletion or heterozygous expression of PGC-1 in skeletal muscle 
respectively. Both display elevated IL-6 expression in muscle and higher IL-6 concentrations in 
plasma (158) reminiscent of the situation in diabetic patients. MKO muscles are further characterized 
by expression of a panel of pro-inflammatory markers like TNF and CD68 (158), worsening after 
exercise, when expression of TNF in muscle and as well as plasma levels are exorbitantly high (139). 
These observations imply that local and/or systemic cytokine levels may be (at least partially) under 
the control of skeletal muscle PGC-1, but neither MCK nor MCK mice have been investigated in 
this regard, and putative anti-inflammatory properties of PGC-1 coactivators remain elusive.  
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1.4 Hypothesis 
 
 The project presented here was designed to explore the role of PGC-1 and PGC-1 in 
inflammatory responses in skeletal muscle cells in vitro and in vivo. Deletion studies in rodent skeletal 
muscle hint at an anti-inflammatory role of PGC-1 while data from diabetic patients with chronic, 
low-grade inflammation denote a reduction of both coactivators in skeletal muscle pointing in the 
same direction. Moreover, exercises induce PGC-1 and counteract inflammation. If these effects are 
causal and PGC-1 coactivators possess anti-inflammatory properties is however not clear to date. To 
settle this question, we overexpressed PGC-1 and PGC-1 in C2C12 cells (manuscript 1) or in 
skeletal muscle of mice (manuscript 2) and studied the effect of different inflammatory stimuli on 
cytokine expression. We further investigated the mechanistic basis of anti-inflammatory PGC-1 action 
with special focus on the NF-B pathway. Finally, we describe an unexpected cross-talk between 
myocytes and macrophages that results in M2 macrophage skewing representing a new kind of anti-
inflammatory PGC-1 impact. 
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2.1 Abstract 
 
A persistent, low-grade inflammation accompanies many chronic diseases that are promoted 
by physical inactivity and improved by exercise. The beneficial effects of exercise are mediated in 
large part by PGC-1 while its loss correlates with propagation of local and systemic inflammatory 
markers. We examined the influence of PGC-1 and the related PGC-1 on inflammatory cytokines 
upon stimulation of muscle cells with TNF, toll-like receptor agonists and free fatty acids. PGC-1s 
differentially repressed expression of pro-inflammatory cytokines by targeting NF-B signaling. 
Interestingly, PGC-1 and PGC-1 both reduced phoshorylation of the NF-B family member p65 
and thereby its transcriptional activation potential. Taken together, the data presented here show that 
the PGC-1 coactivators are able to constrain inflammatory events in muscle cells and provide a 
molecular link between metabolic and immune pathways. The PGC-1s therefore represent attractive 
targets to not only improve metabolic health in diseases like type 2 diabetes but also to limit the 
detrimental, low-grade inflammation in these patients.  
 
2.2 Introduction 
 
A sedentary lifestyle is a strong and independent risk factor for a large number of chronic 
diseases including musculoskeletal, metabolic, cardiovascular and neurological disorders. These 
diseases have been linked to a sterile, persistent, low-grade inflammation with elevated levels of 
circulating cytokines like interleukin 6 (IL-6), tumor necrosis factor  (TNF) and IL-1 that often 
worsen disease progression (1-3). The nuclear factor B (NF-B) pathway is a central regulator of 
inflammatory processes: NF-B activation has accordingly been associated with obesity and insulin 
resistance in different organs (4-6). A wide array of signals including cytokines like TNF and toll-
like receptor (TLR) agonists of pathogenic or dietary origin (e.g. excess free fatty acids as in obesity 
(7)) is able to boost NF-B activity upon cell surface receptor binding. These ligand-receptor 
interactions trigger the recruitment of adaptor proteins and receptor-proximal kinases ultimately 
culminating in the activation of the inhibitor of NF-B (IB) kinase (IKK) complex. IKK 
subsequently phosphorylates IB which is then degraded by the proteasome. Decreased levels of IB 
free NF-B, thereby enabling cytosolic-nuclear translocation and ultimately transcriptional induction 
of a large amount of genes involved in immune function (8). The NF-B family comprises the 5 
members RelA/p65, RelB, c-Rel, p100/p52 and p105/p50, of which the heterodimer p65/p50 is the  
most common form and the target of so-called “classical” NF-B activation (8). The transcriptional 
activity of p65 is further modulated by post-translational modification i.e. inducible phosphorylation 
events that affect the binding affinity to coactivators and corepressors without altering the recruitment 
to DNA response elements (9,10). 
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While physical inactivity clearly has a negative impact on health favoring an inflamed 
environment, regular, moderate exercise is beneficial against systemic inflammation and counteracts 
the development of chronic diseases (11). Besides prevention, exercise also is an effective therapeutic 
strategy to treat obesity, type 2 diabetes, sarcopenia and neurodegeneration (12-14). 
At the molecular level, many of the beneficial effects of exercise are mediated by the 
transcriptional coactivator peroxisome proliferator-activated receptor  coactivator 1 (PGC-1) (15). 
PGC-1 is transiently induced by a single bout of exercise and chronically elevated in endurance 
trained muscle (16). Activated PGC-1 then controls the expression of genes encoding proteins 
involved in mitochondrial biogenesis, oxidative phosphorylation and other features of oxidative 
muscle fibers (17). Accordingly, mice with transgenic skeletal muscle-specific PGC-1 
overexpression perform better in endurance tests and display a switch towards oxidative type I and 
type IIA fibers (18,19). The increased fitness of healthy transgenic animals translates into 
improvement of symptoms when PGC-1 is expressed in the context of different muscle wasting 
conditions as shown for Duchenne muscular dystrophy, sarcopenia, a mitochondrial myopathy and 
denervation- or lovastatin-induced fiber atrophy (20-22). 
Inversely, a skeletal muscle-specific deletion of the PGC-1 gene facilitates a type IIB and 
type IIX fiber type switch, reduces exercise performance and promotes muscle fiber damage (23). 
Furthermore, loss of PGC-1 results in elevated levels of pro-inflammatory factors locally in muscle 
as well as systemically (24). These findings suggest an anti-inflammatory role for PGC-1: in fact, in 
skeletal muscle of diabetic patients, PGC-1 levels negatively correlate with IL-6 or TNF levels 
independent of BMI (24). 
PGC-1, a close related member of the PGC-1 gene family, also exhibits dysregulated 
expression in skeletal muscle of diabetic patients and thereby contributes to the mitochondrial 
dysfunction observed in type 2 diabetes (25). While both PGC-1s share the ability to boost oxidative 
metabolism, PGC-1 is not regulated by exercise and primarily drives the formation of type IIX fibers 
(26). Interestingly, PGC-1 is required for alternative activation of and mitochondrial ROS production 
in macrophages (27,28); an immunomodulatory role in skeletal muscle has however not been 
described so far. 
Based on these observations, we now tested the hypothesis that the PGC-1 coactivators exert 
anti-inflammatory effects in muscle. More precisely, we explored if PGC-1 and PGC-1 are able to 
modify cytokine expression upon exposure of muscle cells to different inflammatory stimuli like 
TNF, TLR agonists and free fatty acids (FFAs). We found that the PGC-1s repress the transcriptional 
activity of p65 and thereby modulate the NF-B signaling pathway. These data represent a prime 
example of crosstalk between metabolic and immune pathways with important implications for 
skeletal muscle function. 
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2.3 Materials and Methods 
 
2.3.1 Cell culture and treatments 
 
The mouse skeletal muscle cell line C2C12 was maintained below confluence in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum and 1x 
Penicillin/Streptomycin (Invitrogen). For differentiation into myotubes, growth medium was 
exchanged for DMEM supplemented with 2% horse serum (Invitrogen) for at least 3 days. PGC-1, 
PGC-1 and GFP were overexpressed from recombinant adenoviral constructs 48 h prior to treatment. 
Stimulation with TNF (Sigma-Aldrich) and TLR agonists (Invivogen) in growth or differentiation 
medium lasted for 2 h unless otherwise stated. Concentrations were as follows: TNF 10ng/ml, 
PAM3CSK4 1g/ml (TLR1/2 agonist), HKLM 108 cells/ml (TLR2 agonist), poly(I:C) 25g/ml (TLR3 
agonist), E.coli K12 LPS 1g/ml (TLR4 agonist), S. typhimurium flagellin 1g/ml (TLR5 agonist), 
FSL1 1g/ml (TLR6/2 agonist), ssRNA40 1g/ml (TLR8 agonist) and ODN18266 5M (TLR9 
agonist). Free fatty acids (FFA, Sigma-Aldrich) were dissolved in ethanol and further diluted to 1mM 
final concentration in DMEM containing 2% fatty acid- and endotoxin-free bovine serum albumin 
(Sigma-Aldrich); FFA treatment lasted for 16 h in serum-free medium. The protein phosphatase 
inhibitor okadaic acid (OA, Sigma-Aldrich, 250nM) was present 30 minutes prior to and during 
treatment with TNF where indicated, while control samples were incubated with vehicle (DMSO, 
0.04%) alone for equal times. The PPAR inhibitor MK 886 (Tocris Bioscience, 20µM) was present 
24 h prior to and during treatment with TNF where indicated, while control samples were incubated 
with vehicle (DMSO, 0.02%) alone for equal times. 
 
 
2.3.2 Semiquantitative real-time PCR 
 
RNA was isolated from treated C2C12 cells using Trizol (Invitrogen) and residual DNA 
contamination was removed by DNase I digestion (Invitrogen). 1g of RNA was reverse transcribed 
with SuperScript II (Invitrogen) and the resulting cDNA used as template for RT-PCR. To detect 
relative expression levels, cDNA was amplified with the SYBR Green Master mix (Applied 
Biosystems) and analyzed on a StepOnePlus RT-PCR System (Applied Biosystems). The respective 
primer pairs are listed in Suppl. Table 1. All values are normalized to the expression of TATA-Box 
binding protein (TBP) and expressed as fold induction over the untreated control condition.  
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2.3.3 ELISA 
 
To determine cytokine concentrations in cell culture supernatants, sandwich immunoassays 
against IL-6 were performed according to the manufacturer’s instructions (Quantikine, R&D Systems).  
 
 
2.3.4 NF-B Customized Array analysis 
 
Differentiated C2C12 cells overexpressing PGC-1, PGC-1 or GFP were treated with TNF 
for 2h and RNA was extracted (NucleoSpin RNA II, Macherey-Nagel). The custom array analysis was 
subsequently performed as previously described (29). Briefly, RNA was processed with the Amino 
Allyl MessageAMP II aRNA Amplification Kit (Ambion) according to the manufacturer’s instructions 
to yield aminoallyl-modified aRNA that was further coupled to Cy3 or Cy5 dyes respectively. 
Biological duplicates were labeled crosswise to control for dye effects. Pairs of samples were 
hybridized on a total of 14 slides containing probes for 524 genes included in the array as described 
elsewhere (29, ArrayExpress A-MEXP-1502). Significantly regulated genes as determined by 
ANOVA (P≤0.01) were subject to cluster analysis. The 3 resulting clusters were the source of further 
KEGG (Kyoto Encyclopedia of Genes and Genomes) and GO (Gene Ontology) terms enrichment 
analysis with FatiGO (30) considering the adjusted p-value≤0.05 as significant. To predict the relevant 
transcription factors for the regulation of each cluster, motif search within a region spanning +200bp 
to -800bp around the transcription start site (TSS) of each gene in the array was performed using 
MotEvo (31) in combination with a non-redundant set of position weight matrices mainly derived 
from JASPAR and TRANSFAC. Overrepresented motifs were retrieved by comparing binding site 
occurrence in each cluster to the occurrence in the whole array and considered significant with a z 
score ≥2. Microarray data were further analyzed with MARA (Motif Activity Response Analysis (32)) 
to predict the most important transcription factors that contribute to the changes in gene expression in 
our set of samples (independent of clustering).  
 
 
2.3.5 Dual-luciferase reporter gene assays 
 
90 – 95% confluent C2C12 myoblasts were transfected using Lipofectamin 2000 (Invitrogen) 
with plasmids containing firefly luciferase under the control of 3 NF-B sites (wild-type, wt) or a 
construct with mutated sites as control in combination with renilla luciferase as internal control. Cells 
were then either treated with TNF/ TLR agonists for 2h, or co-transfected with p65, increasing 
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amounts of PGC-1/ and empty vector (pcDNA3.1) to keep total DNA concentration constant. Cells 
were assayed 24h post transfection with the Dual-Luciferase Reporter Assay System (Promega) 
according to the manufacturer’s protocol. Briefly, cells were lysed and firefly and renilla luciferase 
activities determined on a Centro LB 960 luminometer (Berthold Technologies). Firefly-derived 
luciferase values were normalized to renilla activity and results expressed as ratio of wt to mutated 
reporter with the control condition being arbitrarily set to 1. 
 
 
2.3.6 TransAM NF-B DNA binding assays 
 
Nuclear extracts from myotubes were prepared by swelling of the cells in hypotonic buffer 
(20mM Hepes, pH 7.5, 5mM NaF, 10M Na2MoO4, 0.1mM EDTA) and breaking the cytoplasmic 
membrane with Nonidet P-40 substitute (0.5%). After centrifugation, the residual nuclear pellet was 
resuspended in Complete Lysis Buffer to dismantle nuclear membrane integrity and obtain the nuclear 
extract as supernatant of the final, fast centrifugation step. To determine the amount of active NF-B 
in these nuclear extracts, TransAM assays (Active Motif) were performed following the 
manufacturer’s instructions. In brief, 10g of nuclear extracts were added to wells coated with 
oligonucleotides containing the NF-B consensus sequence (5’-GGGACTTTCC-3’). These 
oligonucleotides trap active transcription factors, which then are detected in an ELISA-like assay with 
specific primary antibodies for the different NF-B subunits and a secondary horseradish peroxidase 
(HRP)-conjugated antibody. A colorimetric reaction accordingly determines the amount of NFB-
DNA binding. Results are expressed in arbitrary units minus the respective blank value, and 
normalized to Ctrl conditions.  
 
 
2.3.7 Western Blotting 
 
After washing away residual culture medium with PBS, cells were scraped off the dish in lysis 
buffer (20mM Tris-HCl pH7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM 
Na4P2O7,1mM -glycerophosphate, 1mM Na3VO4) supplemented with protease (complete tablets, 
Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail 2, Sigma-Aldrich) and kept on ice 
for 10 min with occasional vortexing. Centrifugation at 10’000g yielded the protein lysate, which was 
subjected to SDS-PAGE. The resolved proteins were transferred to a nitrocellulose membrane 
(Whatman) on a semi-dry electroblotting system (Thermo Scientific) with 1.5mA/cm
2
 and transfer 
confirmed by Ponceau S staining (0.1% in 5% acetic acid). Proteins were detected with the following 
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primary antibodies: anti-p65, anti-Pp65(ser536) (both Cell Signaling Technology), anti-p105/p50 
(abcam), anti-p100/p52, anti-RelB, anti-cRel, anti-IB, anti-IBanti-IKK, anti-IKK, anti--
tubulin as loading control (all Cell Signaling Technology) and an anti-rabbit-IgG HRP-coupled 
secondary antibody (Dako). Bands were finally visualized by autoradiography with ECL substrate 
(Pierce) and density quantified with ImageJ software.  
 
 
2.3.8 Statistical analysis 
 
Data were analyzed with student’s t test using P≤0.05 as the significance threshold. 
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2.4 Results 
 
2.4.1 PGC-1 and PGC- differentially suppress pro-inflammatory cytokine expression and 
secretion  
 
To delineate the effect of PGC-1s on inflammatory processes in muscle, myotubes 
overexpressing either adenovirally encoded PGC-1 or PGC-1 were compared to GFP-expressing 
control cells treated with different inflammatory stimuli. PGC-1 coactivator overexpression was high 
and functional as evident from the induction of the known target gene medium-chain acyl-coenzyme A 
dehydrogenase (MCAD, Suppl. Fig. 1A and 1B). Ectopic, recombinant TNF strongly induced the 
gene expression of the pro-inflammatory markers IL-6, TNF and macrophage inflammatory protein-
1 (MIP-1/CCL3). While PGC-1 did not negatively affect basal levels of these pro-inflammatory 
cytokines, it diminished their induction by TNF yielding lower levels than in control cells (Fig. 1A). 
PGC-1 suppressed both basal and TNF-induced expression of IL-6, TNF and MIP-1 (Fig. 1B). 
As a consequence of the PGC-1-mediated repression in gene expression, lower levels of secreted IL-6 
protein were observed in culture media after TNF treatment (Fig. 1C and 1D). 
Next, we examined the effect of PGC-1s on TLR stimulation in muscle cells. First, we 
assessed the expression pattern of the TLRs in our experimental system and found that TLR1, TLR2, 
TLR3, TLR 4, TLR6, and at lower levels TLR5 were detectable in the muscle cells (Fig. 2A). To study 
the activity of the TLRs, selective agonists for TLR2, TLR3, TLR4, TLR5, TLR8, TLR9, or the 
TLR1/2 and TLR6/2 heterodimers were applied. Of those, only TLR1/2, TLR4 and TLR6/2 activators 
consistently elevated expression of IL-6 and TNF (Fig. 2B). Moreover, the same compounds 
increased luciferase reporter gene activity controlled by 3 repeats of a minimal NF-B DNA-response 
element (Fig. 2C). For the subsequent experiments, agonists for TLR1/2, TLR4 and TLR6/2, the 
active TLRs in muscle cells, were utilized and compared to the TLR3 activator that was used as a 
negative, internal control. TLR1/2, TLR4 and TLR6/2 agonists all induced expression of IL-6 and 
TNF in control cells as expected (Fig. 2D). Interestingly, PGC-1 effectively repressed TLR-
mediated TNF expression by all of the active agonists while IL-6 expression was only reduced by 
PGC-1 in the TLR1/2 and TLR4 agonist treatment (Fig. 2D). PGC-1 furthermore lowered basal IL-
6 protein secretion, but not the elevated IL-6 secretion caused by TLR agonist stimulation (Fig. 2E). In 
contrast, PGC-1 significantly decreased IL-6 and TNF gene expression both in the basal state and 
after activation of TLR1/2 while no effect was observed in the TLR4 or TLR6/2 agonist treated cells 
(Fig. 2F). Nevertheless however, IL-6 secretion into culture medium was strongly repressed by PGC-
1 in all of the different experimental conditions (Fig. 2G). 
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As a third inflammatory stimulus besides TNF and TLR agonists, the free fatty acids (FFA) 
palmitic acid (C16H32O2), oleic acid (C18H34O2), myristic acid (C14H28O2), stearic acid (C18H36O2), 
linoleic acid (C18H32O2) and elaidic acid (C18H34O2) were administered to muscle cells to mimick the 
lipid overload that is associated with disease progression in the metabolic syndrome. As expected, 
saturated fatty acids, in particular stearic and palmitic acid and to a lesser extent the shorter-chain 
species, produced a strong pro-inflammatory response as indicated by the transcriptional induction of 
 
 
 
Figure 1 PGC-1and PGC-1 suppress TNF-induced pro-inflammatory cytokines. A-D, Differentiated 
C2C12 myotubes overexpressing PGC-1 and GFP (Panels A and C) or PGC-1 and GFP (Panels B and D) 
were treated with TNF for 2h. Expression of pro-inflammatory cytokines was determined by real-time PCR 
(Panels A and B) and release of IL-6 into the medium quantified by ELISA (Panels C and D). Values represent 
the mean of at least 3 independent experiments +SEM. ## P≤0.01 GFP TNF versus GFP Ctrl, * P≤0.05, ** 
P≤0.01 PGC-1/ versus GFP. 
 
 
the IL-6, TNF and MIP-1 genes (Fig. 3A). In contrast, mono- or polyunsaturated fatty acids did not 
alter pro-inflammatory cytokine expression (Fig. 3A); in fact, oleic acid was even able to reverse the 
negative effects of palmitic acid (Fig. 3A) as previously described (33). Strikingly, PGC-1 potently 
inhibited the increase in IL-6, TNF and MIP-1 gene expression mediated by palmitic, myristic and 
stearic acid (Fig 3A). Likewise, PGC-1 also efficiently blocked the FFA-induced elevation of IL-6  
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Figure 2 PGC-1and PGC-1 differentially suppress TLR agonist-induced pro-inflammatory cytokines. A, 
Differentiated C2C12 myotubes were tested for mRNA expression of TLR1-9. Expression values are arbitrarily 
normalized to those of TLR1. B, C2C12 cells were differentiated and treated with different TLR agonists for 2h. 
Expression of IL-6 and TNF was assessed by real-time PCR. C, C2C12 cells were transfected with an NFB 
reporter construct (or a mutated reporter construct as control) and treated with different TLR agonists for 2h. 
Luciferase activity was determined and is expressed as ratio of wt to mutated reporter gene values. D-G, 
Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panels D and E) or PGC-1 and GFP (Panels 
F and G) were treated with agonists for TLR1/2, TLR4, TLR6/2 and TLR3 for 2h. Expression of pro-
inflammatory cytokines was determined by real-time PCR (Panels D and F) and release of IL-6 into the medium 
quantified by ELISA (Panels E and G). Values represent the mean of at least 3 independent experiments +SEM. 
# P≤0.05, ## P≤0.01 TLR agonist treated versus Ctrl (A, B, D-G) or TLR expression versus TLR1 (C), * P≤0.05, 
** P≤0.01 PGC-1/ versus GFP. 
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Figure 3 PGC-1and PGC-1 differentially suppress fatty acid-induced pro-inflammatory cytokines. A, B, 
Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A), or PGC-1 and GFP (Panel B) 
were treated with different fatty acids (P=palmitic acid, O=oleic acid, M=myristic acid, S=stearic acid, 
L=linoleic acid, E=elaidic acid) for 16h. Expression of pro-inflammatory cytokines was determined by real-time 
PCR. Values represent the mean of at least 3 independent experiments +SEM. # P≤0.05, ## P≤0.01 GFP FFA 
versus GFP Ctrl, * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. 
 
and MIP-1 transcript levels (Fig. 3B). Interestingly however, transcriptional elevation of TNF by 
palmitic, myristic and stearic acid was unaffected by overexpression of PGC-1 (Fig 3B).  
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2.4.2 PGC-1 and PGC-1 target the NF-B pathway to suppress inflammation 
 
To examine the mechanisms behind the repressive effect of the PGC-1 coactivators on TNF-induced 
pro-inflammatory cytokines, a customized array designed to represent the most important 
inflammatory genes and other NF-B targets (29) was employed. Out of the 524 genes that are present 
on the array, 55 genes were found to be differentially regulated by TNF treatment and/or PGC-1 
overexpression (P <0.01) and thus further analyzed. These 55 genes were grouped into 3 clusters (Fig. 
4A): cluster 1 contained 21 genes that were upregulated by PGC-1 and PGC-1 including vascular 
endothelial growth factor (VEGF), a known PGC-1 target (34). The 13 and 21 genes in clusters 2 and 
3, respectively, were repressed by PGC-1 and PGC-1. Importantly, genes in cluster 3 were TNF- 
inducible while the expression of the genes in cluster 2 was not modulated by TNF treatment (Fig. 
4A). To validate the results of the microarray, three representative genes from each cluster were 
chosen and their expression analyzed by real-time PCR. Mitochondrial translational initiation factor 2 
(Mtif2), VEGF and protein arginine methyltransferase 1 (Prmt1) from cluster 1 were indeed induced 
(Suppl. Fig. 2A) while chemokine (C-X-C motif) ligand 12 (Cxcl12), complement component 2 (C2) 
and E2F transcription factor 2 (E2f2) from cluster 2 (Suppl. Fig 2B) and chemokine (C-C motif) 
ligand 2 (Ccl2), Ccl7 and Cxcl1 from cluster 3 (Suppl. Fig. 2C) were repressed by PGC-1 coactivators 
confirming the results of the microarray. Furthermore, TNF-inducibility of genes in cluster 3 was 
verified.  
Functionally, the genes in cluster 1 were enriched in only one Gene Ontology (GO) term 
compared to 18 significant terms in cluster 2 and 96 terms in cluster 3 (of which only 46 terms with a 
p-value≤0.01 are shown) (Suppl. Fig. 3). 12 of the GO categories in cluster 2 and 26 categories in 
cluster 3 are related to inflammation and immunity. Importantly, the inflammation-related GO terms 
comprise the top 10 and top 15 ranking categories in clusters 2 and 3, respectively (Suppl. Fig. 3). 
Likewise, all 3 KEGG pathways assigned to cluster 2 and the top 9 KEGG pathways out of 11 of 
cluster 3 are related to inflammatory signaling (Fig. 4B). These results suggest that the PGC-1s are 
able to repress inflammatory processes in muscle cells. 
To predict which transcription factors are involved in the regulation of each cluster, promoter 
regions were analyzed in regard to their motif composition. Motifs overrepresented in each of the 
clusters are listed in Suppl. Table 2A. As background for this analysis, all promoters of the microarray 
were used, thereby eliminating any putative bias that might have been introduced with the specific 
choice of genes in the customized microarray. The majority of predicted binding sites were unique to 
one cluster, i.e. 26 out of 33 motifs in cluster 1, 20 out of 26 motifs in cluster 2 and 21 out of 28 motifs 
in cluster 3 (Suppl. Table 2B). Intriguingly, one distinct transcription factor binding motif stood out as 
the clear top ranking candidate in each of the three clusters based on z score, namely NFY{A,B,C} in 
cluster 1 (z score of 9.74 compared to the second ranking z score of 4.9 for GFI1), IRF1,2,7 in cluster 
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Figure 4 Inflammatory pathways and NF-B activity are suppressed by PGC-1s. Differentiated C2C12 
myotubes overexpressing PGC-1, PGC-1 and GFP were treated with TNF for 2h and subsequently subjected 
to a customized microarray analysis. A, Significantly regulated genes (P≤0.01) were clustered and are depicted 
as heat map. B, KEGG pathways enriched within each cluster (adjusted p-value≤0.05) are shown, the dotted line 
indicates an adjusted p-value of 0.01. (Abbreviations: cytok. = cytokine, pw = pathway, r. = receptor). C, Motifs 
overrepresented in the promoters of each cluster were identified and their z score distribution plotted. For a 
complete list see Suppl. Table 2A. D, Activity plot of NF-B (top scoring transcription factor motif) over 
different conditions as predicted by MARA (Motif Activity Response Analysis) and the corresponding sequence 
logo of the position weight matrix.  
 
2 (z score of 6.98 compared to 4.46 for FOX{F1,F2,J1}) and NFB1_REL_RELA in cluster 3 (z score 
of 6.67 compared to 4.93 for AR) (Fig. 4C and Suppl. Table 2A). These predictions indicate that the 
NF-B pathway is a likely target for the PGC-1s to suppress TNF-inducible inflammatory gene 
expression represented in cluster 3. Accordingly, NF-B was also the highest scoring motif in the 
Motif Activity Response Analysis (MARA) of the whole array and thus the most likely transcription 
factor to modulate TNF- and PGC-1-dependent gene expression (Fig. 4D).  
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2.4.3 PGC-1 reduces p65 and p50 expression levels 
 
To experimentally validate the biocomputational prediction of PGC-1-mediated repression of 
NF-B signaling as the central mechanism for the anti-inflammatory effect of the PGC-1 coactivators 
on TNF-inducible genes, reporter gene assays were performed with a construct containing the 
luciferase gene under the control of 3 NF-B DNA response elements. The activity of the reporter 
gene construct in response to TNF treatment resembles endogenous IL-6 and TNF gene expression 
(Suppl. Fig. 1C and 1D). Increasing amounts of co-transfected PGC-1 or PGC-1 progressively 
inhibited transcription from a NFB-responsive promoter that is activated by exogenous p65 (Fig. 
5A). 
To elucidate the mechanism by which the PGC-1 coactivators repress NF-B activity even on 
minimal NF-B response element-driven gene expression, we first examined the expression levels of 
the different NF-B family members before and after TNF treatment and PGC-1 overexpression, 
respectively (Fig. 5B and 5C). TNF led to a significant increase in transcript levels of all 5 NF-B 
isoforms (p65, p105/p50, p100/p52, RelB and c-Rel) in GFP-infected control cells. PGC-1 did not 
change the levels of the canonical isoforms p65 and p105/p50 as well as RelB in the basal, vehicle-
treated cells while an induction of p100/p52 was observed suggesting a switch towards the 
noncanonical NF-B pathway. In contrast to the first 4 NF-B isoforms, c-Rel expression was clearly 
reduced by PGC-1 overexpression (Fig. 5B). After TNF treatment, the levels of all NF-B isoforms 
tended to be lower in PGC-1 overexpressing cells, however only reaching statistical significance in 
the case of c-Rel gene expression (Fig 5B). In striking contrast to the PGC-1-mediated effect, PGC-
1 suppressed p65 and p105/p50 as well as RelB and c-Rel gene expression in the basal state (Fig. 
5C). The transcript levels of all 5 NF-B isoforms tended to be lower in PGC-1 overexpressing cells 
after TNF treatment; similar to PGC-1 overexpressing cells, this repression was however only 
significant for c-Rel gene expression (Fig. 5C). Therefore, while the basal repression of p65 and 
p105/p50 could contribute to the strong repression of inflammatory gene expression by PGC-1 in 
non-stimulated cells, it is unlikely that the small differences in expression levels of the different NF-
B isoforms after TNF treatment underlie the profound effects of PGC-1s on pro-inflammatory 
cytokine expression in stimulated muscle cells. Thus, to further elucidate the molecular mechanism 
underlying this observation, we next assessed the DNA binding capability of all NF-B family 
members in the context of TNF treatment and PGC-1 overexpression (Fig. 5D and 5E). Of the 5 NF-
B isoforms, RelB and c-Rel were undetectable in nuclear extracts from C2C12 myotubes in the 
TransAM assay and are thus unlikely to play a major role in the regulation of pro-inflammatory 
cytokine expression in our experimental context of muscle cells as hypothesized in other publications 
(35). The DNA binding of p50 and p52 was detectable though low (Fig. 5D and 5E). In contrast, 
recruitment of p65 to DNA response elements was substantial in non-stimulated cells and further  
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Figure 5 PGC-1s suppress NF-B transcription activation potential without changing DNA binding or 
affecting NF-B expression levels. A, C2C12 cells were transfected with a wild-type and a mutated NFB 
reporter construct, p65 and increasing amounts of PGC-1 or PGC-1. Luciferase activity was determined after 
24h and is expressed as ratio of wt reporter to mutated reporter gene expression. ## P< 0.01 PGC-1 versus Ctrl. 
B-E, Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panels B and D) or PGC-1 and GFP 
(Panels C and E) were treated with TNF for 2h. B, C, Expression of NF-B family members was determined 
by real-time PCR. D, E, DNA binding of NFB family members in nuclear extracts was measured by 
TransAM. Values represent the mean of at least 3 independent experiments +SEM. # P≤0.05, ## P≤0.01 GFP 
TNF versus GFP Ctrl, * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. 
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elevated after TNF treatment. Interestingly however, DNA binding of p65 with and without TNF 
treatment, respectively, was not changed by PGC-1 (Fig. 5D) while PGC-1 strongly inhibited 
binding of p65 and p50 to DNA in the basal, vehicle-treated muscle cells (Fig. 5E). Comparable to 
PGC-1 overexpression, DNA binding of any of the NF-B isoforms was not affected by ectopic 
PGC-1 in TNF-stimulated cells (Fig. 5E). It is thus conceivable that both low p65/p50 expression as 
well as reduced DNA binding account for the PGC-1-mediated reduction in pro-inflammatory 
cytokine expression compared to vehicle-treated control cells. In contrast however, the diminished 
levels of these cytokines upon TNF treatment in both PGC-1- and PGC-1-overexpressing cells 
can neither be attributed to changes in NF-B expression nor to modulation of the NF-B protein 
binding capability to DNA response elements.  
 
 
2.4.4 PGC-1 and PGC-1 diminish the transcriptional activity of p65 
 
Based on our data implying alternative molecular mechanisms distinct from transcriptional 
regulation or DNA binding of NF-B to underlie the repressive action of the PGC-1 coactivators on 
the activity of this transcription factor, we next studied upstream signaling and the post-translational 
modification of p65 that influence the transcriptional activity of NF-B. First, we examined the 
possibility that high levels of IBs after TNF treatment could account for lowered cytokine 
 
 
 
Figure 6 PGC-1s diminish p65 phosphorylation at serine 536. Differentiated C2C12 myotubes overexpressing 
PGC-1, PGC-1 and GFP were treated with TNF for 2h. A, Protein abundance of NFB family members, 
pathway components, phospho-p65 (ser536), PGC-1, PGC-1 and -Tubulin was assessed by immunoblotting. 
B, Quantification of phospho-p65 (ser536) and total p65 protein levels, normalized to -Tubulin. Values 
represent the mean of at least 3 independent experiments +SEM. # P≤0.05, ## P≤0.01 GFP TNF versus GFP 
Ctrl, * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. 
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expression. However, the relative amount of IB protein was not different between conditions (Fig. 
6A). IB, an NF-B target gene, was accordingly increased on the protein level by TNF treatment  
and reduced in muscle cells overexpressing PGC-1 or PGC-1 (Fig. 6A and Suppl. Fig. 4A and 4B), 
similar to other NF-B targets such as IL-6 and TNF (Fig. 1) excluding the possibility of IB-
mediated repression. Subsequently, IKK protein levels were assessed: IKK was not and IKK was 
barely detectable (Fig. 6A). In contrast, IKK was slightly increased by TNF treatment; this effect 
was abrogated in cells overexpressing PGC-1 or PGC-1 (Fig. 6A). IKK is one of the protein 
kinases that is able to phosphorylate p65 at serine 536. Importantly, the phosphorylation status of p65 
at serine 536 affects the transcriptional activity of NF-B even when bound to DNA response elements 
(10). In Western blot analyses of total and phosphorylated p65 protein, a small but significant increase 
in total p65 protein levels was observed after TNF treatment in control cells (Fig. 6A and 6B). PGC-
1 overexpression did not affect basal levels of p65, while PGC-1 diminished total p65 protein 
expression in this context, as expected based on the reduced mRNA expression of p65 in PGC-1 
overexpressing muscle cells (Fig. 5C). Strikingly however, both PGC-1 and PGC-1 reduced TNF-
mediated phosphorylation of p65 by about 50% (Fig. 6A and 6B). None of the other NF-B family 
members underwent regulation by TNF on the protein level. Interestingly, PGC-1 overexpression 
resulted in elevated protein levels of p105, p100, p52 and RelB in non-stimulated muscle cells and, to 
a smaller extent, of p105 and p100 in TNF-treated cells again suggesting a PGC-1-dependent 
increase in the non-canonical NF-B pathway (Fig. 6A and Suppl. Fig. 4A). In contrast, PGC-1 does 
not seem to elevate the non-canonical NF-B family members like PGC-1. Thus, besides the strong 
increase in c-Rel protein and the more moderate elevation of p105 protein in non-stimulated cells, 
PGC-1 significantly reduced RelB protein levels (Fig. 6A and Suppl. Fig. 4B). The discrepancy 
between the PGC-1-mediated repression of c-Rel gene expression compared to the elevation of c-Rel 
protein levels implies post-transcriptional effects in the regulation of this particular NF-B family 
member. 
 
 
2.4.5 Dephosphorylation and transrepression of p65 are potential molecular mechanisms for 
diminished cytokine expression 
 
To further substantiate the findings implying that the PGC-1 coactivators modulate NF-B activity by 
preventing p65 phosphorylation, we examined other upstream effectors for this phosphorylation as 
well as downstream events affecting the DNA-bound NF-B transcriptional complex. The protein 
kinase Akt has been implicated in the regulation of the NF-B signaling pathway upstream of IKK 
(36) one of the protein kinases to mediate p65 phosphorylation and of which protein levels are  
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Figure 7 Dephosphorylation of p65 is a potential molecular mechanism for diminished cytokine expression. 
A, Differentiated C2C12 myotubes overexpressing PGC-1, PGC-1 and GFP were treated with TNF for 2h. 
Protein levels of Akt and phospho-Akt (ser473) were determined by immunoblotting. B, Differentiated C2C12 
myotubes overexpressing PGC-1, PGC-1 and GFP were treated with TNF for 5min and 2h, respectively. 
Protein abundance of Phospho-p65 (ser536) and total p65 was assessed by immunoblotting. C, Quantification of 
Phospho-p65 (ser536) levels from B, normalized to -Tubulin. D, Differentiated C2C12 myotubes 
overexpressing PGC-1, PGC-1 and GFP were treated with TNF for 2h in the presence or absence of okadaic 
acid (OA). Protein abundance of phospho-p65 (ser536), total p65, PGC-1 and PGC-1 was assessed by 
immunoblotting E, F, Quantification of PGC-1 and PGC-1 protein levels from D, normalized to -Tubulin 
(Panel E). Quantification of Phospho-p65 (ser536) protein levels from D, normalized to -Tubulin (Panel F). 
Values represent the mean of at least 3 independent experiments +SEM. # P≤0.05, ## P≤0.01 GFP OA versus 
GFP Ctrl, * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. 
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reduced by PGC-1 and PGC-1 overexpression (Fig. 6A). As expected, based on these findings, 
PGC-1 and PGC-1 diminished Akt activation as evident from diminished phospho-Akt (ser473) 
levels normalized to total Akt protein (Fig. 7A). 
 
 
 
Figure 8 Transrepression of p65 is a potential molecular mechanism for diminished cytokine expression. A, 
B, Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A) or PGC-1 and GFP (Panel B) 
were treated with TNF for 2h. Expression of coactivator and corepressor proteins, and of nuclear receptor 
PPAR was determined by real-time PCR. * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. C, Proposed model of 
PGC-1/ interference with NFB signaling. Gene-, activator- and PGC-1-specific repression of NFB target 
genes is mediated by reduced phosphorylation of p65, transcriptional induction of PPAR and subsequent 
transrepression as well as activation of an unknown protein phosphatase by both PGC-1s. Furthermore, PGC-1 
specifically inhibits p65 and p50 expression while PGC-1 elevates members of the NFB family involved in 
the alternative, non-canonical activation (not depicted). 
 
 
To obtain a more accurate picture of p65 phosphorylation, a time course experiment was 
performed. It revealed that p65 is phosphorylated at serine 536 after 5min of TNF treatment even in 
the presence of PGC-1 and PGC-1 (Fig. 7B and 7C) implying the possibility that not only an altered 
kinase profile but also activity of a protein phosphatase might be involved in the PGC-1-mediated 
modulation of NF-B phosphorylation. We therefore tested whether pharmacological inhibition of 
protein phosphatase 2A (PP2A) and PP1, two enzymes that dephosphorylate p65 (37), by  
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okadaic acid abolishes the repression of p65 phosphorylation mediated by PGC-1 and PGC-1 in 
muscle cells. As expected, okadaic acid powerfully stabilized phosphorylation of p65 at serine 536 
(Fig. 7D and 7F). Strikingly however, PGC-1 and PGC-1 overexpression (Fig. 7D and 7E) still 
reduced p65 phosphorylation, even in okadaic acid-treated cells (Fig. 7D and 7F). Thus, while PP1 and 
PP2A clearly affect the serine 536 phosphorylation of p65 in our experimental context, these two 
phosphatases are most likely not involved in the modulation of p65 phosphorylation by the PGC-1s.  
Since the phosphorylation status of p65 affects its affinity to cofactors (38), we also 
determined the expression levels of the coactivator CBP and corepressors NCoR and SMRT. Of those, 
only SMRT transcript levels were significantly increased by PGC-1 (Fig. 8A and 8B). A well-
described mechanism of inhibition of inflammatory gene expression is mediated by nuclear receptors 
and termed transrepression (39). We evaluated the gene expression of potential candidates for 
transrepression and found PPAR to be strongly induced by both PGC-1 and PGC-1 in non-
stimulated and TNF-treated muscle cells similar to previous data (40) (Fig. 8A and 8B). PPAR 
therefore likely contributes to the PGC-1-dependent reduction in NF-B transcriptional activity by 
impairing the exchange of corepressors for coactivators that is necessary to effectively initiate 
transcription. In fact, inhibition of PPAR recovered expression of IL-6 and TNF in the presence 
PGC-1 (Suppl. Fig 5). 
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2.5 Discussion 
 
With an aging population and an increasingly sedentary lifestyle, chronic diseases are on the 
rise. Obesity and its comorbidities but also some cancers and neurodegeneration have been associated 
with local and systemic inflammation that worsens disease progression, while exercise has beneficial 
effects in many of these disorders and even acts preventive (41). PGC-1 is a major molecular 
mediator of exercise in skeletal muscle and its loss not only disturbs metabolic processes but also 
evokes a local and systemic inflammation (24). In the present report we thus tested the idea that PGC-
1 coactivators have anti-inflammatory properties.  
Indeed, we confirmed such properties as PGC-1 and PGC-1 were able to diminish the 
increase in pro-inflammatory cytokines elicited by different inflammatory stimuli such as TNF, TLR 
agonists and saturated FFAs. We identified the NF-B pathway as main target of PGC-1-dependent 
repression. These results are complemented by in vivo findings of Brault and coworkers who showed 
that NF-B reporter activity decreases after electroporation of tibialis anterior muscle with PGC-1 / 
PGC-1 in the context of anti-atrophic effects of PGC-1s (42). Similar conclusions were derived from 
experiments in human aortic smooth muscle and endothelial cells where PGC-1 suppressed TNF-
induced VCAM-1 and MCP-1 expression that contribute to inflammation in atherosclerosis (43). 
Mechanistically, PGC-1 and PGC-1 lower phosphorylation of the NF-B family member 
p65 which limits its transcriptional activation potential. This is further substantiated by data from 
muscle-specific PGC-1 transgenic animals that also exhibit reduced p65 phosphorylation (44). 
Diametrically opposed to this report, another recent publication states that p65 phosphorylation is 
higher in PGC-1 transgenic muscle before as well as after injection of TNF (45). The exact role of 
PGC-1 on muscle inflammation in vivo thus remains unresolved. In our cellular model, decreased 
p65 phosphorylation unequivocally corresponds to the loss of IKK induction by TNF in PGC-1 
overexpressing cells and, interestingly, to diminished Akt activation. Akt-dependent phophorylation of 
p65 by IKK is an important mechanism to regulate p65 transactivation potential (36,46) and thus a 
good candidate to mediate the reduction observed (Fig. 8C). In addition to modulation of kinase 
activity, the involvement of a phosphatase is suggested by sustained phosphorylation of p65 after 
TNF treatment for 5min even in the presence of PGC-1 and PGC-1. As okadaic acid treatment did 
not abrogate differences between conditions, PP2A and PP1 are however unlikely to account for this 
effect. Therefore, further experiments are needed to determine the contribution of different 
phosphatases in this setting.  
The transactivation potential of p65 is controlled by its phosphorylation status as it defines the 
affinity for cofactors important in suppressing or stimulating transcription of target genes (38). 
Decreased phosphorylation thus favors interaction with corepressors such as SMRT that decreases 
p65/p50 transactivation (47). Interestingly, SMRT levels are slightly induced by PGC-1 and 
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accordingly could contribute to lower cytokine expression. Stabilization of corepressor complexes on 
DNA-bound p65 is also fostered by nuclear receptor-mediated transrepression (39). For example, 
PPAR is able to exert anti-inflammatory action by ligand-dependent and –independent 
transrepressive mechanisms (48,49). We found a marked induction of PPAR by PGC-1 and PGC-
1, which presumably also contributes to negative regulation of pro-inflammatory cytokines by 
transrepression (Fig. 8C). This claim is substantiated by the reversal of the repressive PGC-1 effects 
on pro-inflammatory cytokine expression when PPAR was inhibited. PPAR regulates lipid 
metabolism and FFAs are able to serve as ligands for PPAR (50). Thus, the very pronounced 
suppressive effect of the PGC-1s on inflammatory gene expression observed after FFA treatment 
might reflect an additional ligand-dependent activation of PPAR leading to an even stronger 
transrepression in that experimental context. 
Besides the reduction in p65 phosphorylation that is exerted by both PGC-1 and PGC-1, 
only the latter was further found to repress p65 and p50 transcription in the basal state and accordingly 
the ability of these proteins to bind to DNA response elements. This offers an attractive explanation 
for the very low cytokine levels observed in the presence of PGC-1. The NF-B family members 
RelB and c-Rel were also suppressed transcriptionally in the basal state which puts PGC-1 in the 
position of a broader anti-inflammatory factor in skeletal muscle. Such anti-inflammatory potential 
was previously described only in macrophages, where PGC-1 is essential in alternative activation and 
ROS production (27,28). In contrast, PGC-1 does not alter expression of the classically activated / 
canonical NF-B isoforms p65 and p50. However, PGC-1 overexpression induces transcript and 
protein levels of the alternative isoforms p100/p52 and RelB. This indicates a switch towards 
noncanonical / alternative NF-B signaling. A recent publication outlined that alternative signaling via 
IKK and RelB induces an oxidative phenotype in muscle driven by PGC-1(51). Furthermore, 
activation of c-Rel and p50 was suggested to play a role in disuse atrophy (52). Finally, canonical p65 
activation was linked to mitochondrial biogenesis in mouse embryonic fibroblasts and liver cells 
(53,54). All of these findings together with our data suggest a reciprocal, functional link between NF-
B signaling and oxidative metabolism. A potential induction of the alternative NF-B pathway by 
PGC-1 in muscle therefore warrants further investigations. 
Strikingly, inflammatory gene transcription was often selectively regulated by the two PGC-1 
coactivators depending on the stimulus and the specific gene. These findings argue against a general 
repressive effect of PGC-1 and PGC-1 on tissue inflammation in muscle but rather indicate a 
specific, fine-tuned effect of these coactivators on NF-B target genes. For example, while TLR1/2-
induced cytokine production was suppressed by both PGC-1 and PGC-1, only PGC-1 was able to 
block this production after treatment of the cells with a TLR4-specific ligand. Moreover, TLR6/2-
induced TNF expression was also diminished by PGC-1, which was however not the case for 
TLR6/2-induced expression of IL-6. This probably reflects the activation of pathways other than NF-
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B downstream of TLRs that are not subject to regulation by PGC-1 or targeted by only one of the 
PGC-1 isoforms, respectively. Interestingly, while neither PGC-1 nor PGC-1 affected expression of 
TNF receptor 1 (TNFR1) (Suppl. Fig. 6A and 6B) both coactivators lowered mRNA levels of TLR1, 
TLR4 and TLR6 (Suppl. Fig. 6C and 6D). This downregulation might presumably contribute to the 
repressive effects observed with some TLR agonists. The expression pattern of TLR1, TLR4 and 
TLR6 (Suppl. Fig. 6C and 6D) further resembles genes in cluster 2 of the microarray, confirming a 
broader influence of PGC-1s on inflammatory genes. Moreover, the selectivity of the PGC-1s most 
likely reflects the distinct expression pattern as well as the distinct functions of PGC-1 and PGC-1 
in the regulation of skeletal muscle physiology that will have to be further dissected in future 
experiments. In any case however, the concept that PGC-1s selectively and specifically repress 
inflammatory processes and thereby avoid the harmful consequences of broad and general cytokine 
suppression is compelling. Once understood in greater detail, the therapeutic potential of targeting 
PGC-1s to modulate specific inflammatory responses in muscle would be immense. Obviously, 
patients suffering from obesity and type 2 diabetes would profit from lower systemic inflammation 
mediated by rectified gene expression of PGC-1 and PGC-1 in skeletal muscle. Intriguingly 
however, muscle disorders like cachexia, muscular dystrophies, disuse atrophy or inflammatory 
myopathy also involve an inflammatory component with activation of the NF-B pathway (55-58). In 
fact, chronic stimulation of the classical NF-B pathway in muscle is sufficient to induce muscle 
wasting (5). Accordingly, mice heterozygous for p65 or harboring a genetic ablation of the IKK gene 
in the mdx background, a model for Duchenne muscular dystrophy, have improved pathology (59). 
Strikingly, ectopic elevation of PGC-1 in animal models for some of these diseases resulted in an 
amelioration of fiber damage and muscle functionality, e.g. in Duchenne muscular dystrophy, 
sarcopenia, a mitochondrial myopathy and denervation-induced fiber atrophy (20,21,44,60). Our data 
now suggest that at least part of the therapeutic effect of PGC-1 in these disease paradigms might 
stem from the anti-inflammatory effect. It is, thus, tempting to speculate that elevating PGC-1 and / 
or PGC-1 in muscle would also be beneficial in other conditions of muscle wasting by limiting the 
detrimental inflammatory component of the disease. In fact, muscle adaptation to endurance training 
that correlate with increased PGC-1 expression includes an increased resistance against fiber 
damage, tissue inflammation and, as a consequence, decreased exercise-induced muscle soreness. In 
contrast to PGC-1, the implications of the repressive effect of PGC-1 on inflammatory gene 
expression remain less obvious until the physiological context of PGC-1 regulation and the function 
of this coactivator in muscle tissue have been more clearly delineated. Nevertheless, by virtue of their 
ability to reduce NF-B activation, the PGC-1 coactivators are promising targets to antagonize 
inflammatory reactions in skeletal muscle associated with a large number of diseases. 
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2.7 Supplemetal Material 
 
 
 
Suppl. Figure 1 TNF induces transcription of an NFB-controlled reporter gene similar to endogenous 
pro-inflammatory cytokines. A, B, Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A) 
or PGC-1 and GFP (Panel B) were treated with TNF for 2h. Expression of PGC-1, PGC-1 and the PGC-1 
target MCAD was determined by real-time PCR. Values represent the mean of at least 3 independent 
experiments * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. C, C2C12 cells were differentiated and treated with 
different concentrations of TNF for 2h. Expression of IL-6 and TNF was assessed by real-time PCR. D, 
C2C12 cells were transfected with a NFB reporter construct (or a mutated reporter construct as control) and 
treated with different concentrations of TNF for 2h. Luciferase activity was determined and is expressed as 
ratio of wt to mutated reporter gene expression. Values represent the mean of at least 3 independent experiments 
+SEM. # P≤0.05, ## P≤0.01 TNF versus Ctrl.  
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Suppl. Figure 2 Confirmation of microarray results by real-time PCR. A, B, C, Differentiated C2C12 
myotubes overexpressing PGC-1 or PGC-1 or GFP were treated with TNF for 2h. Expression of three 
representative genes from each cluster of the microarray (Panel A - cluster 1, Panel B – cluster 2, Panel C – 
cluster 3) was determined by real-time PCR. # P≤0.05, ## P≤0.01 GFP TNF versus GFP Ctrl, * P≤0.05, ** 
P≤0.01 PGC-1/ versus GFP. 
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Suppl. Figure 3 Inflammatory pathways are associated with PGC-1-repressed gene expression clusters. GO 
terms assigned to each cluster (P<0.05) are shown, dotted line indicates an adjusted p-value of 0.01. 
Abbreviations: bp=biosynthetic process, d.=derived, diff.=differentiation, intrac.=intracellular, m.=molecule, 
pos.=positive, pw=pathway, r.=receptor , reg.=regulation, rsp.=response, *of nerve impuls.  
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Suppl. Figure 4 Changes in protein levels of NFB family members only partially explain repressive 
properties of the PGC-1s. A, B, Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A) or 
PGC-1 and GFP (Panel B) were treated with TNF for 2h. Quantification of protein levels of PGC-1 
coactivators, IB and NFB family members, normalized to -Tubulin (see Figure 6). Values represent the 
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mean of at least 3 independent experiments +SEM. # P≤0.05, ## P≤0.01 GFP TNF versus GFP Ctrl, * P≤0.05, 
** P≤0.01 PGC-1/ versus GFP. 
 
 
 
Suppl. Figure 5 Inhibition of PPAR rescues PGC-1-depressed pro-inflammatory gene expression. 
Differentiated C2C12 myotubes overexpressing PGC-1 and GFP were treated with TNF for 2h in the presence 
or absence of the PPAR inhibitor MK 886. Expression of IL-6, TNF, MCAD, PPAR and PGC-1 was 
determined by real-time PCR. Values represent the mean of at least 3 independent experiments +SEM. # P≤0.05, 
## P≤0.01 GFP TNF versus GFP Ctrl, * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. 
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Suppl. Figure 6 PGC-1 coactivators reduce expression of relevant TLRs but not TNFR. A, B, C, D, 
Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A and C) or PGC-1 and GFP (Panel 
B and D) were treated with TNF for 2h. Expression of TNFR1 and TNFR2 (Panel A and B) and TLR1, TLR2, 
TLR3, TLR4 and TLR6 (Panel C and D) was determined by real-time PCR. * P≤0.05, ** P≤0.01 PGC-1/ 
versus GFP. 
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Gene Forward primer Reverse primer 
C2 GGTGACTGCTTTCTTGGGAG GAGGTTCTCATCCGCGTTTA 
CBP TCAGACAAGACTGTGGAGGTCAAG TTCCGACATCTCTCCAGAATCC 
Ccl2 TTCCTCTTGGGGATCTTTTG TCTGTGCCTGCTGCTCATAG 
Ccl7 TCTCCAGCCTACTCATTGGG AGGTCCCTGTCATGCTTCTG 
c-Rel TCGCAGTCTTCAATGTCCAG TCAAAATTTGGGTATTCGGTG 
Cxcl1 TCTCCGTTACTTGGGGACAC ACCCAAACCGAAGTCATAGC 
Cxcl12 TTTCAGATGCTTGACGTTGG GCGCTCTGCATCAGTGAC 
E2f2 GAAGAGGGTGTGACAGCTCC GGGATCGCAGAGACCATAGA 
IL-6 CCACGGCCTTCCCTACTTC TTGGGAGTGGTATCCTCTGTGA 
MCAD AACACTTACTATGCCTCGATTGCA CCATAGCCTCCGAAAATCTGAA 
MIP-1 TCCCAGCCAGGTGTCATTTT TTGGAGTCAGCGCAGATCTG 
Mtif2 AGTCTTCTTTGACTTGGGCTG GACCTCGCCTGGGAGTTG 
NCoR1 GACCCGAGGGAAGACTACCATT ATCCTTGTCCGAGGCAATTTG 
p100/p52 GAGCGTGATAAATGACGTGG CACAGGACGAGAACGGAGAC 
p105/p50 GAACGATAACCTTTGCAGGC TTTCGATTCCGCTATGTGTG 
p65 TAGGTCCTTTTGCGCTTCTC GCTCCTGTTCGAGTCTCCAT 
PGC-1 TGATGTGAATGACTTGGATACAGACA GCTCATTGTTGTACTGGTTGGATATG 
PGC-1 GGCAGGTTCAACCCCGA CTTGCTAACATCACAGAGGATATCTTG 
PPAR GCGTACGGCAATGGCTTTAT ACAGAACGGCTTCCTCAGGTT 
Prmt1 GAAACTTCTTCAAGAGGCGG GACTCGGGTGAAGATGGC 
RelB AGTCTTTCCCCACGAGGCTA CCATCGAGCTTCGAGACTG 
SMRT CCTTCCGTGAGAAGTTTATGCA CACACTCAGCGACCGTCTTTC 
TBP GGCCTCTCAGAAGCATCACTA GCCAAGCCCTGAGCATAA 
TLR1 GGCTTTGCAGGAACTCAATGTA CCCCGCACCCAGGAA 
TLR2 CCCTGTGCCACCATTTCC CCACGCCCACATCATTCTC 
TLR3 GATTCTTCTGGTGTCTTCCACAAA AATGGCTGCAGTCAGCTACGT 
TLR4 GCAGCAGGTGGAATTGTATCG TGTGCCTCCCCAGAGGATT 
TLR5 TCACCTGCCATTGATGTCCTT ACGCAATAGGATGGAGGGAAA 
TLR5 ACCTGGATGTCTCACACAATCG GCCTCAGGCTCGCCATAG 
TLR7 CAGTGAACTCTGGCCGTTGA CAAGCCGGTTGTTGGAGAA 
TLR8 GGAGACACTGCTACTGAGCCATAA TCCTGGCTTCGGAGAGGAA 
TLR9 AGCTGAACATGAACGGCATCT CCAGCCATCTGAGCGTGTACT 
TNF CACAAGATGCTGGGACAGTGA TCCTTGATGGTGGTGCATGA 
TNFR1 ATGGATGTATCCCCATCAGC CTTCATTCACGAGCGTTGTC 
TNFR2 AGATCTGGCACTCGTACCCA GTCTTCGAACTGCAGCTGTG 
Vegfa CATCTTCAAGCCGTCCTGTGT CTCCAGGGCTTCATCGTTACA 
 
Suppl. Table 1 Real-time PCR primers. 
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Suppl. Table 2 Gene expression clusters are associated with a distinct set of transcription factor binding 
motifs. A, List of motifs overrepresented in the promoters of each cluster with a z score ≥2. B, Proportion of 
distinct and shared motifs between clusters. Numbers indicate absolute amount of motifs. 
 
Cluster 1   Cluster 2   Cluster 3   
motif z score motif z score motif z score 
NFY{A,B,C} 9.74 IRF1,2,7 6.98 NFKB1_REL_RELA 6.67 
GFI1 4.9 FOX{F1,F2,J1} 4.46 AR 4.93 
PAX5 4.32 PRDM1 4.23 NFIX 4.72 
RFX1 3.79 NR5A1,2 4.22 TBP 4.06 
SOX17 3.73 TBP 4 SPI1 3.84 
TP53 3.72 MAFB 3.47 FOS_FOS{B,L1}_JUN{B,D
} 
3.84 
CTCF 3.48 HNF4A_NR2F1,2 3.46 CTCF 3.32 
SOX2 3.4 REST 3.27 AIRE 3.01 
AIRE 3.33 FOXQ1 3.18 T 2.93 
HNF4A_NR2F1,2 3.32 BACH2 3.14 TLX1 2.82 
SP1 3.04 RUNX1 2.9 GFI1B 2.69 
PITX1 3.04 STAT1,3 2.74 FOXP3 2.52 
PPARG 3.03 HOXA9_MEIS1 2.65 STAT2,4,6 2.49 
MZF1 3.03 E2F1 2.6 EN1,2 2.47 
EVI1 2.89 HMGA1,2 2.6 VSX1,2 2.47 
SPZ1 2.72 NKX2-1,4 2.59 BACH2 2.42 
RXR{A,B,G} 2.63 PPARG 2.5 TGIF1 2.38 
ZNF423 2.63 FOXA2 2.44 CEBPA,B_DDIT3 2.31 
AR 2.6 DMAP1_NCOR{1,2}_SMA
RC 
2.25 NFE2 2.3 
AHR_ARNT_ARNT2 2.58 NFATC1 2.21 PAX2 2.28 
ELK1,4_GABP{A,B1} 2.5 CDC5L 2.15 ZBTB16 2.24 
FOXD3 2.48 ZNF423 2.13 KLF4 2.22 
FOX{I1,J2} 2.41 NFIX 2.12 HIF1A 2.19 
PBX1 2.35 NR1H4 2.07 HOX{A5,B5} 2.17 
LMO2 2.29 ESR1 2.05 NR6A1 2.14 
BPTF 2.26 POU6F1 2.01 TBX4,5 2.09 
MSX1,2 2.24    ARNT_ARNT2_BHLHB2_
MAX_MYC_USF1 
2.04 
KLF4 2.18    RXRA_VDR{dimer} 2.01 
TLX2 2.16      
RORA 2.08       
ZNF384 2.04       
GATA1 2.03       
PAX6 2       
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3.1 Abstract 
 
 An aging and increasingly obese population is confronted with a number of pathologies, many 
of which are accompanied by a persistent, sterile inflammation. While an altered immune cell content 
in adipose tissue is a major driver of inflammation in metabolic pathologies, less attention was given 
to immune reactions in muscle so far. Importantly, regular muscle use is both therapeutic and 
preventive against many chronic diseases. The transcriptional coactivator peroxisome proliferator-
activated receptor  coactivator 1 (PGC-1) mediates most of the beneficial effects of exercise and 
its absence results in less endurant and inflamed muscles. Inversely, PGC-1 and PGC-1 are both 
downregulated in inactive skeletal muscle as well as in diseases that are associated with a sedentary 
life-style, including type 2 diabetes. We now tested if PGC-1 and PGC-1 have anti-inflammatory 
effects in vivo after exposure of muscle to lipopolysaccharide (LPS) and tumor necrosis factor  
(TFN) injection as well as eccentric exercise. Surprisingly, we observed a PGC-1-dependent change 
in macrophage polarization from M1 to M2 type with a concomitant alteration of the cytokine profile 
characterized by an increase in anti-inflammatory factors and a strong suppression of the pro-
inflammatory interleukin 12 (IL-12). The anti-inflammatory environment in muscle that is promoted 
by the PGC-1s might contribute to the beneficial effects of these coactivators on muscle function and 
provides a molecular link underlying the tight mutual regulation of metabolism and inflammation. 
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3.2 Introduction 
 
 Many chronic diseases are fostered by a sedentary lifestyle and are associated with a 
subclinical, systemic inflammation, for example metabolic pathologies like obesity and type 2 
diabetes, cardiovascular diseases such as atherosclerosis, but also neurodegenerative disorders 
including Alzheimer´s (1,2). The link between metabolic and immune dysregulation has been 
demonstrated in fat tissue with massive accumulation of macrophages in obese humans and rodents 
(3). Mechanistically, the expansion of fat cells under conditions of overnutrition alters the adipokine 
expression profile and the levels of free fatty acids, which subsequently activate adipose tissue 
macrophages (ATMs) (4-6).  
Macrophages display high plasticity and can adopt different states on a continuous scale from 
highly inflammatory “M1” to anti-inflammatory “M2” cells. The broad spectrum of macrophages 
reflects their diverse roles in various processes and is regulated by different stimuli: M1 or “classically 
activated” macrophages release large quantities of pro-inflammatory cytokines, e.g. tumor necrosis 
factor  (TNF), interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1), and possess high 
microbicidal capacity according to their role in the innate immune response against pathogens (7,8). 
Exposure to T helper cell 1 (Th1) cytokines like interferon- or toll-like receptor (TLR) ligands primes 
macrophages for this pro-inflammatory M1 phenotype. In contrast, M2 or “alternatively activated” 
macrophages are polarized by Th2 cytokines including IL-4, IL-13, IL-10, or by immune complexes. 
These cells are implicated in tissue remodeling and repair, immunomodulation, the resolution of 
inflammation as well as allergy, parasite infection and the progression of some tumors (9). Therefore, 
they express a distinct set of chemokines, e.g. C-C motif chemokine 1 (CCL1), CCL22 or IL-1Ra, cell 
surface receptors e.g. CD206 / macrophage mannose receptor 1 (Mrc-1), CD163 or macrophage 
scavenger receptor 1 (MSR-1) / CD204, and have higher phagocytic activity (7).  
In lean animals, ATMs are primarily of the M2 phenotype. Obesity changes adipokine 
secretion and subsequently skews macrophages towards an M1 phenotype. This initiates a vicious 
cycle of cytokine secretion, further macrophage recruitment into adipose tissue and an inflammatory 
reaction in the adipocytes themselves. Finally, insulin resistance, exacerbated lipolysis and systemic 
inflammation ensue (10-12). In skeletal muscle, the main site of glucose disposal in the body, the 
situation is less clear. Obesity gives rise to intramuscular adipose depots and, analogous to fat tissue, 
M1-type macrophage accumulation (3). Their contribution to the development of diet-induced insulin 
resistance was shown in mouse models with macrophage-specific deletion of IKK (12) or JNK (13), 
respectively, which renders two main inflammatory pathways in macrophages innocuous. Similarly, 
depletion of CD11c positive cells, which correspond to the main M1 population in muscle (14), 
reduces insulin resistance. In contrast, macrophage-specific expression of PPAR, which is linked to 
suppression of inflammation and thus an M2 phenotype, is required to maintain normal insulin 
sensitivity in skeletal muscle (15). The balance of macrophage polarization in muscle and signals that 
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lead to dysregulation and finally inflammation and insulin resistance in this tissue have however not 
been explored in depth so far.  
Insulin resistance and type 2 diabetes can be counteracted by regular exercise (16), which also 
limits systemic inflammation (17). An important factor that translates training-induced changes into 
metabolic adaptations in skeletal muscle is the peroxisome proliferator-activated receptor  coactivator 
1 (PGC-1). By coactivating an array of nuclear receptors and transcription factors, PGC-1 induces 
genes involved in mitochondrial biogenesis and oxidative phosphorylation to enable a higher 
endurance capacity (18,19). Mice carrying an extra allele of PGC-1 in skeletal muscle (MCK) 
consequently score better in running tests and exhibit a larger proportion of slow-twitch fibers than 
wild-type (WT) littermates (20). Transgenic overexpression of the related PGC-1 family member 
PGC-1 (MCK) also mediates lower fatigability and a switch towards IIX fibers in skeletal muscle 
(21). Inversely, skeletal muscle-specific deletion of PGC-1 results in poorer performance (22). This 
effect is aggravated by concomitant ablation of PGC-1 (23). Hence, both PGC-1s are drivers of 
oxidative metabolism with shared as well as distinct functions in skeletal muscle. 
In human diabetic patients, the expression of PGC-1 and PGC-1 is reduced in skeletal 
muscle with coordinated depression of mitochondrial oxidative phosphorylation (24,25). Importantly, 
in these patients, PGC-1 levels inversely correlate with IL-6 or TNF independent of body mass 
index (BMI) (26), which suggests anti-inflammatory action of the PGC-1s. Further evidence for such 
properties derives from the skeletal muscle-specific PGC-1 deletion model that exhibits elevated 
levels of tissue and systemic inflammation (26). In the present study, we therefore explored the role of 
the PGC-1s in skeletal muscle in vivo on local and systemic inflammatory events triggered by injection 
of inflammatory agents (LPS or TNF) into tibialis anterior (TA) or a bout of muscle damage-
inducing downhill running. 
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3.3 Material and Methods 
 
3.3.1 Mice and treatments 
 
C57BL/6 mice expressing PGC-1 ((27), MCK) and FVB/N mice expressing PGC-1 ((21), 
MCK) under the control of the muscle creatine kinase (MCK) promoter were bred with respective 
WT mice to obtain WT and transgenic littermates. Male mice were maintained on a standard rodent 
chow with 12h light/dark cycle and subjected to experiments at 8 – 12 weeks of age. Injections were 
performed under sevoflurane anesthesia. Mice were randomly assigned to one experimental group and 
subsequently injected intramuscularly (i. m.) into TA with either PBS (30l/TA), or LPS (2g/TA) or 
TNF (50ng/TA)in both legs. 4h post injection, mice were euthanized and blood as well as TAs 
collected for further analysis. Downhill running was performed on a motor-driven treadmill 
(Columbus Instruments) after 2 days of acclimatization at 5m/min with gradually declining slope. 
Mice were then randomly assigned to the exercise or sedentary control groups. The exercise group ran 
at a decline of -10° at alternating speeds (5min at 6m/min, 10min at 12m/min) for 2h (MCK) or 3h 
(MCK) or until exhaustion. 24h post running, mice were euthanized and blood, TAs and quadriceps 
muscles collected for further analysis. All animal experiments were approved by the institutional and 
federal authorities. 
 
 
3.3.2 Cell culture 
 
The mouse myoblast cell line C2C12 was maintained below confluence in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum and 1x 
Penicillin/Streptomycin (Invitrogen). For differentiation into myotubes, growth medium was 
exchanged for DMEM supplemented with 2% horse serum (Invitrogen) for 3 days. PGC-1, PGC-1 
and GFP were overexpressed from recombinant adenoviral constructs 48h prior to treatment with 
TNF (10ng/ml, Sigma-Aldrich) and LPS (40ng/ml, Sigma-Aldrich), which lasted for an additional 
4h.  
 
 
3.3.3 Semiquantitative real-time PCR 
 
Muscle tissue was homogenized using matrix particles (Qbiogene) in a FastPrep FP120 cell 
disrupter (Thermo Scientific) and RNA isolated with Trizol (Invitrogen) while residual DNA 
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contamination was removed by DNase I (Invitrogen) digestion. 1g of RNA was reverse transcribed 
with SuperScript II (Invitrogen) and the resulting cDNA used as template for RT-PCR. To detect 
relative expression levels cDNA was amplified with the SYBR Green Master mix (Applied 
Biosystems) and analyzed on a StepOnePlus RT-PCR System (Applied Biosystems). The respective 
primer pairs are listed in Suppl. Table 1. All values are normalized to the expression of TATA-Box 
binding protein (TBP) and expressed as fold induction over untreated WT animals.  
 
 
3.3.4 ELISA 
 
To determine serum cytokine concentrations, sandwich immunoassays for TNF and IL-6 
were performed according to the manufacturer’s instructions (Quantikine, R&D Systems).  
 
 
3.3.5 Histology 
 
TA and quadriceps muscles were snap frozen in liquid nitrogen-chilled isopentane and cut into 
cross sections on a microtome/cryostat (Leica CM1950). Specimen were either stained with Mayer’s 
hematoxylin and eosin (Sigma) and light microscopically analyzed or stained with 
immunofluorescence methods. For the latter, sections were fixed in paraformaldehyde (4%, 10min), 
washed (3 times with PBS), blocked (0.2% Triton X-100, 2% bovine serum albumin in PBS, 30min) 
and stained with specific antibodies against CD68 and CD206 (AbD serotec, 1:400, 1h). After 
washing, samples were immunofluorescently labeled with an Alexa Fluor 488-conjugated anti-rat IgG 
secondary antibody (Invitrogen, 1:100, 1h), washed again and mounted with DAPI-containing medium 
(Vectashield, Vector Laboratories). Macrophage staining was visualized on a fluorescent microscope 
(Leica DMI 4000 B) and images analyzed with the Imaris software (Bitplane).  
 
 
3.3.6 Statistical analysis 
 
Data were analyzed with Student’s t test using P<0.05 as significance threshold.  
 
84
Manuscript 2 
 
3.4 Results 
 
3.4.1 PGC-1 and PGC-1 do not alter systemic cytokine levels in inflammation 
 
To delineate the role of skeletal muscle PGC-1 in inflammation, we exposed transgenic and 
WT animals to different inflammatory stimuli. Specifically, we injected LPS, TNF or PBS as control 
i.m. into TA and analyzed blood and muscles 4h later. PGC-1 expression was not affected by the 
injections and remained about 6 fold above WT levels in muscles of MCK mice (Fig. 1A). Similarly, 
PGC-1 levels were not changed by overexpressing PGC-1 in PBS-injected, but were reduced in 
LPS-treated mice (Fig. 1A). LPS injection also lowered PGC-1 expression in the MCK model, 
although PGC-1 levels remained considerably higher compared to WT controls (about 9 fold, Fig. 
1B). PGC-1 levels in these animals were reduced to about a third of WT levels (Fig. 1B). Plasma 
 
 
 
Figure 1 PGC-1 and PGC-1 do not alter systemic cytokine levels after inflammatory stimulation. A-F, 
MCK mice (Panel A, C, E) and MCK mice (Panel B, D, F) and respective WT controls were injected i.m. into 
TA with PBS, LPS or TNF. A, B, mRNA expression levels of PGC-1 isoforms in TA were measured by RT-
PCR. C, D, Serum levels of TNF and IL-6 were determined 4h post injection. Values represent the mean of at 
least 7 animals +SEM. ** P<0.01, * P<0.05, WT versus MCK. E, F, TA cross sections were stained with 
hematoxylin and eosin 4h post injection for histological analysis. Representative images are shown. 
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levels of the pro-inflammatory cytokines TNF and IL-6 were not detectable in PBS injected mice 
except for small amounts of TNF in WT mice with FVB background from the breeding of the MCK 
mouse line (Fig. 1C, D). Transgenic expression of PGC-1 reduced plasma TNF levels below 
detection limit. As expected, IL-6 and TNF were found at high levels in the plasma of MCK, 
MCK and the respective WT mice after LPS injection and at moderately elevated levels after TNF 
injection. Skeletal muscle-specific overexpression of PGC-1 and PGC-1, respectively, did not affect 
systemic TNF or IL-6 levels after either stimulus (Fig. 1C, D). 
 
 
3.4.2 PGC-1 and PGC-1 alter macrophage populations in skeletal muscle after injection of 
inflammatory agents 
 
Since no evidence for an immunomodulatory role of the PGC-1s on systemic inflammation 
was found, we next focused our attention on tissue inflammation. Therefore, to assess immune cell 
infiltration of muscle tissue after injection of inflammatory stimuli, TA cross sections were first 
stained with H&E. MCK and to a smaller extend also MCK mice harbored more non-muscle 
mononuclear cells already under basal conditions. LPS and TNF both evoked a further substantial 
influx of immune cells compared to PBS-injected muscle (Fig. 1E, F). The difference between 
transgenic and WT animals persisted after injection of inflammatory agents, (especially in case of 
MCK (Fig. 1E, F). The high number of regenerating fibers with centrally located nuclei in some 
areas of the TA in the MCK model finally indicated a basal, low level of continuous fiber damage 
and regeneration in these animals. This was not observed in MCK mice. 
 To obtain a more detailed picture of the immune cell distribution in TA after injection of LPS 
and TNF, mRNA expression of F4/80, which reflects the total amount of M1 and M2 macrophages 
in the muscle, was analyzed. In line with the H&E staining, F4/80 levels in TA of MCK mice were 
considerably higher than in WT animals (Fig. 2G). A similar, though qualitatively much lower 
increase was also present in MCK mice after injection of LPS or TNF (Fig. 2C). LPS and TNF 
injection did not substantially alter macrophage infiltration in any of the experimental groups (Fig. 2C, 
G). As expected for the early time point of analysis post insult (4 h), the infiltrate after LPS and TNF 
injection that is observed in H&E staining thus predominantly consists of neutrophils that rapidly 
invade injured muscle tissue. Importantly, potential changes in macrophage polarization are therefore 
likely to be attributed to activation of tissue-residing and not of newly infiltrating macrophages at the 
time of analysis. 
To characterize polarization of tissue macrophages, TA cross sections were stained with 
specific antibodies against CD68 to capture M1 and against CD206 to reveal M2 macrophages. While  
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Figure 2 PGC-1 and PGC-1 change macrophage populations in TA after injection of inflammatory agents. 
A-H, MCK mice (Panel A-D) and MCK mice (Panel E-H) and respective WT controls were injected i.m. into 
TA with PBS, LPS or TNF. A, B, E, F, Immunofluorescence stainings of TA cross sections with CD68 (Panel 
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A, E, M1), CD206 (Panel B, F, M2) and DAPI to detect macrophage populations 4h post injection. 
Representative images and quantifications are shown. C, D, G, H, Relative mRNA expression F4/80 (pan-
macrophage marker) and MSR-1 (M2) in TA of injected MCK (Panel C, D), MCK (Panel G, H) and WT 
mice was determined by RT-PCR. Values represent the mean of at least 7 animals +SEM. ** P<0.01, * P<0.05, 
WT versus MCK. 
 
 
a non-significant trend for a higher CD68 signal was observed in PBS-injected MCK mice, 
transgenic expression of PGC-1 reduced CD68-positive cell number in LPS-injected animals (Fig.  
2A). Based on the CD206 staining, the number of M2 macrophages was not affected by muscle PGC-
1 except for a lower M2 content after TNF injection (Fig. 2B). Accordingly, expression of the M2 
macrophage marker MSR-1 remained unchanged (Fig. 2D). Thus, in the experimental context of 
strong, acute inflammation, PGC-1 appears to influence mainly M1 activation, at least at the time of 
analysis. 
F4/80 mRNA expression was consistently elevated by PGC-1 in muscle (Fig. 2G). 
Accordingly, MCK muscles contained significantly more M1 macrophages based on CD68 staining 
in PBS-injected mice. Interestingly, while a trend for higher M1 macrophages levels remained, the 
difference became non-significant in MCK mice after LPS- and TNF injection, respectively (Fig. 
2E). M2 macrophage polarization was significantly increased by transgenic PGC-1 after LPS 
injection whereas no difference was observed in TNF-treated mice (Fig. 2F). Accordingly, higher 
expression of the M2 macrophage marker MSR-1 underlined the results obtained with CD206 staining 
in PBS- and LPS-treated animals (Fig. 2D, H).  
 
 
3.4.3 PGC-1 and PGC-1 evoke an anti-inflammatory environment in skeletal muscle after 
injection of inflammatory agents 
 
 Based on the shift in macrophage polarization mediated by PGC-1 and PGC-1 after the 
injection of inflammatory agents, we next mapped the cytokine environment in TA in the different 
animal models. For that purpose, expression levels of pro-inflammatory cytokines associated with M1 
activation and anti-inflammatory cytokines associated with M2 activation were determined. The M1 
cytokines TNF, IL-6, MIP-1 and MCP-1 were strongly induced in WT muscles by injection of 
inflammatory agents (Fig. 3A, C). However, skeletal muscle-specific overexpression of PGC-1 did 
not affect the elevation of these pro-inflammatory cytokines in stimulated muscle (Fig. 3A). Likewise, 
PGC- did not change expression levels of these M1 cytokines (Fig. 3C). In stark contrast, the pro-
inflammatory M1 cytokine IL-12 was potently suppressed by PGC-1 (Fig. 3A) and PGC-1 (Fig. 
3C).  
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The M2 cytokines CCL1, CCL22, IL-1Ra and TGF were all significantly augmented by LPS 
and TNF (Fig. 3B, D). IL-10 was only induced by LPS and not by TNF at the concentration tested 
(Fig. 3B, D). PGC-1 did not alter the levels of CCL22, IL-1Ra and IL-10, but it clearly enhanced 
expression of CCL1 after LPS and TNF injection compared to WT muscles (Fig. 3B). TGF 
expression was also elevated in MCK mice across all experimental conditions (Fig. 3B). The M2 
cytokines tested here were all upregulated by PGC-1 after PBS injection (Fig. 3D). This effect was 
potentiated after LPS injection except for TGF. TNF did not elicit such clear differences between 
genotypes and only CCL1 expression was significantly higher in MCK muscles compared to WT 
(Fig. 3D). This cytokine expression pattern matches the smaller effects in macrophage polarization 
after TNF injection as compared to LPS. 
 
 
 
Figure 3 PGC-1 and PGC-1 cause an anti-inflammatory environment in TA after injection of 
inflammatory agents. A-D, MCK mice (Panel A, B) and MCK mice (Panel C, D) and respective WT controls 
were injected i.m. into TA with PBS, LPS or TNF. Relative expression of different M1 (Panel A, C) and M2 
cytokines (Panel B, D) in TA was analyzed by RT-PCR 4h post injection. Values represent the mean of at least 7 
animals +SEM. ** P<0.01, * P<0.05, WT versus MCK. 
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3.4.4 PGC-1 and PGC-1 alter macrophage populations in skeletal muscle after downhill 
running 
 
 LPS- and TNF-injection trigger a strong, acute immune reaction. However, based on their 
known function, the PGC-1s are not necessarily expected to exert general immunomodulatory effects 
when exclusively overexpressed in skeletal muscle. Therefore, to include an exercise paradigm that 
more closely resembles a pathophysiological process linked to the function of the PGC-1s in muscle, 
downhill running as a milder and more physiological inflammatory stimulus was examined next. As 
expected, MCK animals were able to complete the downhill running protocol with a decline of -10° 
(see Materials and Methods) as their WT littermates (Suppl. Fig. 1A). Surprisingly, MCK mice 
performed significantly worse compared to their WT controls covering only about half the distance 
before reaching exhaustion (Suppl. Fig. 1B). Plasma IL-6 levels accordingly increased in the MCK 
model, but not in MCK mice post-exercise (Suppl. Fig. 1C and 1D). Nevertheless, absolute levels 
were very low compared to LPS and TNF injections confirming the more moderate inflammatory 
effect of downhill running. Systemic TNF levels remained below detection limit in all sedentary and 
exercised groups.  
 Overexpression of PGC-1 in TA and quadriceps of the MCK animals was about 8 fold and 
not changed by running in neither genotype (Suppl. Fig. 1E, F). PGC-1 overexpression in the MCK 
model was about 17 fold in both muscles (Suppl. Fig. 1G, H). PGC-1 expression was induced in WT 
muscles by exercise, reaching statistical significance only in quadriceps, but repressed in transgenic 
MCK muscles to about a third of WT levels (Suppl. Fig. 1G, H).  
F4/80 transcript expression was higher in exercised MCK animals compared to controls suggesting a 
higher number of total M1 and M2 macrophages (Fig. 4C). Importantly, the CD68-positive M1 
macrophage cell number in MCK mice was statistically not distinguishable from WT controls (Fig. 
4A). In contrast, CD206-positive M2 macrophages remained higher in transgenic animals after 
running resulting in a marked difference between genotypes (Fig. 4B). MSR-1 expression analysis 
revealed a non-significant trend for higher levels in MCK mice (Fig. 4D). Transgenic PGC-1 in TA 
thus fosters a stronger M2 polarization 24h after the inflammatory insult caused by eccentric muscle 
contractions.  
In PGC-1 transgenic mice, total as well as M1 macrophage numbers were augmented 
compared to WT in sedentary and exercised animals as indicated by the higher F4/80 expression and 
CD68 staining, respectively (Fig. 4E, G). In these mice, M2 macrophage occurrence in TA was also 
increased (Fig. 4F). Accordingly, higher expression of the M2 macrophage marker MSR-1 was 
observed in MCK animals post exercise (Fig. 4H).  
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Figure 4 PGC-1 and PGC-1 change macrophage populations in TA after downhill running. A-H, MCK 
mice (Panel A-D) and MCK mice (Panel E-H) and respective WT controls were running on a treadmill at a 
decline of 10°. A, B, E, F, Immunofluorescence stainings of TA cross sections with CD68 (Panel A, E, M1), 
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CD206 (Panel B, F, M2) and DAPI to detect macrophage populations 24h post injection. Representative images 
and quantifications are shown. C, D, G, H, Relative mRNA expression of F4/80 (pan-macrophage marker) and 
MSR-1 (M2) in TA of sedentary and exercised MCK (Panel C, D), MCK (Panel G, H) and WT mice was 
determined by RT-PCR. Values represent the mean of at least 6 animals +SEM. ** P<0.01, * P<0.05, WT 
versus MCK. Abbreviations: sed = sedentary, run = exercised. 
 
 
3.4.5 PGC-1 and PGC-1 cause an anti-inflammatory environment in skeletal muscle after 
downhill running 
 
To complement the quantification of macrophage polarization in the downhill running paradigm, we 
again characterized the cytokine environment in TA and quadriceps 24h post running. In the MCK 
model, IL-6 expression remained unchanged in all experimental conditions (Fig. 5A). The pro-
inflammatory cytokines MIP-1 and MCP-1 were elevated in sedentary MCK muscle, while this 
difference vanished upon running. Interestingly, IL-12 and TNF expression levels were repressed by 
PGC-1 in exercised mice, the former even in sedentary animals (Fig. 5A). Similar findings were 
obtained in the analysis of the quadriceps muscle (Suppl. Fig. 3A). In contrast to the mixed M1 
macrophage gene expression pattern, M2 cytokines were augmented in sedentary PGC-1 transgenic 
TA and quadriceps (Fig. 5B and Suppl. Fig. 3B). Expression of CCL22 remained elevated in exercised 
TA and quadriceps of MCK mice ( Fig. 5B and Suppl. Fig. 3B) while in TA CCL1 and TGF 
induction further persisted after down-hill running (Fig. 5B).  
In MCK animals, MIP1 expression was increased compared to WT mice while TNF 
levels were not significantly altered (Fig. 5C). In the exercised groups, MIP-1 and MCP-1 were 
elevated in MCK animals, diametrically opposite to the reduced levels of IL-6. Strikingly, IL-12 
expression was strongly inhibited by PGC-1 in both groups. Again, analysis of the quadriceps muscle 
confirmed the mixed expression pattern of M1 macrophage-type genes controlled by PGC-1 (Suppl. 
Fig. 3C). More coherently, the M2 cytokines CCL1, CCL22, IL-1Ra and IL-10 were all elevated by 
PGC-1 in both muscles of sedentary animals (Fig. 5D and Suppl. Fig. 3D). In addition to these genes, 
TGF was also induced by PGC-1 post-exercise (Fig. 5D and Suppl. Fig. 3D). PGC-1 and PGC-1 
in skeletal muscle therefore clearly favour the expression of a panel of anti-inflammatory cytokines 
corresponding to M2-type macrophage activation. 
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Figure 5 PGC-1 and PGC-1 cause an anti-inflammatory environment in TA after downhill running. A-D, 
MCK mice (Panel A, B) and MCK mice (Panel C, D) and respective WT controls were running on a treadmill 
at a decline of 10°. Relative expression of different M1 (Panel A, C) and M2 cytokines (Panel B, D) in TA was 
analyzed by RT-PCR 24h post running. Values represent the mean of at least 6 animals +SEM. ** P<0.01, * 
P<0.05, WT versus MCK. Abbreviations: sed = sedentary, run = exercised. 
 
 
3.4.6 PGC-1 and PGC-1 suppress IL-12 in isolated skeletal muscle cells after treatment 
with inflammatory agents 
 
Due to the high complexity of skeletal muscle tissue in vivo, it was impossible to distinguish 
muscle-derived cues from those produced and secreted by cells of the immune system in our 
experimental settings. To delineate the direct effects of the PGC-1s on muscle fibers distinctly from 
secondary effects on macrophages and other immune cells, we treated C2C12 myotubes 
overexpressing PGC-1 or PGC-1 with LPS or TNF to mimic the injection experiment. We 
subsequently determined the mRNA expression of IL-12, IL-1Ra, TGF, CCL22, CCL1 and IL-10 by 
semiquantitative real-time PCR. The expression levels of CCL1 and IL-10 were below detection limit 
and thus most likely derived from immune cells in vivo. IL-1Ra, TGF and CCL22 were traceable; 
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Figure 6 PGC-1 and PGC-1 suppress IL-12 in skeletal muscle cells after treatment with inflammatory 
agents. A, B, C2C12 myotubes adenovirally overexpressing PGC-1 (Panel A), PGC-1 (Panel B) or GFP as 
control were treated with PBS, LPS or TNF for 4h. Relative expression of different cytokines was determined 
by RT-PCR. Values represent the mean of at least 3 independent experiments +SEM. ** P<0.01, * P<0.05, WT 
versus PGC-1. 
 
 
however, they were not regulated in the same way as in vivo indicating that neither PGC-1 nor PGC-
1 boosted their expression after an inflammatory insult directly in the muscle cell (Fig. 6A, B). 
Importantly however, the strong suppression of IL-12 was recapitulated in the cellular system by 
overexpression of PGC-1 or PGC-1 (Fig. 6A, B). Thus, the very low IL-12 levels detected in 
muscle of transgenic mice are likely due to very low expression of this cytokine in muscle cells 
themselves. In contrast, the anti-inflammatory cytokines that are induced in transgenic muscle in vivo 
are presumably released from immune cells that reside in the muscle.  
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3.5 Discussion 
 
 Metabolism and inflammation are two biological processes that are tightly linked. We now 
report that the PGC-1 coactivators PGC-1 and PGC-1 constitute a molecular link between 
metabolism and inflammation in skeletal muscle. Strikingly, PGC-1 coactivators altered the balance of 
M1/M2 macrophages in skeletal muscle from M1 to M2 cells accompanied by a profoundly altered 
muscle cytokine profile. In particular, anti-inflammatory factors like CCL1, CCL22, IL-1Ra, TGF or 
IL-10 were induced in one or both MCK models depending on the experimental context, thereby 
creating an environment favoring M2 activation. Inversely, the pro-inflammatory M1 cytokine IL-12 
was strongly suppressed in both models and this suppression could be replicated in vitro in C2C12 
cells. It is therefore likely that the lack of IL-12 is a direct consequence of muscle-specific 
overexpression of either PGC-1. Studies in mice with an IL-12 deletion showed deficits in type 1 
cytokines and more importantly, a bias in macrophage activation towards M2 (28,29), which supports 
our hypothesis that defective IL-12 production causes an altered macrophage polarization.  
Systemically, we did not find a difference between PGC-1 overexpressing and WT animals at 
the time-points chosen as plasma levels of TNF and IL-6 were comparable after the challenge. PGC-
1s in skeletal muscle are therefore not able to suppress an acute inflammatory reaction of the immune 
system on whole-body level. A recent study with the MCK animals that were injected i.p. with LPS 
yielded similar results: Plasma IL-6 and TNF levels were not different between genotypes after LPS 
injection even though there was a reduction in basal TNF levels (30). This is reminiscent of the 
situation in our MCK model. However, it remains to be determined if PGC-1 and PGC-1 in 
skeletal muscle are beneficial in conditions of chronic systemic inflammation, e.g. obesity-related 
morbidities, where cytokine levels are only slightly but permanently elevated as opposed to the acute, 
strong but transient inflammatory response in both the above mentioned and our study. 
Classifying macrophages as M1 or M2 is a useful but simplified model, as there is a 
continuous spectrum in-between and several types of alternatively activated macrophages have been 
described. These are also referred to as M2a (alternative), M2b (type II) and M2c (deactivated) (31). 
M2a macrophages are induced by IL-4 and IL-13, produce IL-10, Il-1Ra and CCL22 among others 
and are involved in Th2 responses, allergy and parasite defense (32). M2b macrophages are induced 
by TLR or IL-1R ligands (e.g. LPS) together with immune complexes, are characterized by low IL-12 
and high IL-10 levels and produce CCL1 which primes T cells towards Th2 and Tregs (33,34). Like 
M2b macrophages, M2c cells also serve immunoregulatory purposes. Induced by IL-10, they further 
amplify this signal and are the main players in tissue remodeling by their ability to produce TGF 
(31). We could not detect substantial amounts of IL-4 or IL-13 in muscle and it appears that the PGC-
1s, in particular PGC-1, favor M2b macrophage specification based on the low IL-12 and high CCL1 
levels (34). It will be interesting to evaluate M2 numbers at a time-point later than 4h post injection to 
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follow up priming of these M2b cells in the injection model. The downhill running experiment 
provides evidence for this hypothesis as there are more M2 macrophages after running in MCK 
muscles compared to WT 24h after the exercise. We however do not know if there are immune 
complexes involved in the activation as has been described for this macrophage type (33). How these 
M2b cells influences other cells of the innate and adaptive immune system notably via CCL1 in the 
course of the inflammation would also be of great interest as there were no T cells or eosinophils 
detectable at these early time-points. PGC-1 might also prime towards M2c as higher TGF levels 
were found throughout the experiment, yet IL-10 levels did not differ. PGC-1 seems to affect a 
broader spectrum of M2 macrophages as signature cytokines of all 3 types were detected.  
Surprisingly, although the MCK mice have been reported to exhibit a higher endurance 
capacity than WT animals in an exercise protocol with a positive incline (21), these animals performed 
significantly worse during down-hill running in our hands. Obviously, PGC-1 might affect muscle 
function differently in concentric compared to eccentric contractions. Intriguingly however, signs of 
fiber damage and inflammation were detected even in sedentary MCK mice. It is thus conceivable 
that the supraphysiological expression of the PGC-1 transgene in these animals confers some 
detrimental effects on muscle fibers, similar to the pathological changes described in higher-
expressing muscle-specific PGC-1 transgenic lines (27,35). In contrast, normal running behavior and 
much fewer signs of fiber damage and inflammation were detected in the MCK mice. Importantly, 
despite these potentially confounding effects of increased M1-type macrophage activation and 
inflammation intrinsic to the animal models, PGC-1 and PGC-1 are still able to promote M2 type 
macrophage activation and an anti-inflammatory cytokine environment. 
PGC-1 was shown to substantially improve the pathology of Duchenne muscular dystrophy 
and other muscle wasting diseases (36). Injured and dystrophy muscles also depend on M2 
macrophages to undergo repair. After a first phase in which necrotic muscle fibers are removed by M1 
cells, M2c macrophages govern the second phase of regeneration (37,38). Given the beneficial effect 
of physiological PGC-1 overexpression in Duchenne muscular dystrophy and its ability to shift the 
balance towards less M1 or more M2 cells after inflammatory insults as shown here, it is tempting to 
speculate that PGC-1 and maybe PGC-1 are instrumental in muscle regenerative processes by 
modulating immune responses that are vital to proper recovery.  
In conclusion, the results presented here prove that PGC-1 coactivators are not only 
fundamental to control metabolism in muscle cells but also have a profound effect on the cytokine 
environment in this tissue. Due to crosstalk between muscle and immune cells, the balance of 
macrophages is skewed after an inflammatory insult from M1 to M2 cells providing a predominantly 
anti-inflammatory and immunomodulatory context. The consequences of this changed M1/M2 ratio in 
conjunction with obesity, diabetes and other diseases that are accompanied by a low-grade 
inflammation will be the subject of future studies. The possibility of influencing this ratio by 
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modulating PGC-1s bears tremendous potential to delay or even prevent the development of insulin 
resistance that requires pro-inflammatory M1 cells. Thus pharmacological targeting of the 
immunomodulatory effect of the PGC-1s in muscle and thereby promoting an M2 tissue macrophage 
phenotype could be a novel strategy for metabolic and muscle wasting diseases. 
 
97
Manuscript 2 
 
3.6 References 
 
1. Hotamisligil, G. S. (2006) Nature 444, 860-867 
2. Haffner, S. M. (2006) The American journal of cardiology 97, 3A-11A 
3. Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., and Ferrante, A. W., 
Jr. (2003) The Journal of clinical investigation 112, 1796-1808 
4. Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., and Spiegelman, B. M. (1995) The 
Journal of clinical investigation 95, 2409-2415 
5. Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. 
R., Ahima, R. S., and Lazar, M. A. (2001) Nature 409, 307-312 
6. Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., 
Quadro, L., and Kahn, B. B. (2005) Nature 436, 356-362 
7. Biswas, S. K., and Mantovani, A. (2010) Nature immunology 11, 889-896 
8. Olefsky, J. M., and Glass, C. K. (2010) Annual review of physiology 72, 219-246 
9. Mosser, D. M., and Edwards, J. P. (2008) Nature reviews 8, 958-969 
10. Lumeng, C. N., Bodzin, J. L., and Saltiel, A. R. (2007) The Journal of clinical investigation 
117, 175-184 
11. Hotamisligil, G. S., Shargill, N. S., and Spiegelman, B. M. (1993) Science (New York, N.Y 
259, 87-91 
12. Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z. W., Long, J. M., Wynshaw-
Boris, A., Poli, G., Olefsky, J., and Karin, M. (2005) Nature medicine 11, 191-198 
13. Solinas, G., Vilcu, C., Neels, J. G., Bandyopadhyay, G. K., Luo, J. L., Naugler, W., 
Grivennikov, S., Wynshaw-Boris, A., Scadeng, M., Olefsky, J. M., and Karin, M. (2007) Cell 
metabolism 6, 386-397 
14. Patsouris, D., Li, P. P., Thapar, D., Chapman, J., Olefsky, J. M., and Neels, J. G. (2008) Cell 
metabolism 8, 301-309 
15. Hevener, A. L., Olefsky, J. M., Reichart, D., Nguyen, M. T., Bandyopadyhay, G., Leung, H. 
Y., Watt, M. J., Benner, C., Febbraio, M. A., Nguyen, A. K., Folian, B., Subramaniam, S., 
Gonzalez, F. J., Glass, C. K., and Ricote, M. (2007) The Journal of clinical investigation 117, 
1658-1669 
16. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. 
A., and Nathan, D. M. (2002) The New England journal of medicine 346, 393-403 
17. Gleeson, M. (2007) J Appl Physiol 103, 693-699 
18. Puigserver, P., Adelmant, G., Wu, Z., Fan, M., Xu, J., O'Malley, B., and Spiegelman, B. M. 
(1999) Science (New York, N.Y 286, 1368-1371 
19. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, 
S., Lowell, B., Scarpulla, R. C., and Spiegelman, B. M. (1999) Cell 98, 115-124 
20. Calvo, J. A., Daniels, T. G., Wang, X., Paul, A., Lin, J., Spiegelman, B. M., Stevenson, S. C., 
and Rangwala, S. M. (2008) J Appl Physiol 104, 1304-1312 
21. Arany, Z., Lebrasseur, N., Morris, C., Smith, E., Yang, W., Ma, Y., Chin, S., and Spiegelman, 
B. M. (2007) Cell metabolism 5, 35-46 
22. Handschin, C., Chin, S., Li, P., Liu, F., Maratos-Flier, E., Lebrasseur, N. K., Yan, Z., and 
Spiegelman, B. M. (2007) The Journal of biological chemistry 282, 30014-30021 
23. Zechner, C., Lai, L., Zechner, J. F., Geng, T., Yan, Z., Rumsey, J. W., Collia, D., Chen, Z., 
Wozniak, D. F., Leone, T. C., and Kelly, D. P. (2010) Cell metabolism 12, 633-642 
24. Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., 
Kohane, I., Costello, M., Saccone, R., Landaker, E. J., Goldfine, A. B., Mun, E., DeFronzo, 
R., Finlayson, J., Kahn, C. R., and Mandarino, L. J. (2003) Proceedings of the National 
Academy of Sciences of the United States of America 100, 8466-8471 
25. Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A., Sihag, S., Lehar, J., 
Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., Houstis, N., Daly, M. J., Patterson, 
N., Mesirov, J. P., Golub, T. R., Tamayo, P., Spiegelman, B., Lander, E. S., Hirschhorn, J. N., 
Altshuler, D., and Groop, L. C. (2003) Nature genetics 34, 267-273 
98
Manuscript 2 
 
26. Handschin, C., Choi, C. S., Chin, S., Kim, S., Kawamori, D., Kurpad, A. J., Neubauer, N., Hu, 
J., Mootha, V. K., Kim, Y. B., Kulkarni, R. N., Shulman, G. I., and Spiegelman, B. M. (2007) 
The Journal of clinical investigation 117, 3463-3474 
27. Lin, J., Wu, H., Tarr, P. T., Zhang, C. Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., 
Isotani, E., Olson, E. N., Lowell, B. B., Bassel-Duby, R., and Spiegelman, B. M. (2002) 
Nature 418, 797-801 
28. Magram, J., Connaughton, S. E., Warrier, R. R., Carvajal, D. M., Wu, C. Y., Ferrante, J., 
Stewart, C., Sarmiento, U., Faherty, D. A., and Gately, M. K. (1996) Immunity 4, 471-481 
29. Bastos, K. R., Alvarez, J. M., Marinho, C. R., Rizzo, L. V., and Lima, M. R. (2002) Journal of 
leukocyte biology 71, 271-278 
30. Olesen, J., Larsson, S., Iversen, N., Yousafzai, S., Hellsten, Y., and Pilegaard, H. (2012) PLoS 
One 7, e32222 
31. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., and Locati, M. (2004) Trends 
in immunology 25, 677-686 
32. Mosser, D. M. (2003) Journal of leukocyte biology 73, 209-212 
33. Gerber, J. S., and Mosser, D. M. (2001) J Immunol 166, 6861-6868 
34. Sironi, M., Martinez, F. O., D'Ambrosio, D., Gattorno, M., Polentarutti, N., Locati, M., 
Gregorio, A., Iellem, A., Cassatella, M. A., Van Damme, J., Sozzani, S., Martini, A., 
Sinigaglia, F., Vecchi, A., and Mantovani, A. (2006) Journal of leukocyte biology 80, 342-349 
35. Handschin, C. (2009) Trends in pharmacological sciences 30, 322-329 
36. Handschin, C., Kobayashi, Y. M., Chin, S., Seale, P., Campbell, K. P., and Spiegelman, B. M. 
(2007) Genes & development 21, 770-783 
37. Villalta, S. A., Rinaldi, C., Deng, B., Liu, G., Fedor, B., and Tidball, J. G. (2010) Human 
molecular genetics 20, 790-805 
38. Villalta, S. A., Deng, B., Rinaldi, C., Wehling-Henricks, M., and Tidball, J. G. (2011) J 
Immunol 187, 5419-5428 
 
 
99
Manuscript 2 
 
3.7 Supplemental Material 
 
 
 
Suppl. Figure 1 PGC-1 and PGC-1 do not suppress systemicIL-6 levels. A-H, MCK mice (Panel A, C, E, 
F) and MCK mice (Panel B, D, G, H) and respective WT controls were running on a treadmill at a decline of 
10°. A, B, Total distance covered by the different genotypes until reaching exhaustion or the end of the protocol 
is displayed. C, D, Serum levels of IL-6 were determined 24h post running. E-G, mRNA expression levels of 
PGC-1 isoforms in TA (Panel E, G) and quadriceps (Panel F, H) were measured by RT-PCR. Values represent 
the mean of at least 6 animals +SEM. ** P<0.01, * P<0.05, WT versus MCK. Abbreviations: sed = sedentary, 
run = exercised. 
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Suppl. Figure 2 PGC-1 but not PGC-1 changes macrophage populations in quadriceps after downhill 
running. A-D, MCK mice (Panel A, C) and MCK mice (Panel B, D) and respective WT controls were 
running on a treadmill at a decline of 10°. A, B, Quantification of immunofluorescence stainings of quadriceps 
cross sections with CD68 (M1) and CD206 (M2) to detect macrophage populations 24h post running. C, D, 
Relative mRNA expression of F4/80 (pan-macrophage marker) and MSR-1 (M2) in quadriceps of sedentary and 
exercised MCK, MCK and WT mice was determined by RT-PCR. Values represent the mean of at least 6 
animals +SEM. ** P<0.01, * P<0.05, WT versus MCK. Abbreviations: sed = sedentary, run = exercised. 
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Suppl. Figure 3 PGC-1 and PGC-1 cause an anti-inflammatory environment in quadriceps after downhill 
running. A-D, MCK mice (Panel A, B) and MCK mice (Panel C, D) and respective WT controls were 
running on a treadmill at a decline of 10°. Relative expression of different M1 (Panel A, C) and M2 cytokines 
(Panel B, D) in quadriceps was analyzed by RT-PCR 24h post running. Values represent the mean of at least 6 
animals +SEM. ** P<0.01, * P<0.05, WT versus MCK. Abbreviations: sed = sedentary, run = exercised. 
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Gene Forward primer Reverse primer 
CCL1 ACAGGAGGAGCCCATCTTTC CTGCCGTGTGGATACAGGAT 
CCL22 TGGAGTAGCTTCTTCACCCA TCTGGACCTCAAAATCCTGC 
CD206 GTGGATTGTCTTGTGGAGCA TTGTGGTGAGCTGAAAGGTG 
CD68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
CXCL-10 CTTCCCTATGGCCCTCATTC AAGTGCTGCCGTCATTTTCT 
F4/80+ CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
IL-1Ra AAATCTGCTGGGGACCCTAC TGAGCTGGTTGTTTCTCAGG 
IL-10 CTGGACAACATACTGCTAACCG GGGCATCACTTCTACCAGGTAA 
IL-12 GCTTCTCCCACAGGAGGTTT CTAGACAAGGGCATGCTGGT 
IL-6 CCACGGCCTTCCCTACTTC TTGGGAGTGGTATCCTCTGTGA 
MCP-1 CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
Mgl1 CAGGATCCAGACAGATACGGA GGAAGCCAAGACTTCACACTG 
MIP-1 TCCCAGCCAGGTGTCATTTT TTGGAGTCAGCGCAGATCTG 
MSR1 TGAACGAGAGGATGCTGACTG GGAGGGGCCATTTTTAGTGC 
PGC-1 TGATGTGAATGACTTGGATACAGACA GCTCATTGTTGTACTGGTTGGATATG 
PGC-1 GGCAGGTTCAACCCCGA CTTGCTAACATCACAGAGGATATCTTG 
TBP GGCCTCTCAGAAGCATCACTA GCCAAGCCCTGAGCATAA 
TGF CAACCCAGGTCCTTCCTAAA GGAGAGCCCTGGATACCAAC 
TNF CACAAGATGCTGGGACAGTGA TCCTTGATGGTGGTGCATGA 
 
Suppl. Table 1 RT-PCR primers. 
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4 Discussion 
 
In the following section, general issues of this project, considerations that were beyond the 
scope of either manuscript, and a comparison between the in vitro and the in vivo model will be 
discussed. The first manuscript “The PGC-1 coactivators repress transcriptional activity of NF-B in 
skeletal muscle cells” will be referred to as Ms1, the second manuscript “The PGC-1 coactivators 
promote M2 polarization of tissue macrophages in skeletal muscle” will be referred to as Ms2.  
 
 
4.1 General discussion 
 
 The work presented here explored the relationship between PGC-1 coactivators and 
inflammatory reactions in skeletal muscle. The project was undertaken in order to clarify whether 
PGC-1 and PGC-1 have anti-inflammatory properties, a question that had not been resolved 
previously. Using a C2C12 cell culture model and adenoviral PGC-1 overexpression, this question 
was first addressed in vitro. In this system both PGC-1 and PGC-1 had repressive effects on pro-
inflammatory gene expression elicited by TNF, different TLR agonists and saturated FFAs. The 
repression was however target gene- and stimulus-specific arguing against a general 
immunosuppressive function of PGC-1 coactivators but rather for a differential fine-tuning of 
inflammatory reactions. The observation that PGC-1 coactivators are indeed able to reduce pro-
inflammatory cytokine expression positions them at a major crossroad of two relevant physiological 
areas, namely, metabolism and inflammation. Innumerous studies in recent years have uncovered 
manifold interactions between those two areas and more importantly, their mutual dysregulation in 
many diseases. It is therefore not too surprising that a versatile, metabolic regulator like PGC-1 also 
plays a role in immune function, which however had not been proven so far. The anti-inflammatory 
effects of PGC-1s are also consistent with the beneficial effects of exercise involving the attenuation 
of chronic systemic inflammation (375).  
 In an attempt to elucidate how PGC-1 coactivators influence inflammatory reactions, 
stimulation with TNF was analyzed in greater detail. Computational predictions pointed to the NF-
B pathway as main target of PGC-1´s repressive action. Analysis of the components in this pathway 
showed that both PGC-1 and PGC-1 interfered with an activating phosphorylation of the NF-B 
family member p65. Lack of phosphorylation then leads to incomplete activation of transcription, 
explaining the lowered pro-inflammatory cytokine levels. As PGC-1 and PGC-1 have been 
described as coactivators so far, a direct corepressor function was unlikely and would have been hard 
to reconcile with their structure including an AD. The modulation of PTMs of members of the NF-B 
pathway is therefore a more reasonable, indirect model. The ability to affect p65 phosphorylation 
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furthermore confirms the specific influence of PGC-1 coactivators on inflammatory reactions as 
opposed to a general immunosuppressive role. More precisely, PGC-1 coactivators do not repress 
transcription driven by NF-B dimers that lack p65. In this way, they shape the response of muscle 
cells to inflammatory stimuli without completely repressing it. As p65 is responsible for many of the 
detrimental effects brought about by chronic inflammation, PGC-1 coactivators may act protective in 
this regard. Moreover, PGC-1 but not PGC-1 induced several components of the noncanonical NF-
B signalling pathway, which might explain differences between the two coactivators and further 
supports the concept that PGC-1s shape NF-B-driven inflammatory responses. As the function of 
noncanonical NF-B signalling in skeletal muscle is poorly understood, the consequences of this 
altered signalling remain to be determined. Recently, oxidative muscle metabolism was associated 
with activation of noncanonical NF-B signalling, which fits well with the known roles of PGC-1 
coactivators as potent inducers of oxidative pathways (359).  
 The p65 phosphorylation deficit has several causes: On the kinase side, insufficient Akt 
phosphorylation presumably fails to activate IKK which in turn limits the scale of p65 
phosphorylation. Concerning phosphatases, an involvement is likely as short-term TNF stimulation 
did not yield overt differences in p65 phosphorylation as observed at later time points. Unfortunately, 
we were not able to identify the corresponding enzyme(s), but can exclude that PP1 and PP2A play a 
role. It would be of great interest to pinpoint that phosphatase as it might have a broader effect on 
other phosphorylation-sensitive processes in the cell (for further discussion of that point see 4.2.2). 
Induction of such a phosphatase would also be a good model to explain repressive effects of 
coactivator proteins as their primary function would be transcriptional initiation within the 
phosphatase promoter in accordance with their known molecular mode of action. Only the secondary 
effect would then be a repression as the phosphatase removes activating phospho residues. It is even 
possible, that the same phosphatase that dephosphorylates p65 also dephosphorylates Akt and 
therefore negatively affects its activity.  
A second mechanism operating in conjunction with decreased phosphorylation to diminish 
pro-inflammatory cytokine expression is transrepression by PPAR. PGC-1 and PGC-1 both 
considerably increase expression of PPAR while inhibition of this nuclear receptor normalizes 
cytokine production at least for PGC-1. Several subforms of transrepression have been described 
involving direct binding of nuclear receptors to NF-B subunits as well as competitive binding to 
coactivators without direct contact. PPAR could potentially associates with p65 directly when bound 
to B sites which might sterically block access to serine residues within p65 and thus hamper 
phosphorylation. If a sumoylation-dependent mechanism plays a role as previously shown for PPAR 
(278) remains an interesting open question. Anti-inflammatory properties have been ascribed to many 
nuclear receptors including PPAR, underlining the feasibility of this result. Furthermore, fibrate 
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drugs that target PPAR and are widely used to lower cholesterol and triglyceride levels in humans, 
have been linked to anti-inflammatory action in most clinical studies on that issue (379). 
In nonstimulated cells, PGC-1 but nor PGC-1 further repressed expression of p65 and p50, 
and consequently, DNA binding of these NF-B family members representing another example of 
differential regulation between both coactivators. The repressive effect of PGC-1 as opposed to PGC-
1 on cytokine expression in the basal state can be attributed to this property. As PGC-1 is not 
induced upon exercise in skeletal muscle and its function in this organ remains obscure, the 
physiological meaning of this observation is not immediately evident. The fact that skeletal muscle 
does however express considerable amounts of PGC-1 suggest some relevance of this factor. One 
putative role could be the prevention of inflammation as inflammatory reactions accompany many 
musculoskeletal disorders and deteriorate muscle function.  
To our knowledge, this is the first report investigating the impact and mechanistic basis of 
PGC-1 and PGC-1 in cultured skeletal muscle cells regarding inflammatory responses. As NF-B 
signalling also negatively acts on PGC-1 coactivator levels (at least in the long run, see 4.2.1 for 
further discussion), and thus on oxidative metabolism, these two pathways are more closely 
intertwined than supposed so far. In the context of metabolic disorders that are accompanied by low 
levels of both coactivators in skeletal muscle and a persistent, subclinical inflammation, these findings 
strongly suggest a causality between dysregulated PGC-1 coactivator expression and elevated 
inflammatory markers. Inversely, healthy muscles expressing sufficient amounts of PGC-1 and PGC-
1 are protected from inflammatory insults to a certain degree. As chronic inflammation is detrimental 
and accelerates the progression of many diseases, preventing the decline of PGC-1 and PGC-1 in 
skeletal muscle during the course of such diseases appears as an attractive strategy to improve overall 
health. Reducing these diseases only to the antagonism of PGC-1 coactivators and NF-B in skeletal 
muscle is however certainly an oversimplification and many other factors need to betaken into account 
to understand the pathology. The in vitro model that was used here however resolves basic 
mechanisms of this antagonistic action that are less evident in more complex systems for example 
diabetic human patients due to the multitude of confounding factors.  
 In an attempt to replicate the data in vivo, we encountered that PGC-1 and PGC-1 
expression in skeletal muscle influenced macrophage polarization within the tissue. Even though pro-
inflammatory gene expression was not changed in this model during an inflammatory response 
compared to WT animals, a higher number of alternatively activated macrophages and a cytokine 
profile associated with this state prevailed in the presence of PGC-1 coactivators. Therefore, PGC-1 
coactivators exerted an anti-inflammatory role also in vivo, however in an unexpected indirect way. 
Most likely, this skewing of macrophages towards alternative activation was mediated by low IL-12 
levels derived directly from muscle cells while high M2 cytokine expression probably originated from 
the activated macrophages themselves.  
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An influence of PGC-1 or PGC-1 expression in any tissue on immune cells has not been 
demonstrated before but this observation again shows how immune and metabolic pathways are 
intricately linked within and between cells. The involvement of the immune system in obesity and its 
sequelae is well characterized and classically activated macrophages foster the chronic inflammation 
and thus contribute to deterioration of patients´ health. In contrast, alternative macrophage activation 
confines inflammation and may even act protective. Although there are major gaps in our knowledge 
on macrophage polarization, its regulation and function in skeletal muscle, our findings provide 
another jigsaw piece to understand mutual influences of immune and muscle cells under conditions of 
inflammation. As this crosstalk is harmful in chronic diseases, the results presented here underline the 
importance of considering an integrated picture of muscle not only as metabolic but also as immune 
organ. The potential of PGC-1 coactivators to influence macrophage polarization therefore adds 
another layer of complexity to the multiple functions of these coactivators in skeletal muscle and 
represents an elegant, indirect way of anti-inflammatory action. Targeting PGC-1 coactivators could 
therefore be a valid strategy in metabolic as well as in skeletal muscle disorders that are accompanied 
by detrimental, inflammatory reactions.  
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4.2 The PGC-1 coactivators repress transcriptional activity of NF-B in skeletal 
muscle cells 
 
4.2.1 Inflammatory stimuli and their influence on PGC-1 coactivators in skeletal muscle cells 
 
 The chronic, low-grade inflammation that accompanies obesity is characterized by elevated 
levels of FFAs and pro-inflammatory cytokines including TNF and IL-6. To evaluate the effect of 
PGC-1 coactivators on inflammation in our C2C12 model, we applied different inflammatory stimuli 
to elicit an immune response evident from the production of inflammatory cytokines. We found that 
TNF, TLR1/2, TLR4 and TLR6/2 agonists as well as saturated fatty acids induced IL-6 and TNF 
expression and transcription from an NF-B reporter in this model in accordance with previous reports 
(Ms1, Fig. 1, Fig. 2, Fig. 3, Suppl. Fig 1C and 1D) (380-383). Besides TNF, it seemed obvious to 
also employ IL-6 in this regard, as both cytokines are commonly linked to the development of 
metabolic diseases. In contrast to TNF, IL-6 failed to elicit pro-inflammatory cytokine expression 
(Fig. 9A). IL-6 binds to the IL-6 receptor (IL-6R) that signals in conjunction with gp130. Hyper-IL-6 
is a fusion protein of IL-6 and the soluble IL-6 receptor that acts on cells expressing gp130 but 
insufficient amounts of membrane-bound IL-6R (384). Its bioactivity was shown to be 100-1000 fold 
higher than unlinked IL-6/IL-6R on hematopoietic progenitor cell proliferation, but treatment of  
 
 
 
Figure 9 IL-6 does not elicit transcription of inflammatory markers. A, C2C12 cells were differentiated and 
treated with IL-6 for 2h. Expression of IL-6 and TNF was assessed by real-time PCR. B, C2C12 cells were 
transfected with a NFB reporter construct (or a mutated reporter construct as control) and treated with IL-6 or 
Hyper-IL-6 (384) for 2h. Luciferase activity was determined and is expressed as ratio of wt to mutated reporter 
gene expression. Values represent the mean of at least 3 independent experiments SEM.  
 
 
C2C12 cells with neither IL-6 nor Hyper-IL-6 yielded NF-B activation (Fig. 9B) although these cells 
have been previously shown to express gp130 (385). This fits the notion that IL-6 is a potent inducer 
of the JAK/STAT and the MAPK/ERK pathway but not the NF-B pathway (386). The expression of 
IL-6 itself is however under the control of NF-B, JNK and PKC and possibly other pathways in 
skeletal muscle cells. Its effect on the muscle depends on the exposure time: While chronically 
elevated IL-6 levels, as present in obesity, impair insulin signalling, transient bouts of IL-6 enhance 
insulin sensitivity (385,387). This dual regulation also suits its role as a myokine in exercise. The 
108
Discussion 
 
absence of pro-inflammatory cytokine expression (Fig. 9A) and the lack of NF-B activation (Fig. 
9B), which both are possibly harmful events in skeletal muscle, are therefore well in line with the 
beneficial effect attributed to short-term IL-6 exposure. As this study was focused on pro-
inflammatory cytokine production and the NF-B pathway, which were both unaffected by IL-6, this 
cytokine did not fulfil the criteria of an inflammatory stimulus in our model. 
 Expression from adenoviral vectors leads to a strong and persistent elevation of the respective 
mRNA and protein levels. Therefore, the in vitro study exhibited high differences in PGC-1 and 
PGC-1 expression between PGC-1 and GFP expressing cells that tended to be slightly induced by 
treatment with TNF, albeit without reaching statistical significance (Ms1, Suppl. Fig. 1A and 1B). 
Endogenous levels of PGC-1 coactivator were repeatedly described to be affected by inflammatory 
reactions, although with inconsistent results. LPS-induced sepsis has been studied most extensively in 
this regard: In liver, heart and kidney, mRNA levels of PGC-1, ERR and MCAD were found to be 
markedly reduced 16h after LPS injection (388). The suppression of PGC-1 by LPS was further 
confirmed by another study in heart in vivo (389) and by treatment of cardiac cells with LPS or TNF 
in vitro (390,391). PGC-1 levels could be rescued by inhibition of NF-B indicating the involvement 
of this pathway. Reduced oxygen delivery and swollen mitochondria with impaired function are found 
in sepsis-associated acute kidney injury due to reduced PGC-1 levels that correlate with the degree of 
renal impairment (392). Along these lines, TNF treatment of tubular cells for 48h reduced PGC-1 
expression and oxygen consumption. This effect could be reversed by excess PGC-1 (392). 
Inversely, mice with a PGC-1 deletion had normal kidneys if unchallenged, but suffered from 
persistent injury after endotoxemia (392). In contrast to the findings of Kim et al. (388), PGC-1 and 
PGC- were both found to be induced in livers of septic mice in a TLR2-dependent manner (393). 
This induction further depended on the adaptor proteins TRAM and TRIF as well as on IRF3/7 as 
shown with deletion models (393). However, signalling of TLR2 through these alternative adaptors 
has not been confirmed by any other report.  
In skeletal muscle, the situation is similar as both repression and induction of PGC-1 
coactivators were observed. In an early study both, LPS and the pro-inflammatory cytokines TNF 
and IL-1 elevated PGC-1 expression in cultured skeletal muscle cells via the MAPK/p38 pathway, 
leading to increased expression of genes in oxidative phosphorylation (106). More recently, sepsis was 
shown to decrease PGC-1 and PGC-1 in skeletal muscle of rats and mice 16h after LPS injection 
(394). These data are supported by a study in diaphragm, where LPS diminished fatty acid oxidation 
alongside a decrease in PGC-1 and PGC-1 at the same time-point (395). The differences may 
depend on the time-point chosen, as intraperitoneal injection of LPS induced PGC-1 in skeletal 
muscle after 2h but decreased its expression after 24h, arguing for a dual mode of action with a short-
term up- but a long-term down-regulation (396). This model would also fit the induction of PGC-1  
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after exercise in the presence of myokines that return to basal levels quickly whereas the low-grade 
inflammation in metabolic disorders impairs PGC-1 and PC-1 expression in skeletal muscle due to 
the chronic nature of the inflammatory mediators involved. Similar observations with palmitate back 
such a model, as long-term treatment (16h) of C2C12 cells repressed PGC-1 (but not PGC-1) 
expression while at earlier time-points, PGC-1 was induced under these conditions (397). In 
accordance with our results, palmitate, but not oleate, elicited these effects that were furthermore 
dependent on MEK1/2 and NF-B (397). In contrast to that, a study in vascular smooth muscle cells 
implicated oleic acid in a decrease and palmititc acid in an increase of PGC-1 levels after 24h (398).  
 Our cell culture model also supports a biphasic regulation of both PGC-1 coactivators by 
inflammatory stimuli as mRNA levels of both PGC-1 and PGC-1 tended to be increased by TNF 
after 2h in cells expressing the transgene (Ms1, Suppl. Fig. 1A and 1B), which is also evident for 
PGC-1 on protein level (Ms1, Fig. 6A and Suppl. Fig. 4B). The effect is however absent in cells 
overexpressing GFP (Ms1, Suppl. Fig. 1A and 1B) suggesting that short-term TNF treatment acts 
mainly on the transgene and not on the endogenous PGC-1 isoforms. To further elaborate on the effect 
of inflammatory stimuli on PGC-1 coactivator expression, two PGC-1 reporter constructs containing 
either the canonical or the alternative promoter were employed. The PGC-1 isoforms that derive 
from the alternative promoter (PGC-1-b and PGC-1-c) are upregulated by exercise and, in fact, 
they constitute the major share in contraction-induced PGC-1 in skeletal muscle (44). Their more 
dynamic expression raised the possibility that inflammatory stimuli might specifically act on those 
 
 
 
Figure 10 Short-term inflammatory stimulation does not induce the PGC-1 promoter and p65 
overexpression only at high levels. A, C2C12 cells were transfected with a canonical (6kb promoter) or an 
alternative (4kb alternative promoter) reporter construct for PGC-1. After 24h, cells were treated with TNF or 
TLR agonists for 2h and luciferase activity determined. B, C2C12 cells were transfected with a canonical (6kb 
promoter) or an alternative (4kb alternative promoter) reporter construct for PGC-1, increasing amounts of p65 
or treated with forskolin (Fsk) for 4h as positive control and luciferase activity was determined. Values represent 
the mean of at least 3 independent experiments SEM. # P<0.05, treatment versus Ctrl. 
 
 
isoforms in skeletal muscle as has been shown for -adrenergic signalling previously (44). A 2h 
stimulation with TNF or different TLR agonists (at the concentration used for all experiments) did 
not yield a significant induction of either construct (Fig. 10A) in accordance with results from GFP 
overexpressing cells. Cotransfection of high levels of p65 did however induce the canonical promoter 
slightly and the alternative promoter more strongly (Fig. 10B) confirming that the alternative promoter 
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is subject to a more variable regulation with higher plasticity than the canonical promoter. These 
results illustrate that regulation of PGC-1 by inflammatory stimuli is complex and not only depends 
on the duration of the stimulus but also the concentration. The differential effect on the canonical and 
the alternative isoform further increases the intricacy and may explain why previous reports varied 
considerably in their results. As the alternative PGC-1 isoform only accounts for a fraction of total 
PGC-1 amounts in muscle cells, the functional significance of this increase warrants further 
investigation. Biologically, an acute induction of PGC-1 (and presumably PGC-1) elicited by high 
levels of inflammatory mediators could be a means of ensuring an adequate energy supply under 
conditions of infection where the muscle cell needs to fight pathogens which requires an additional 
amount of transcription, translation, secretion etc.  
Opposed to acute, high levels of inflammatory mediators, their chronic presence decreased 
PGC-1 coactivator levels in the biphasic model. Examining long-term (48h) stimulation in our model, 
TNF tended to decrease both coactivators (Fig. 11A), while TLR1/2 and TLR4 agonists did not have 
an influence on PGC-1 levels (Fig. 11B). TLR6/2 agonists tended to decrease PGC-1 and all 3 
significantly lowered PGC-1 levels (Fig. 11B) supporting the biphasic regulation of PGC-1  
 
 
 
 
 
 
 
 
 
 Figure 11 Long-term inflammatory stimulation 
 diminishes PGC-1 coactivators. A, C2C12 cells 
 were differentiated and treated with TNF for 48h. 
 Expression of IL-6, PGC-1, and PGC-1 was 
 assessed by real-time PCR. B, C2C12 cells were 
 differentiated and treated with TLR agonists for 48h. 
 Expression of IL-6, PGC-1, and PGC-1 was 
 assessed by real-time PCR. Values represent the mean 
 of at least 3 independent experiments SEM. # P<0.05, 
 treatment versus Ctrl.  
 
 
 
coactivators. Treatment of C2C12 cells with fatty acids for 48h was not possible as the medium used 
was devoid of serum to exclude endotoxin contaminations not allowing for cell survival for such long 
periods of time. The repression of PGC-1 and PGC-1 at least by some chronically applied 
inflammatory stimuli fits in well with the dysregulation of these coactivators in skeletal muscle of 
obese patients that also suffer from a chronic inflammation, and it proposes that chronically elevated 
cytokine levels are causal to this dysregulation.  
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Furthermore, chronic obstructive pulmonary disease (COPD) is frequently associated with 
peripheral muscle wasting, and patients exhibit high TNF levels in skeletal muscle with decreased 
oxidative capacity (399). In these muscles, PGC-1 is diminished and this suppression can be 
recapitulated by chronic treatment (>24h) of C2C12 cells with TNF (399,400). TNF-induced 
inhibition of oxidative phosphorylation is NF-B dependent (399) and according to their function, 
more evident in oxidative than in glycolytic muscle fibers if mice are exposed to cigarette smoke 
(400). Interestingly, blood levels of TNF negatively correlate with PPAR expression in skeletal 
muscle of COPD patients that show low PGC-1 levels (401).  
Our data, the examples of sepsis (at least the majority of published data) and COPD therefore 
establish a negative regulation of oxidative metabolism including its master regulators, PGC-1, by 
chronic inflammatory signals in skeletal muscle. Furthermore, we showed that at least in vitro, PGC-1 
coactivators suppress pro-inflammatory cytokine expression in C2C12 cells by targeting NF-B 
phosphorylation. The NF-B pathway thus appears to be a nodal point between two fundamental 
biological programs, namely inflammation and oxidative metabolism which are subject to reciprocal 
regulation by one another. This notion may extend to other organs especially those with high oxidative 
capacity and to inflammatory diseases that are often accompanied by mitochondrial dysfunction.  
From an evolutionary perspective, this mutual regulation is not so surprising as metabolic and 
immune functions have developed from a common ancestral structure, i.e. the fat body in Drosophila 
(402). This organ comprises homologues of liver, adipose tissue and immune system and functions to 
sense nutrient and energy status but also pathogen presence. These cues are then translated into an 
appropriate metabolic or immune response to assure survival. In mammals, these tasks are divided 
between specialized organs that however still carry their developmental heritage, a putative common 
regulatory network of metabolic and immune signalling. Importantly, both liver and adipose tissue still 
contain large numbers of immune cells (Kupffer cells and ATMs) enabling constant interaction and an 
integration of metabolic and immune signals (402).  
 
 
4.2.2 Regulation of other NF-B pathway modulators by PGC-1 coactivators 
 
In an attempt to delineate the mechanism of PGC-1-mediated downregulation of inflammatory genes, 
we identified the NF-B pathway as crucial player and more specifically, decreased phosphorylation 
of p65. To answer the obvious question about the responsible kinase and/or phosphatase, we assessed 
the levels of different kinases able to change p65 phosphorylation. Among these, MSK1 and PKAc 
directly target p65 but their levels were either unchanged or even induced in the presence of PGC-1 
and PGC-1 (Fig. 12A and 12B). Although kinase activities are often regulated at the 
posttranscriptional level, these results did not imply an involvement of these two kinases in 
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downregulating p65 activity. We further analysed levels of p38 and activity of Akt, both kinases that 
do not directly target p65 but modulate MSK1 and IKK activity, respectively. While p38 levels were 
unchanged (Fig. 12A and 12B), Akt was markedly decreased (Ms1, Fig. 7A). We therefore postulate a 
mechanism of PGC-1-dependent repression of Akt that acts on IKK which subsequently is unable to 
phosphorylate p65 sufficiently, ultimately resulting in diminished NF-B activity.  
 
 
 
Figure 12 p38, MSK1, PKAc and WIP-1 are not responsible for lower p65 phosphorylation. A, B, 
Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A) or PGC-1 and GFP (Panel B) 
were treated with TNF for 2h. Expression of the p65 kinases p38, MSK1, PKAc and the phosphatase WIP-1 
was determined by real-time PCR. Values represent the mean of at least 3 independent experiments SEM. ** 
P<0.01 PGC-1/ versus GFP. 
 
 
As we observed similar levels of p65 phosphorylation between conditions after 5min of TNF 
treatment (compared to reduced levels after 2h in the presence of PGC-1/ Ms1, Fig. 7B and 7C), 
we also considered phosphatase involvement. The only known p65-specific enzyme, WIP-1, did not 
change expression (Fig. 12A and 12B) and is therefore unlikely to be important in the phenomenon 
observed. Inhibition of the broad target phosphatases PP1 and PP2A that are known to also 
dephosphorylate p65 yielded the expected stabilization of p65 phosphorylation. The effect of lower 
p65 phosphorylation levels in the presence of PGC-1/ was however still present albeit at 
substantially higher levels (Ms1, Fig. 7D, 7E and 7F). PP2A and PP1 are therefore also most likely not 
involved in these processes. Interestingly, okadaic acid (the PP1/PP2A inhibitor) also enhanced PGC-
1 levels (Ms1, Fig. 7D and 7E). So far, an effect of okadaic acid on PGC-1 has only been described 
with regard to localization: hyperphosphorylated PGC-1 moves out of inactive nuclear speckles, a 
feature common to classic SR proteins that are involved in pre-mRNA splicing (41). Investigating 
which serine and/or threonine residues within PGC-1 are targeted by PP2A and PP1 would broaden 
our knowledge on the regulation of PTMs and might open up new ways to influence PGC-1 protein 
stability (see 1.1.3).  
In addition to phosphorylation of p65, multiple signals are able to modulate NF-B activation 
and impinge on signalling (see 1.2.2). Bcl3 is an atypical IB (see 1.2.1) and was shown to interact 
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with PGC-1 in order to synergistically coactivate ERR and PPAR in cardiac cells (403). This 
interaction led us to determine whether Bcl3 might be implicated in the repression of inflammatory 
NF-B signalling in our model. However, Bcl3 mRNA levels (Fig. 13A and 13B) followed the 
expression pattern of pro-inflammatory cytokines (Ms1, Fig. 1A and 1B) rendering it a likely 
downstream target of NF-B, but not an upstream regulator. The same holds true for the dual ubiquitin 
editing enzyme A20 (Fig. 13A and 13B), and indeed a negative feedback loop has been known for a 
long time (404). Higher A20 levels that would decrease pro-inflammatory cytokine expression would 
also change DNA binding of the p65/p50 heterodimer. Therefore, these data fit results from the 
TransAM where no such difference could be detected. An induction of IB as previously described 
in quadriceps of whole body PGC-1 transgenic mice (405) would also influence p65/p50 DNA 
binding. We could not recapitulate this induction in our in vitro system in line with TransAM results.  
 
 
 
Figure 13 Bcl3, A20, PPAR and GR do not contribute to a common PGC-1 /-mediated mechanism of NF-
 repression. A, B, Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A) or PGC-1 
and GFP (Panel B) were treated with TNF for 2h. Expression of Bcl3, A20, PPAR and GR was determined by 
real-time PCR. Values represent the mean of at least 3 independent experiments SEM. # P<0.05, ## P<0.01 
GFP TNF versus GFP Ctrl, * P<0.05, ** P<0.01 PGC-1/ versus GFP.  
 
 
As transrepression is a mechanism that does generally not change DNA binding of the targeted 
transcription factor, we also investigated nuclear receptors that had previously been shown to mediate 
transrepression. We focused on PPAR, PPAR and GR that are furthermore coactivated by PGC-1. 
PPAR, that is also coactivated by PGC-1, was strongly induced in the presence of both PGC-1  
coactivators (Ms1, Fig. 8A and 8B), while PPAR and GR were induced by PGC-1 but reduced by 
PGC-1 (Fig. 13A and 13B). The opposite regulation of PPAR and GR precludes a uniform 
transrepression mechanism mediated by these coactivators, even though PPAR and GR might 
contribute to transrepression in the presence of PGC-1. An in vivo study on inflammatory bowl 
disease found indeed amelioration of colitis by treatment with conjugated linoleic acid that was 
mediated by PPAR. (406). Treated mice also exhibited higher PGC-1 levels while NF-B activation 
and TNF expression were repressed reminiscent of the situation in our model. Unfortunately, 
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confirming the large increase of PPAR on protein levels was impossible due to inferior quality of 
commercially available antibodies.  
 
 
4.2.3 Direct interaction of PGC-1 coactivators and NF-B subunits  
 
An inhibitory effect may stem from a direct protein-protein interaction that depending on the 
function of the inhibited protein either hinders it from DNA binding, or interaction with other proteins, 
or blocks its enzymatic activity. Therefore, a direct interaction of PGC-1 and PGC-1 with p65 
and/or p50 was a possible inhibitory mechanism which could have diminished pro-inflammatory 
cytokine production. In bone marrow stromal cells constitutive, direct binding of PGC-1 to p65 and 
p50 was reported which decreased in the presence of PPAR ligands (407). The authors therefore 
hypothesized that NF-B and PPAR compete for the shared coactivator PGC-1. Its recruitment to 
PPAR would limit NF-B-dependent IL-6 expression and consequently activation of multiple 
myeloma cells in their model (407).  
In hepatocytes, p50 and PGC-1 were shown to interact upon treatment with FFAs regardless 
of their saturation status (408). Both saturated and unsaturated FFAs further led to binding of this 
complex to the IL-10 promoter. Complex formation and IL-10 expression could be abolished by 
inhibition of NF-B. However, inhibition of PGC-1 by antisense oligonucleotides in liver resulted in 
a significant increase in IL-10 expression (408) which would render PGC-1 a transcriptional 
corepressor of p50 on the IL-10 promoter. The domain structure of PGC-1 that enables recruitment 
of cofactors for initiation complex formation (see 1.1.1) and the multitude of coactivation events 
published, yet rather argue against such a function.  
The most careful characterization of a PGC-1-NF-kB interaction was accomplished in 
cardiomyocytes (409). By means of EMSA and co-immunoprecipitation, an interaction of PGC-1 
and p65 was observed that increased upon TNF treatment and involved the LXXLL motifs in the 
PGC-1 N-terminus. On the basis of this interaction the authors propose a model of direct PGC-1 
inhibition by p65 which leads to lower PDK4 levels and subsequently to a higher glucose oxidation 
rate (409). However, siRNA directed against PGC-1 did not change PDK4 expression nor were NF-
B target genes like IL-6 and MCP-1 affected by siRNA directed against p65 and PCG-1. The 
functional consequences of this interaction are therefore not fully clear and the study did not comprise 
any ChIP experiments.  
 In skeletal muscle cells, no direct interaction between a NF-B family member and either 
PGC-1 or PGC-1 has been found so far. If an interaction takes place, we argued that at least in our 
model, PGC-1/ has to remain bound to p65 on B sites, as DNA binding of p65 was not changed in  
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PGC-1/ overexpressing cells after TNF treatment despite diminished cytokine expression (Ms1, 
Fig. 5D and 5E). To test this possibility, we performed chromatin immunoprecipitation (ChIP) in 
PGC-1 overexpressing cells and evaluated the abundance of PGC-1 on B sites in the IL-6 and 
TNF promoter. We could not detect any PGC-1 present at these sites whereas a clear enrichment 
was found in the MCAD promoter, a known PGC-1 target gene (Fig. 14). The lack of a specific, high 
affinity PGC-1 antibody prevented us from assessing the same parameters in PGC-1 overexpressing 
cells. The ChIP data for PGC-1 however do not support a model with a direct PGC-1-p65 interaction 
at the promoters of inflammatory p65 target genes and thus rather point to an indirect mechanism. 
Direct binding to p65 at the DNA with negative effects on gene expression (as observed for IL-6 and 
TNF for example) would again put PGC-1 in the role of a corepressor. Although not completely  
 
 
 
Figure 14 PGC-1 does not bind to the promoters of IL-6 and TNFDifferentiated C2C12 myotubes 
overexpressing PGC-1 were treated with TNF for 2h. DNA fragments enriched after crosslinking, sonication, 
and subsequent ChIP against flag-tagged PGC-1 were analyzed by real-time PCR and values are expressed as 
fold enrichment over the intronic region of TBP (a non-target region of PGC-1). IL-6 1, IL-6 2, TNF 1 and 
TNF 2 denote experimentally validated B sites in the IL-6 and the TNF promoter respectively. MCAD 
stands for the ERR binding site in the MCAD promoter (a known PGC-1 target region).  
 
 
excluded, it would be difficult to reconcile such a corepressor function with the well-established 
coactivator role of PGC-1 and PGC-1, which both effectively tether proteins to the promoter that 
activate transcription. Also from a conceptual point of view, an indirect mechanism with an 
intermediate step in which PGC-1 coactivators induce expression of a factor that inhibits NF-B 
activity is therefore the more likely model. Our data suggest that this factor is PPAR which is 
induced by both PGC-1 and PGC-1, and is capable of acting transrepressive on NF-B. 
Furthermore, the involvement of a p65 phosphatase (different from the known p65 phsophatases 
PP2A, PP1 and WIP1) is likely. 
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4.3 The PGC-1 coactivators promote M2 polarization of tissue macrophages in 
skeletal muscle 
 
4.3.1 Anaesthesia and PGC-1 transgene expression in skeletal muscle  
 
 As isoflurane anaesthesia is a standard method to etherize mice and has been administered in 
our lab previously, the protocol for our in vivo experiments first comprised this form of inhalation 
anaesthesia to be able to inject mice i.m. The first batch of mice investigated for their response to 
TNF and LPS were MCK and WT animals that were sacrificed 4h post injection. At the mRNA 
levels, we observed a complete loss of PGC-1 transgene expression in TA which we first ascribed to 
the inflammatory agents injected. Further experiments without injection proved this theory false but 
isoflurane anaesthesia alone elicited the same effect (Fig. 15A). We therefore had to adjust the 
anaesthetic, and tested the related substance sevoflurane. Anaesthesia induction was similarly fast 
compared to isoflurane, as was recovery. However, the repressive effect on transgenic PGC-1 
expression after 4h was completely relieved (Fig. 15A). We also evaluated the expression of the PGC-
1 transgene in MCK mice after anaesthesia with isoflurane and sevoflurane. Again, isoflurane  
 
 
 
Figure 15 Transgenic PGC-1 expression is sensitive to anaesthesia A, WT and MCK mice were 
anaesthetized for 3 minutes by inhaling isoflurane (Isofl), sevoflurane (Sevofl) or left untreated (Ctrl). 4h post 
anaesthesia, TA muscles were analyzed for PGC-1 expression by real-time PCR. B, WT and MCK mice were 
anaesthetized for 3 minutes by inhaling isoflurane (Isofl), or sevoflurane (Sevofl), by intraperitoneal injection of 
a ketamine/xylazine mixture (Ket/Xyl) or left untreated (Ctrl). 4h post anaesthesia, TA muscles were analyzed 
for PGC-1 expression by real-time PCR. n ≥ 3 animals per group.  
 
 
reduced transgenic PGC-1 expression while sevoflurane did not interfere with mRNA levels (Fig. 
15B). Additionally, we tested ketamine/xylazine injection as alternative anaesthesia method. Due to 
the different administration form, induction took longer, and more importantly, recovery was much 
delayed (hours versus minutes with both volatile anaesthetics). Besides not being justified regarding 
the relatively small intervention against the long duration of anaesthesia, this method depressed 
transgenic PGC-1 expression to an even greater extent than isoflurane inhalation. These data thus 
validate sevoflurane as anaesthetic of choice as it does not interfere with the transgene.  
The depressive effect of isoflurane and ketamine/xylazine on transgenic PGC-1 expression 
was unexpected and no such interference has been described before. An important determinant in this 
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depression is the time of sacrifice which was rather short (4h post anaesthesia) as longer periods of 
recovery compensate the effect. The complete repression of transgenic PGC-1 by isoflurane versus 
the partial repression of transgenic PGC-1 can be explained by different levels of overexpression 
which are higher in MCK animals (about 15 fold versus 7 fold in MCK mice, see Ms2, Fig. 1A and 
1B). It is astonishing that isoflurane and sevoflurane differ so fundamentally in their effects on PGC-1 
transgene expression despite sharing a similar chemical structure and very similar properties regarding 
anaesthesia. The elimination of sevoflurane in the first 2h after discontinuation of anaesthesia is 
however 1.6 fold faster than with isoflurane, possibly accounting for the difference between the two 
anaesthetics (410). Transgene expression in both models is under the control of the MCK promoter. 
Why this promoter is sensitive to isoflurane exposure is not known but a possible mechanism could 
involve calcium fluxes. While isoflurane perturbs calcium homeostasis in skeletal muscle (411), 
sevoflurane has less influence in this regard (412). As the MCK promoter contains MEF2 sites (413) 
and MEF2 is sensitive to intracellular calcium concentrations (414), PGC-1 transgene depression 
could be a consequence of inadequate calcium levels under isoflurane anaesthesia. This would also fit 
the notion that isoflurane is a strong but sevoflurane only a weak muscle relaxant.  
 
 
4.3.2 PGC-1 coactivators and anti-inflammatory cytokines  
 
Numerous studies dealing with inflammatory reactions in diverse contexts have described 
levels of pro-inflammatory cytokines like TNF, IL-6 and IFN as these are the main drivers of 
inflammation. Cytokines however rarely act individually but are rather part of a complex cytokine 
network that involves pro- but also anti-inflammatory factors which may synergize or neutralize each 
other depending on stimulus, timing etc. We evaluated a range of cytokines that are known to be 
involved in M1 or M2 macrophage responses in our injection and downhill running experiments to 
gain insight into the cytokine network acting in the MCK/ models. Surprisingly, we did not observe 
a difference in expression of the pro-inflammatory cytokines TNF, IL-6, MIP-1 and MCP-1 after 
PBS, LPS or TNF injection i.m. (Ms2, Fig. 3A). A recent study that also employed the MCK model 
and LPS injection i.p. reported similar findings with unchanged TNF and IL-6 levels in skeletal 
muscle of transgenic mice (415). Unaffected IL-10 levels in skeletal muscle in this study are further in 
accordance with our results as are the previously discussed systemic levels of IL-6 and TNF (415). 
The authors did not evaluate IL-12 expression or levels of anti-inflammatory cytokines other than IL-
10. Our report is therefore the first to show the effect of PGC-1 coactivators on IL-12 expression in 
skeletal muscle and in myocytes in culture. The diminished IL-12 levels in muscle are likely the cause 
of the observed M2 skewing of tissue macrophages accompanied by a changed cytokine expression 
profile. 
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In primary hepatocytes, PGC-1 induction after fasting, exercise, glucagon, or cAMP 
exposure has previously been associated with an increase in IL-1Ra and IL-15R (416). The induction 
of these anti-inflammatory cytokines was further dependent on PPAR (416). We also detected higher 
expression of IL-1Ra in sedentary MCK animals and in untreated, cultured myocytes overexpressing 
PGC-1, this difference was however lost with any kind of injection (even PBS, which also causes a 
microinjury), treatment or training. A direct effect of PGC-1 on IL-1Ra in naïve muscle cells is 
therefore likely (similar to the situation in hepatocytes). A major role for IL-1Ra in M2 macrophage 
skewing is however implausible. In MCK mice, IL 1Ra expression was augmented after PBS and 
LPS injection as well as in sedentary and exercised animals, but the effect was not recapitulated in 
C2C12 cells overexpressing PGC-1 suggesting an indirect effect in this case with IL-1Ra release 
from immune cells.  
 Yet another study in liver established a mechanistic link between mitochondrial biogenesis 
and anti-inflammatory gene expression via the enzyme heme oxygenase 1 (HO-1) (417). Induction of 
HO-1 after LPS and carbon monoxide treatment induced IL-10 and IL-1Ra mRNA and protein 
expression and at the same time nuclear abundance of the TFs MEF2, Nfe2l2, and NRF-2, which is 
involved in mitochondrial biogenesis. These TFs were shown to be recruited to the promoter regions 
of IL-10 and IL-1Ra as opposed to the promoter regions of pro-inflammatory cytokines which are 
regulated primarily by NF-B (417). HO-1 is thus another nexus of metabolic and (anti-)inflammatory 
signalling. As HO-1 appears upstream of MEF2 and thus upstream of PGC-1, a direct effect of PGC-
1 on anti-inflammatory cytokine expression is unlikely matching our results.  
Interestingly, the same study established that this mechanism is also active in the macrophage 
cell line J774.1 (417), which fits the concept of anti-inflammatory M2 activation with higher 
expression of IL-10 and IL-Ra, and a concomitant switch in metabolism from glycolytic to oxidative. 
PGC-1 was shown to be vital in the induction of this oxidative, anti-inflammatory macrophage 
phenotype (327) while PGC-1levels were found to be elevated in macrophages that undergo M2-like 
changes during prolonged high fat feeding (418). Inversely, LPS exposure downregulated PGC-1 
(and PPAR) in bone-marrow derived macrophages thus enabling ROS production, a feature 
characteristic of pro-inflammatory M1 macrophages, as antioxidative enzymes like glutathione 
peroxidise and catalase were diminished (419). The suppression of PGC-1 in these cells depended on 
IRAK-1, which is also critically involved in the induction of Nox-1, a key component of the NADPH 
oxidase complex (419). As HO-1, the enzyme that connected mitochondrial biogenesis and anti-
inflammatory gene expression in hepatocytes and macrophages (416), is also able to counteract 
NADPH oxidase function at least in endothelial cells (420), HO-1 seems to play a prominent role in 
the determination of the macrophage phenotype that correlates with PGC- expression. In contrast to 
all the previously described results, one report claimed that PGC-1 is a target of the IFN/STAT1 
axis (M1) and that PGC-1 together with ERR induces mitochondrial ROS production (421). 
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Therefore, more research is needed to fully establish the role of PGC-1 coactivators in macrophage 
activation. The currently available studies do foster an involvement in M2 determination though. It has 
to be stressed in this context, that the MCK/ model we employed only expressed the transgene in 
skeletal muscle and that all other cells including macrophages had a WT genotype. If skeletal muscle-
specific overexpression of PGC-1/ also influences the expression of these coactivators in 
macrophages remains to be determined. In the light of a skewing towards the M2 phenotype, it seems 
likely that this would be accompanied by higher PGC-1 expression levels.  
 
120
Discussion 
 
4.4 Comparison of in vitro and in vivo models  
 
 The general idea behind both the in vitro and the in vivo approach was to test if the presence of 
PGC-1 coactivators in skeletal muscle would influence inflammatory reaction. Therefore, we 
employed cultured C2C12 myotubes overexpressing PGC-1 or PGC-1 from adenoviral constructs 
and skeletal muscle-specific transgenic mice, respectively. In vitro, both coactivators were strongly 
overexpressed: PGC-1 yielded about 30000 fold while PGC-1 reached about 1500 fold compared to 
control cells overexpressing GFP (Ms1, Suppl. Fig. 1A and 1B). In vivo, the rate of overexpression 
was more moderate, i.e. about 7 fold for PGC-1 and about 15 fold for PGC-1 compared to WT 
animals (Ms2, Fig. 1A and 1B). The profoundly higher rates in vitro are on the one hand due to the 
very low expression of PGC-1 and the low expression of PGC-1 in control cells whereas WT 
animals do express significant amounts of both coactivators. The in vitro model thus rather resembles 
a comparison between MCK/MCK animals and the respective skeletal muscle-specific deletion 
models that lack PGC-1 or PGC-1. On the other hand, adenoviral expression is driven by the very 
potent CMV promoter also leading to sustained overexpression while in the animal model, the tissue 
specific MCK promoter controls PGC-1 coactivator expression. The sensitivity of this promoter e.g. to 
suppression by specific anaesthetics is discussed above (see 4.2.1). Yet another difference between the 
in vitro and the in vivo model derives from the fact that recombinant adenovirus remains 
epichromosomal whereas the transgene in vivo was inserted into the host genome during the creation 
of the MCK/MCK line. The position of this insertion is however not known and therefore abnormal 
expression of genes at the insertion site cannot be excluded.  
 Generally, viral overexpression may not seem a good idea in the context of inflammatory 
studies as the virus itself may induce inflammatory signalling in the host cell. As control cells 
overexpressed GFP from a viral vector as well, the bias of the infection should be removed by 
comparing these two conditions. We further evaluated non-infected cells in comparison to GFP-
expressing cells and did not find major differences at least in the expression of genes we were 
interested in. Therefore, we assumed that adenoviral infection is a valid model especially in the 
context of cultured myocytes that are postmitotic and difficult to transfect rendering standard plasmid 
transfection techniques unfeasible. Another possibility would have been the generation of stable cell 
lines overexpressing PGC-1 coactivaotrs or the isolation of primary muscle cells from WT and 
transgenic mice respectively. However, transgene expression in primary cells declines after a few 
passages which turns this strategy prone to errors.  
 The big differences described above between PGC-1 expression in the in vitro and the in vivo 
model are likely also part of explanation for divergent results. While in vitro, we observed a repression 
of IL-6, TNF and MIP-1 by PGC-1 and PGC-1 after treatment with TNF, injection of TNF 
into TA of transgenic and WT mice did not yield such a difference. Furthermore, the basal repression 
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exerted by PGC-1 on these cytokines in vitro was not replicated in vivo. Considering that the GFP 
control cells barely express PGC-1 and are thus similar to MKO mice, we might extend this thought 
to the expression of pro-inflammatory cytokines. Their levels are higher in skeletal muscle of MKO 
than WT mice (158). Envisioning these levels as baseline would probably bring the in vitro and in vivo 
results closer together, as these pro-inflammatory cytokines should be lower in MCK mice (because 
they are not different from WT in our experiments and levels in MKO muscle are higher than in WT 
according to literature). For PGC-1, no data on inflammatory markers in a deletion model are 
available. Taking this scenario and our in vitro results including mechanistic details into account, an 
anti-inflammatory role of both PGC-1 coactivators is manifest. However, only lowered levels of these 
coactivators as present in diseases like diabetes or in genetically engineered animals make this 
property become evident in the way that inflammation cannot be confined. In contrast, WT levels 
seem to be high enough to control excessive inflammation in muscle cells, precluding the formation of 
a difference. This observation leads to the interesting hypothesis that PGC-1 coactivators act in a 
“threshold mode”, meaning that expression above a certain level is necessary to exert their biological 
function (but further induction is not beneficial), while a drop below this threshold is detrimental.  
 Besides mere differences in expression levels of PGC-1 coactivators, the complexity of 
skeletal muscle as an organ as opposed to a pure myocyte culture should not be neglected. In addition 
to myofibers, skeletal muscle also contains satellite cells and connective tissue like the endomysium, 
the perimysium, and the epimysium, lining fibers, bundles and the whole organ, respectively. 
Furthermore, blood and lymphatic vessels traverse the organ while  motoneurons and sensory neurons 
extend into the muscle spindle. Finally, immune cells like tissue resident macrophages and dendritic 
cells within skeletal muscle monitor the immune status of the organ. The complex interplay of these 
different cells types ensures proper muscle function. It is therefore not too surprising that results from 
in vitro experiments with only myocytes present cannot be readily translated into the in vivo setting. 
Injection of inflammatory stimuli and also of PBS causes a microinjury not present when treating cells 
with cytokines or TLR antagonists. This alone would lead to activation of the immune system at the 
injured site. This is also a very likely cause for differences between the control groups in the injection 
and the downhill running experiment. While sedentary animals in the latter were completely 
untouched apart from the short acclimatization period, control animals in the former were subject to 
injection which brought about similar effects as injection of inflammatory agents albeit at mush lower 
intensity. The inflammatory agents injected then again acted both on myocytes and immune cells. As 
immune cells are specialized to react to infection and injury their contribution to the cytokine response 
we measured was likely high. It is therefore possible that suppression of IL-6, TNF and MIP-1 
within myocytes due to PGC-1 overexpression occurred but was overridden by the powerful immune 
response mounted by immune cells and could thus not be detected. As we did not deplete 
macrophages from muscle and analyzed lysates of the whole organ, the origin of cytokines could not 
be traced back.  
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4.5 Perspectives 
 
The interface of metabolic and immunological research is an active area of investigation and 
multiple layers of crosstalk between both sides have just started to emerge and to be understood. In the 
present study we explored the effect and the mechanisms of PGC-1 and PGC-1 overexpression on 
inflammatory reactions in vitro and in vivo in skeletal muscle. We found that both coactivators act in 
an anti-inflammatory manner in muscle cells as they suppress the expression of pro-inflammatory 
cytokines and diminish phosphorylation of p65 upon stimulation with inflammatory agents. In this 
regard, it would be of great interest to identify the kinase(s) involved in p65 phosphorylation under 
these conditions as well as a putative phosphatase that decreases p65 phosphorylation in the presence 
of either coactivator. We hypothesized that IKK downstream of Akt could engage in such a 
phosphorylation as Akt activation was decreased by PGC-1/. Reconstituting Akt activity e.g. by 
adenoviral co-overexpression would therefore reverse the effect as would activation if IKK. 
Experimentally validating these assumptions would support the mechanism by which PGC-1 
coactivators decrease pro-inflammatory gene expression. A phosphatase screen could also help to 
identify a putatively new p65 phosphatase which is induced by PGC-1/ and removes the TNF-
induced phospho-residue from p65 quickly.  
Concerning PPAR-mediated transrepression, characterizing the complex in detail that is 
tethered to/kept at the p50/p65 dimer bound to DNA, would also broaden our understanding of anti-
inflammatory actions exerted by nuclear receptors. The role of SUMOylation in this respect would 
merit special attention as an elegant study on PPAR revealed its important function in the repression 
of NF-B-dependent genes (278). Investigating mechanisms downstream of stimuli other than TNF 
(like TLR agonists or FFAs) would further complement the present work. 
In vivo, skewing of M2 macrophages by skeletal muscle PGC-1 is a very interesting and 
unexpected finding, some questions however remain unresolved to date. Primarily, determining the 
factor(s) responsible would be a major contribution to understand the complex interplay between 
muscle and immune cells under pro-inflammatory conditions. As we suspect diminished muscle IL-12 
levels in transgenic mice to play an important role in this process, an illustrative experiment would be 
the reconstitution of IL-12. Several strategies would be possible: First, cross-breeding of 
MCK/MCK mice with skeletal muscle-specific IL-12 transgenic mice would constitute a genetic 
model that according to our hypothesis would reverse M2 macrophage activation after inflammatory 
stimulation. Second, and less time-consuming, electroporation of TA with IL-12 plasmid DNA (422) 
would give the same result. As not all fibers are hit by this procedure, the effect would presumably be 
more subtle or maybe even insufficient to prevent M2 polarization. Third, exogenous IL-12 
administration i.m. or i.p. could be employed to reverse the phenotype. If the low expression of IL-12 
has a systemic effect in our model still remains to be clarified.  
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To follow up on the mechanisms and the factors mediating preferential M2 polarization upon 
inflammatory stimulation in transgenic mice, a cell culture model would complete the current study. 
Therefore, conditioned medium either from primary myocytes of MCK/MCK mice or from C2C12 
cells overexpressing PGC-1/ could be transferred onto primary macrophages or an immortalized 
macrophage cell line and their polarization status monitored. Stronger M2 polarization as compared to 
macrophages exposed to control medium would be expected. Another advantage of this technique 
would be the possibility to analyse the conditioned medium for factors it contains. Of course, IL-12 
would be an obvious candidate to look for, but a complete secretome analysis would be a more 
unbiased approach.  
Isolating macrophages from skeletal muscle of our model would further facilitate to 
characterize these cells more comprehensively e.g. by flow cytometry. Analysis of the cytokines that 
were higher in whole muscle lysates but not in the C2C12 model like CCL1 for example, would 
confirm that they derive from immune and not muscle cells and that changes in their expression are 
thus secondary effects. Inversely, depletion of macrophages from skeletal muscle (312) would be 
another interesting tool to dissect which cues originate from muscle and which from immune cells.  
As PGC-1 levels in skeletal muscle of obese and diabetic patients are dysregulated, exposing 
mice to a high fat diet (HFD) which evokes a systemic, low-grade inflammation instead of the more 
acute inflammatory stimulation with LPS and TNF injection or a single bout of downhill running 
would be of prime interest in the long term. Investigating macrophage populations in skeletal muscle 
under these conditions in the presence of PGC-1 would validate the claim that restored PGC-1 levels 
not only improve metabolic but also inflammatory components in the metabolic syndrome by 
preventing pro-inflammatory M1 macrophage activation. The complex phenotype of the MCK model 
on HFD regarding glucose homeostasis however has to be taken into account. Reciprocally, studies on 
macrophages in skeletal muscle-specific deletion models of PGC-1 and PGC-1 would complement 
this work. Higher mRNA levels of CD68 in skeletal muscle of MKO mice (158) already point towards 
a higher degree of M1 polarization supporting our results. A more careful analysis still warrants 
further investigation.  
Elucidating basic mechanisms of direct PGC-1 coactivator action in muscle cells and their 
crosstalk to cells of the immune system is an important step in understanding the role of these 
cofactors in health and diseases. This knowledge is also indispensable to be able to develop strategies 
aimed at combating the consequences of dysregulation of PGC-1 and PGC-1. Applying our 
findings to benefit patients suffering from the metabolic syndrome but maybe also from skeletal 
muscle disorders that involve an immune component would imply the availability of a specific PGC-1 
agonist as genetic approaches are not yet in a safe stage regarding treatment of humans. Such an 
agonist has however not been found to date and intensive research in this direction is needed to 
translate our basic findings into a therapy. Our work shows that PGC-1 and PGC-1 are worthwhile 
targets that deserve the attention of future investigations to finally improve patients´ health. 
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